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ABSTRACT
Human cytomegalovirus (HCMV) UL141 is a potent modulator of natural killer (NK) 
cell function that acts by suppressing cell surface expression of CD155, a recognised 
ligand for the ubiquitous NK cell activating receptors DNAM-1 and CD96. CD 155, also 
known as nectin-like molecule 5 (necl-5) or poliovirus receptor (PVR), is an important 
adhesion molecule that impacts on cell motility, proliferation and cellular signalling 
complexes. The focus of this study is to characterise UL141 expression, interactions and 
biological properties.
Consistent with the role of CD 155 as a cell adhesion molecule, UL141 expression was 
associated with reduced cellular adhesion whether expressed in continuous cell lines or 
by adenovirus vector. UL14 and UL141 exhibit significant amino acid sequence 
homology and are members o f the same HCMV gene family. Interestingly, UL14 also 
impaired cell adhesion. Consistent with HCMV downregulating multiple adhesion 
molecules, productive infection was associated with greatly reduced cell adhesion. 
Against this background, deletion of UL141 from the virus had no overt effect in 
adhesion assays. When co-expressed with C-terminal fluorescent tags, gpUL141 and 
CD 155 co-localise with each other and endoplasmic reticulum marker. When over­
expressed CD 155 and gpUL141 co-localised in inclusion bodies along with calnexin; 
implying gpUL141 may hold CD 155 in a partially destabilised form.
gpUL141 was identified as a component of the envelope of mature HCMV virus 
particles, whilst CD 155 and gpUL14 were excluded. gpUL141 is predominantly an 
endoglycosidaseH (Endo-H)-sensitive, ER-resident glycoprotein in HCMV infected cell 
that is subject to post-translational modification, consistent with proteolytic cleavage, 
during the later stages o f infection. However, the protein incorporated into virions is full 
length and had acquired Endo-H resistance, consistent with transit through the Golgi 
apparatus. As CD 155 is recognised to be a cellular receptor for poliovirus and other 
herpesviruses, the identification of UL141 as a virion protein may have implications for 
virus entry.
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1 INTRODUCTION
1.1 HUMAN CYTOMEGALOVIRUS
Human Cytomegalovirus (HCMV) is a ubiquitous virus associated with opportunistic 
disease. Serious pathology can be caused by congenital infection or infection of 
immunosuppressed individuals. The virus was first isolated by Wallace Rowe in the 
1950s from human adenoids (Rowe et al. 1956). It was later recognised to be the 
causative agent of cytomegalic inclusion disease, a severe congenital disease associated 
with a characteristic owl’s eye cytopathology.
HCMV is a member of the herpesvirus family, betaherpesvirus subfamily. It is one of 
eight herpesviruses that infect humans (table 1.1). HCMV shares virion structure with 
other herpesviruses and, like other herpesviruses, has the ability to establish long term 
persistent and latent infection. Like other betaherpesviruses, HCMV infection is limited 
to its natural host. HCMV-associated disease remains an important medical issue as a 
prominent opportunistic infection of immunocompromised hosts. Congenital infection of 
newborns can cause severe disease leading to prolonged hospitalisation and death in 10% 
of symptomatic infants. HCMV infection of transplant recipients can cause a systemic 
febrile illness and will often causes dysfunction of the transplanted organ increasing the 
risk of organ rejection.
HCMV biology, especially in vivo, is complex and our understanding is incomplete. 
However modem techniques have advanced our understanding.
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Table 1.1. Human Herpesvirus (HHV) classification
Name Subfamily
HHV 1 Herpes simplex virus 1 (HSV 1) Alpha
HHV 2 Herpes simplex virus 2 (HSV 2) Alpha
HHV 3 Varicella zoster virus (VZV) Alpha
HHV 4 Epstein-Barr virus (EBV) Gamma
HHV 5 Human cytomegalovirus (HCMV) Beta
HHV 6 Human herpes virus 6 Beta
HHV 7 Human herpes virus 7 Beta
HHV-8 Kaposi’s sarcoma-asssociated herpesvirus (KSHV) Gamma
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1.2 VIRUS STRUCTURE
1.2.1 Genome
HCMV has the largest genome of a human virus at 236kb and is predicted to encode 
-167 open reading frames, ~10 miRNAs and additional non-protein coding transcripts 
(Davison et al. 2003; Grey and Nelson 2008). The virus has a class E genome (Karlin et 
al. 1994) consisting of a unique long region (Ul) and a unique short region (Us), each 
flanked by inverted internal and terminal repeats (terminal repeat long (TRL), internal 
repeat long (IRL), terminal repeat short (TRS) and internal repeat short (IRS) (fig 1.1). 
The length of the repeats varies between strains and passage history. A directly repeated 
sequence, termed cr, is present at the termini and between the Ul and Us regions (fig 1.1). 
The arrangement of the terminal and internal a sequences encourage genome 
isomerisation producing four isomers of the genome which are equally packaged into 
mature virions (Weststrate et al. 1980). The a repeats contain the herpesvirus conserved 
p a d  and pac2 elements (Spaete and Mocarski 1985a). These sequences act as a signal 
for the packaging of the genome into the capsid.
Most studies on HCMV have been performed using the laboratory strains AD 169 and 
Towne. Strain ADI 69 was originally isolated during culture of adenoid tissue from a 7 
year old girl and cultured 14 times in human fibroblasts and a defined stock was 
generated (Rowe et al. 1956). This stock was passaged another 56-64 times in fibroblasts
3
— I—
50
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—r
150
kbp
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AD 169
237
Toledo ■no—
Figure 1.1. HCMV strain AD169 and Toledo genome structures.
The HCM V genome is split into two main regions U l  (unique long) and Us (unique 
short). These regions are flanked by terminal and inverted terminal repeats. The b and b ’ 
repeats are also termed terminal repeat long (TRL) and internal repeat long (IRL). The c 
and c ’ repeats are also termed internal repeat short (IRS) and internal repeat long (IRL). 
The a sequence is directly repeated sequence and the number o f  copies can vary between 
strains. The top line is a scale in kilobasepairs. Adapted from (Mocarski et al. 2007).
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at St Georges Hospital (London) before being used to produce batches o f  an attenuated in 
vitro  for use in vaccination (Bradley et al. 2009; Elek and Stern 1974). The genome o f  
this virus (strain A D 169varl!K ) was cloned (Oram  et al. 1982). and then these clones 
used to generate the first complete sequence o f  the HCM V genom e (Chee et al. 1990a). 
The attenuation o f  strain AD 169 can be attributed to the multiple mutations that 
accum ulated  during extensive passage in vitro. Most significantly. 13 and 15Kb 
respectively have been deleted from high passage strains o f  Tow ne and A D I 69 (Bradley 
et al. 2009; Cha et al. 1996). This region, termed U L /b '.  is located at the right end o f  the 
C[ region o f  the genome. In AD  169 the UL/b' region has been replaced with an inverted 
duplication o f  10Kb from the left end o f  the UL region. In addition to other minor 
defects, some v ariants o f  strain AD 169 hav e also suffered a 929 base pair deletion 
affecting l !L42 and UL43 (Dargan et al. 1997; Mocarski et al. 1997). H C M V  clinical 
isolates rapidly acquire mutations when propagated in vitro  (Akter et al. 2003a; Davison 
et al. 2003; Dolan et al. 2004). These mutations a llow the virus to adapt to growth in 
fibroblasts. Merlin strain H C M V  is currently the best characterised clinical isolate (fig 
1.2). has been designated the prototype HC M V  clinical isolate by GenBank and will be 
the preferred virus strain used in this study.
H C M V  open reading frames (ORFs) were classified originally in strain AD 169 based on 
which sequence element encoded it and their relative order on the genome (fig 1.2). For 
example. UL44 was the forty-fourth ORF o f  the Ui region and US8 is the eighth ORF o f  
the Us region. Following the sequencing o f  the U L/b ' region in strain Toledo (Cha et al. 
1996). the closely-related o f  chim panzee C M V  (CCM V ). and the low passage strain
L L ^
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Figure 1.2. Genomic map of Merlin strain HCMV.
Annotation o f  the wild type genome o f  Merlin strain HCMV. Protein coding regions are 
indicated by arrows with ORF nomenclature below. Reproduced from (Wilkinson et al. 
2008) adapted from (Dolan et al. 2004).
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Merlin, the annotation o f  the genom e evolved. A significant num ber o f  the original l\ 
designated O RFs lacked credible translation start codons and were not conserved in 
C C M V ; these were removed. A num ber o f  ORFs (designated R L 1-13) were artificially 
duplicated in extended repeat sequences in strain AD  169 (and Tow ne) still retain their 
erroneous designation even though they are now known to be single copy genes encoded 
by the I j  region o f  clinical isolates. Additional letters after the O RF number can denote 
revised or previously unidentified open reading frames. W hen a protein coding region is 
overlapped by a larger ORF the smaller ORF is given a .5 suffix (Davison et al. 2003). 
Further modifications to HCM V gene designation can be anticipated as our 
understanding develops. The most current G enB ank strain Merlin gene designation will 
be used throughout this thesis (fig 1.2).
1.2.2 Capsid
The H C M V  and HSV-I capsids have a similar structure and appearance, although the 
HCM V capsid has a 17% greater volume and packages a genom e - 5 0 %  larger (Bhella et 
al. 2000; Chee et al. 1989; Dittmer and Bogner 2005; Gibson 1983; Gibson et al. 1996a; 
Gibson et al. 1996b; Irmiere and Gibson 1985a). The H C M V  capsid displays T=16 
icosahedral symm etry which consists o f  five herpesv irus core proteins arranged in 
hexons. pentons and triplexes (fig 1.3). The 5 proteins are m ajor capsid protein (MCP. 
CT86). minor capsid protein (mCP. UL85). m inor capsid-binding protein (mCPBp. 
l !L46). smallest capsid protein (SCP. UL48.5) and PO RT (portal protein. UL104)
7
Genomi
B
Glycoprotein Complex 
Envelope 
Tegument 
Capsid
Figure 1.3. HCMV virus particle
A) Cartoon o f  the HCM V virion (not to scale). The genome is enclosed in an icosahedral 
capsid which is surrounded by the tegument. The virion is surrounded by a host-derived 
m embrane envelope. B) electron micrograph o f  two HCM V virions. Capsid, tegument 
and envelope are visible. Scale bar is lOOnm. Reproduced from (Bhella et al. 2000).
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(Booy et al. 1991; Butcher et al. 1998: Chen et al. 1999: Gibson et al. 1996a: Gibson et 
al. 1996b: Irmiere and Gibson 1985b: Yu et al. 2005). Hexons are the most abundant 
capsom er. with 150 hexons per capsid each consisting o f  six copies o f  MCP (Irmiere and 
G ibson 1983: Varnum et al. 2004). There are 12 pentons present in each capsid: eleven 
consist ot five copies o f  M CP and one consists o f  twelv e copies o f  the portal protein 
pi LI 04 (Sarcinella et al. 2004: Varnum et al. 2004). The triplexes consist o f  a 2:1 ratio 
o f  m C P to m C PB p (M unger et al. 2006). SCP binds to the tip o f  M CP in hexons. but not 
to M CP in pentons (Chen et al. 1999: Irmiere and G ibson 1983).
Within infected cells three different forms o f  capsids are observed. These are termed A.
B and C capsids. C capsids are the fully mature nucleocapsids and are the only form with 
DN A incorporated into the capsid (Baxter and Gibson 2001). A capsids consist o f  only 
the protein shell with no DNA in the cavity (Irmiere and Gibson 1983). B capsids are an 
intermediate in the assembly o f  the fully mature nucleocapsid consisting o f  the capsid 
shell containing Assembly protein (AP. UL80) (Bechtel and Shenk 2002: M unger et al. 
2006: Sanchez et al. 2000b: Silva et al. 2003). All three capsid forms are capable o f  
acquiring envelopes, but only C capsids go on to produce mature infectious virus.
Lnv eloped A and B capsids are found in cytoplasmic and cell-free preparations o f  virus 
particles. They are classified as non-infectious enveloped particles (NIHP) and can be 
purified free o f  infectious v irions by density gradient centrifugation: the absence o f  DNA 
alters their density (Chev illotte et al. 2009).
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1.2.3 Tegument
Surrounding the nucleocapsid is the tegum ent which appears in electron micrographs as 
an am orphous region between the capsid and the envelope (fig 1.3). M ore than halt' o f  all 
recognised virion proteins are believed to be located within the tegument. 22 in total 
(V arnum  et al. 2004). Tegument proteins have a tendency to be both phosphorvlated and 
highly im m unogenic (Varnum  et al. 2004). The most abundant tegument protein is the 
UL83 gene product pp65 (lower matrix protein) which accounts for 15% o f  HCM V 
virion protein (Varnum  et al. 2004). Other tegum ent proteins which are present at high 
levels include p p 7 1 (Virus Transactivator. VTA. ppUL82). pp 150 (Large matrix protein. 
pL'L32) and the largest tegument protein (LTP. pUL48) (Baxter and Gibson 2001;
Bechtel and Shenk 2002; Benko et al. 1988; Liu and Stinski 1992). Sev eral proteins 
encoded by m em bers o f  the US22 family are also com ponents  o f  the tegument, including 
L L23. I T .24. 1RS1 and I RS 1 (Adair et al. 2002; Rom anowski et al. 1997). The 
tegum ent also contains a sampling o f  cellular and viral m R N A s (Baldick et al. 1997).
Although the tegument appears amorphous, it is known to participate in highly structured 
ordered interactions with both the capsid and the envelope (Liu and Stinski 1992).
Distinct interactions between the capsid and tegument have been observed by comparing 
capsids with various levels o f  tegumentation by cryo-electron m icroscopy (Romanowski 
et al. 1997; Trus et al. 1999; Winkler and Stam m inger 1996). pp 150 binds to the capsid 
v ia a conserved am ino-term inus region (Baxter and Gibson 2001). while pUL47 (a 
tegum ent protein) co-precipitates with the capsid protein M CP (Baldick and Shenk 
1996); the latter interaction being implicated in the unpackaging o f  the viral DNA
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following infection. The tegum ent protein pp28 (ppUL99) interacts with the virion 
envelope m em brane via a m yristylated domain (Silva et al. 2003). This interaction is 
important for the accum ulation o f  tegument proteins prior to env elopment (Sanchez et al. 
2000a).
Tegum entation occurs in two separate cellular locations during the assembly o f  the virus 
particle. Initial com ponents  o f  the tegument, including pp65 (Sanchez et al. 1998) and 
IJL97 kinase (W o lfe t  al. 2001). initiate interactions with the nucleocapsid in the nucleus. 
These tegum ent com ponents have both functional and structural roles important for the 
efficient assem bly o f  the virion; UL97 kinase is involved in D N A  replication and capsid 
assem bly ( W o l f  et al. 2001). while the major tegum ent protein pp65 is required for the 
recruitment o f  other tegum ent proteins, including pUL25 and pUL69. into the v irion 
(C'hev illotte et al. 2009; Zini et al. 1999). Following nuclear egress, a second round o f  
tegum entation occurs in the cytoplasm. The tegument protein pp28. which is added in 
the cytoplasm  (Sanchez et al. 2000b) is required for the final envelopm ent o f  the virion 
(Silva et al. 2003).
In addition to their structural roles in assembling the virus, the virion tegument proteins 
play important roles in the initiation o f  productive infection. The tegument proteins are 
present in productively infected cells prior to immediate early (IID gene expression. pp71 
plays a critical role in the initiation o f  infection by reliev ing hDax.x repression o f  virus 
replication by promoting its proteasome-m ediated degradation (Baldick et al. 1997;
C antrell and Bresnahan 2006; Lukashchuk et al. 2008; Woodhall et al. 2006). pUL69 is a 
viral transactivator which is incorporated into the tegument (W inkler et al. 1994; Winkler
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and S tam m inger 1996). It is expressed as three differentially phosphorylated forms, 
however, only one o f  these forms is incorporated into the tegument (W inkler and 
S tam m inger 1996).
1.2.4 Envelope
The processes involved in virus envelopm ent are the object o f  intensive ongoing research 
(fig 1.3). The virus nucleocapsid and tegument are known to be enclosed in a membrane 
derived from the host cell endoplasm ic reticulum (ER)-Golgi intermediate compartment 
(E R G IC ) m em brane (Sanchez et al. 2000a). H C M V  encodes m any putative 
glycoproteins or transm em brane proteins, many o f  which potentially could be 
incorporated into the virus envelope. There were originally believed to be three major 
glycoprotein com plexes present on the envelope: gCI (gB). gCII (gM :gN) and gC111 
(glE.gL) (Gretch et al. 1988). These glycoproteins are m em bers o f  the herpesvirus core 
set and are essential for v irus replication. gCI consists o f  a disulphide-linked gB 
( g p l !L55) hom odim er (Cranage et al. 1986; Kari et al. 1990). gB is translated as a 
160kDa m onomer, which is then processed by a host protease to generate 1 16kDa and 
55kDa polypeptides. The 55kDa species on the outside o f  the envelope remains in 
com plex with the 1 16kDa transm em brane component by disulphide bonding (Britt and 
Auger 1986; Spaete et al. 1988). Proteolytic cleav age o f  gB is dispensable for virus 
growth (Strive et al. 2002b). gB is involved in the initial v irion:ce!l attachment through 
its reaction with cellular heparan sulphate (Boyle and C om pton 1998; Com pton et al. 
1993). after which the glycoprotein also promotes specific interactions with EGER, and 
u vp; integrin (W ang et al. 2005). The glycoprotein is a major target o f  human
neutralising antibodies (Marshall et al. 1992); neutralising antibodies prevent both 
a ttachm ent and fusion o f  the v irus (Gicklhorn et al. 2003).
I he gCII com plex  is comprised o f  gM (gpULlOO) and gN (gpUL73). the two 
com ponents  also being covalently linked by a disulphide bond (M ach et al. 2000). gCII 
com plex will form in the absence o f  disulphide bonding (M ach et al. 2005). Most o f  the 
multiple trans-m em brane spanning gM is dispensable for the interaction with gN. only 
the initial 1 18 am ino acids are essential (Mach et al. 2005). Com plex formation occurs 
within the HR. and is required for the transport o f  gM :gN to the secretory system. gM:gN 
has also been reported to interact with heparan sulphate proteoglycans on entry (Kari and 
Ciehrz 1992; M ach et al. 2000). As with gCI. gCII is also a target for neutralizing 
antibodies in hum an serum (M ach et al. 2000; Shim am ura et al. 2006).
gC'III. consist o f  gH (gpUL75). gL (gpU Ll 15) and gO (gpUL74) in virions purified from 
laboratory-adapted HCMV7 strains (Huber and C om pton 1997. 1998; Kaye et al. 1992; Li 
et al. 1997) and has been implicated in v iral fusion; antibodies against gH or gO will 
inhibit v iral fusion (Milne et al. 1998; Paterson et al. 2002). gH is linked to gL by 
disulphide bonds which form in the LR (Huber and C om pton 1999). gL is required for 
the transport o f  gH to the cell surface (Spaete et al. 1993). The gH:gL complex binds to a 
gO precursor forming a 22()kDa gClIl precursor (Theiler and Com pton 2001). before gO 
is post-translationally modified in a post-LR com partm ent for the formation the fully 
mature gC'III complex. It has been reported that gH binds LCiFR and integrin 
(Baldwin et al. 2000; Wang et al. 2005). although antibodies to gH block viral fusion but 
do not inhibit attachment (Keay and Baldwin 1991).
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A second envelope glycoprotein com plex involving gH and gL has been described (W ang 
and Shenk 2005b). gH:gL:pUL 13 1A pUL 130/128 comprises o f g H .  gL and the products 
o f  I ' L l 28. U L 130 and U L 131 A. The co-expression o f  U L 128. U L 130 and U L 131A 
increases the transport o f  g lLgL  from the HR. suggesting that the complex forms in the 
LR (R yckm an et al. 2008b). The gH:gL:UL 13 1 A - 128 complex is required for epithelial 
and endothelial cell tropism (Adler et al. 2006; Patrone et al. 2007; Ryckm an et al. 2008a; 
W ang and Shenk 2005a). HCM V cells lacking this complex can internalise in epithelial 
cells but do not express immediate early genes (S inzger et al. 2000). When HCM V is 
passaged in fibroblasts mutations tend to be selected rapidly in one o f  UL128. UL130 or 
CL 13 1 that leads to an inability to productively infect epithelial cells (Akter et al. 2003b; 
Dolan et al. 2004).
In addition to the major glycoprotein complexes there are also other virus-encoded 
glycoproteins present in the v irion envelope. H C M V  encodes four G coupled protein- 
receptor hom ologues CL33. CS27. US28 and UL74 (Chee et al. 1990b; Wang et al. 
2004b). Tw o o f  these proteins. UL33 and UL76. have been described as components o f  
the v irion (Fraile-Ram os et al. 2001; Wang et al. 2004b) and it has been suggested that 
one. CS28. is also present on the v irion (Fraile-Ramos et al. 2001). US28 is a functional 
chem okine receptor (discussed in section 1.5.4) but its role in the virion envelope is still 
unclear (Gao and Murphy 1994).
Varnum  and colleagues (Varnum  et al. 2004) identified seventeen virus encoded 
glycoproteins in H C M V  virion envelopes. The most abundant envelope glycoproteins 
are the g lycoprotein complexes discussed above; however, they detected approximately
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twelve HC M V  glycoproteins that are minor envelope constituents including RL10, UL33 
and UL5.
1.2.5 O ther Components
In addition to the viral encoded proteins present in the HC M V  virion over 70 host 
encoded proteins have been identified in the virion including actin. clatharin. and 
translation elongation factors (V arnum  et al. 2004). The presence o f  many o f  these host 
proteins in the virion is controversial as cellular contam ination may occur during the 
purification o f  the v irus particles (Hudecz et al. 1985). Howev er, support for the activ e 
incorporation o f  cellular protein com e from electron m icroscopy or functional studies 
(Grundy et al. 1987: Spear et al. 1995: Stannard 1989). For example, the host cell 
phospholipase cPLA 2u was detected in v irions (A 11 a 1 et al. 2004). and inhibition o f  
cPL A 2u activity in the v irion correlated with a decrease o f  immediate early (IE) virus 
gene expression. Over 1000 annexin II molecules are present per virus particle (Wright 
et al. 1995). and HCM V infectivity could be inhibited by treating the virus with annexin 
II-specitic monoclonal antibodies.
There have also been several reports o f  viral and host RNA being present in the virion 
(Greijer et al. 2000: Sarcinella et al. 2004: Ierhune et al. 2004). IE. early and late 
transcripts have all been detected in the tegument (Greijer et al. 2000: Sarcinella et al. 
2004). Initial reports identified a selectiv e concentration o f  specific transcripts implying 
a biological function (Sarcinella et al. 2004). However, later studies have shown that
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RNA m olecules are incorporated into the virion in proportion to their cellular 
concentration (Terhune et al. 2004). Incorporation is most likely via non-specific 
interactions with RN A-binding virion proteins such as pp28 (Terhune et al. 2004). RNA 
is also present within the capsid (Prichard et al. 1998). Viral RNA molecules bind to the 
genom e at the oriLyt region forming a persistent D N A -RN A  hybrid structure.
Investigation into H C M V  virion components have been performed predominantly using 
laboratory adapted stains. There is strong selection against m em bers o f  the UL128- 
C L 131A com plex  during fibroblast growth. It remains possible that further HCM V 
encoded v irion protein may be identified (or lost) when more detailed studies are 
performed with wild type HCM V.
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1.3 VIRUS GROWTH AND LIFE CYCLE
1.3.1 Infection And Entry
H C M V  infection can be detected in a wide range o f  cell types in vivo . including 
fibroblasts, endothelial cells, epithelial cells, smooth muscle cells, macrophages, dendritic 
cells and neuronal cells (Gerna et al. 2005; Luo et al. 2008; Sinzger et al. 2008; Sinzger et 
al. 1905; Wang et al. 2008). The replication cycle in all cell types that support productive 
infection consists o f  sev eral stages; attachment, entry. DN A replication, capsid assembly, 
D N A  encapsidation. nuclear egress, secondary envelopm ent and release (tig 1.4).
H C M V  v irions initially bind heparan sulphate proteoglycans on the cell surface 
(Com pton et al. 1993; Nowlin et al. 1991). The envelope glycoprotein gB is crucial for 
this interaction, however. gM :gN and g lLgL  are also involved (Boyle and Com pton
1998). Following the initial interaction with heparan sulphate it is thought that a series o f  
subsequent interactions with receptors and co-receptors occur to facilitate virus entry. 
Integrins. including u\ (f, integrin and Pi integrins. have been implicated in the entry 
process (Feire et al. 2004). The wide range o f  cellular targets implies the primary 
receptor should be a ubiquitous host protein, yet it is also possible that the virus exploits 
multiple cell type-specific receptors to expand its tropism. Infection is not controlled 
entirely by entry; HCM V can enter cell lines yet fail to replicate efficiently, e.g. African 
green monkey kidney cells (Hllsmore et al. 2003). Following the interaction with the host 
cell receptors the virion enters the cell by fusing directly with the plasma m embrane
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N uclear m em brane
Figure 1.4. Lifecycle of HCMV.
A) Attachment and entry. B) Uncoating and transport to nucleus. C) DNA Replication. 
D) Capsid assembly. E) Nuclear egress consisting o f  primary envelopment and de­
envelopment F) Tegumentation and secondary envelopment. G) Release. Adapted from 
(Mocarski et al. 2007).
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releasing the tegument and nucleocapsid to the cytoplasm. However, in endothelial cells 
the viruses can internalise by endocytosis (Sinzger et al. 2000) as well as by direct fusion 
(W ang et al. 2007). This process is dependent on the UL128-U L131A complex (Adler et 
al. 2006; Schuessler et al. 2008; Wang and Shenk 2005a). indicating HC M V  can utilise 
different entry pathways depending on the cell type infected.
1.3.2 Immediate Early Gene Expression
IE genes are defined as those transcribed in the presence o f  an inhibitor o f  protein 
synthesis, and thus their expression is independent o f  de novo  virus encoded gene 
expression. Four regions o f  IF gene expression have been m apped on the HCM V 
genome: the major IF gene region encodes IF1 (UF123). IE2 (U F122) and additional less 
abundant products via differential splicing. UF36 and UL37. TRS1 1RS1 and US3. By 
definition. IF genes expression is required to progress productive infection. Although IF 
genes are primarily associated with their key functions as transcriptional trans-activators, 
the majority o f  characterised H C M V  IF gene functions have been attributed to evading 
intrinsic, innate and adaptive host immunity to infection.
The expression o f  IF1 and 11:2 genes are under the control o f  the major immediate early 
promoter (M il:)  and is purported to contain the strongest enhancer element identified to 
date (Boshart et al. 1985). The core sequence elem ent that regulate the M1FP are located 
between -580 and -40 relative to the start o f  transcription and contains a remarkable array 
o f  16. 18. 19 and 21 base-pair repeats (Akrigg et al. 1985; Boshart et al. 1985; Thomsen
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et al. 1984). However, transcription has also been shown to be modulated by sequences 
lying both upstream and dow nstream  o f  the core promoter (reviewed in( Sinclair and 
Sissons 2006). The M IEP also contains binding sites for a remarkable array o f  
transcription factors, which include NF-kB and CR EB (Sambucetti et al. 1987). As well 
as being activated by a range o f  host transcription factors, the M IEP is also regulated by 
viral proteins. The tegument proteins pp71 and ppUL35 can stimulate expression from 
the M IEP (Spaete and Mocarski 1985b). Virion transactivators ensure IE gene 
expression without relying on de novo  viral gene expression or host factors.
T ranscription from the M IEP produces differentially spliced and polyadenylated 
transcripts encoding two major proteins. IE 1 p72 and IE2p86 (Stenberg et al. 1985: 
W ilkinson et al. 1984). These proteins contain the same N-terminal 85 amino acid (exons 
2 and 3) but following differential splicing IE1 fuses with exon 4 and IE2 with exon 5. 
Three less abundant products are also produced; I E 1 p38. IE2p55 and IE2p 18. These 
proteins play an important role in initiating and m aintaining gene regulation during 
infection.
1E1 stimulates expression from its own promoter, but by itself tends to be a relatively 
weak activator o f  heterologous promoters. However, by interacting with other factors, 
including IE2. it can influence gene expression.
The 1E1 gene product (IE-72K) initially traffics to and induces the disruption o f  PML- 
bodies (also known as ND 10 or PODs). PM L-bodies are punctuated intranuclear 
dom ains defined by their association with the tum our suppressor protein PML. The
20
expression o f  PM L and additional PM L-body associated protein (notably hDaxx and 
SplOO) are enhanced by interferon. PM L-bodies are believed to constitute an intrinsic 
barrier to DNA virus infection; knock down o f  PML or hDaxx using RNAi technology 
will significantly enhance the efficiency o f  HCM V infection (Tavalai et al. 2008). 1H1 
traffics to PM L-bodies and induces disruption PML bodies during the first 6 h p.i. (Ahn 
et al. 1998a; Ahn and Hayward 1997; Kelly et al. 1995; Lafem ina et al. 1989; Wilkinson 
et al. 1998). While pp71 also promotes proteolysis o f  hDaxx. 1H1 induces its dislocation 
from PM L-bodies; the site H C M V  transcription and D N A  replication. The interaction o f  
hDaxx w ith histones (H2A. H2B. H3 and H4) and chromatin-associated proteins are 
related to its capacity to recruit histone deacetylase to sites o f  transcription. HCM V 
replicates by altering the chromatin structure o f  the M IEP ( Woodhall et al. 2006). By 
preventing the recruitment o f  Daxx-dependant histone deacetylase to the site o f  
transcription. 1E1 and pp71 together act to counter an intrinsic harrier to HCM V infection 
(Hollenbach et al. 2002; Murphy et al. 2002). 1E1-72K remains in a complex with PML 
and can he seen to induce its association with m etaphase chromatin. Interestingly. IH1 
also has a similar effect on STAT-2; 1E1 thereby contributes to suppression o f  one aspect 
o f  the interferon response (Huh et al. 2008).
IE2p86 functions as a promiscuous transactivator o f  v iral and host promoter (Pizzorno et 
al. 1988) while efficiently negatively autoregulates transcription from the M IEP 
(Cherrington et al. 1991; Liu et al. 1991). 1E2-86K does not localise exactly with PML- 
bodies. but is found in discrete domains adjacent to them, in close association with input 
H C M V  genomic DNA (Ahn and Hayward 1997; Ishov et al. 1997). IE2 hinds the 15 
hase-pair c /.v repression signal (tr.v) immediately upstream o f  the transcription initiation
site (Ahn et al. 1998b; Cherrington et al. 1991; Lang and Stamm inger 1993) negatively 
regulating expression (Liu et al. 1991). Through its function as a transcriptional trans­
activator. IL2 mediates the switch from the IE to early phase o f  gene expression. At early 
and late times in infection two addition proteins are expressed from the IL2 gene. IH2p40 
and lH2p60 (Jenkins et al. 1994). While IE2p40 represses the M IEP. the other two 
proteins are required for efficient early and late gene expression by maintaining 1E2 
functions throughout infection (White et al. 2007).
UL36 and UL37 are both IE inhibitors o f  apoptosis. They are individually dispensable 
but the presence o f  one is essential for HCM V growth (Colberg-Polev 1996; Patterson 
and Shenk 1999). pUL36 codes for a protein termed vICA which blocks Fas-mediated 
apoptosis by binding to caspase 8 (Skaletskaya et al. 2001). UL37 encodes a protein 
termed v MIA. which functions downstream o f  caspase 8 to inhibit apoptosis 
(Cioldmachcr et al. 1999). While vM lA  is functionally similar to the human anti- 
apoptotic factor Bcl2. there is no sequence similarity. IE1 and IE2 also have anti- 
apoptotic functions as they both inhibit TN Fa-induced  apoptosis (Zhu et al. 1995).
In addition to being IE proteins. pT R Sl and pi RSI are both present in the virion and are 
thus introduced into cells prior to IF gene expression. pTR Sl and pi RSI prevents the 
shut-off  o f  host cell protein synthesis by interacting directly with and sequestering the 
inducible Protein Kinase R (PKR). preventing the phosphorylation o f  FIF-2« (Child et al. 
2004; Hakki et al. 2006). thereby prev enting interferon-induced inhibition o f  protein 
svnthesis.
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Li S3 encodes an HR-resident m em brane glycoprotein that inhibits antigen presentation by 
M HC class I by retaining the antigen-M H C class I complex in the HR (Jones et al. 19%). 
By preventing egress o f  MHC class 1 complexes to the cell surface, pUS3 suppresses 
M H C -1-restricted antigen presentation o f  antigen. This is this first stage in a multistep 
process o f  counterm easures against M HC class I antigen presentation that continue 
throughout infection (as discussed in section 1.5.2).
1.3.3 Early And Late Gene Expression And Regulation
Early phase gene expression is defined as that which precedes the initiation o f  viral DNA 
synthesis. Operationally, this can readily be achieved by infecting and harvesting RNA 
in the presence o f  an inhibitor o f  the HCM V DN A polymerase. Many early genes 
continue to express at the same level or greater during the late phase. True late gene 
expression is characterised by a dependency on viral DN A replication. The regulation o f  
early and late phase gene expression is incompletely understood with detailed studies 
being based primarily on the study o f  a small num ber o f  genes; (32.7, UL1 12-1 13. UL54 
and IJL34 for early gene expression and UL99. UL94 and UL44 for late gene expression 
(Biegalke et al. 2004; Isomura et al. 2008).
The most abundant early transcript. (32.7. which accounts for more than 20%  o f  viral 
transcripts, does not appear to produce a translated protein (Greenaway and Wilkinson 
1987; M cSharry et al. 2003). Rather, the 2.7Kbp RNA molecule interacts with the 
mitochondrial enzym e complex 1 (Reeves et al. 2007). to preserve mitochondrial
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m em brane integrity while suppressing apoptosis. U L 1 12-1 13 encodes four nuclear 
phosphoproteins which are in v o k e d  in the initiation o f  viral DN A synthesis (Penfold and 
Mocarski 1997; W right et al. 1988). The proteins are detectable in the nucleus o f  
infected cells 8 h post infection (p.i.) and increase in abundance through late time points; 
transcription is controlled by promoter containing A TF/C REB and IE2p86 binding sites 
(Rodem s et al. 1998). The A TF/CREB binding site is required for early expression; 
m utation o f  this binding site prevents early phase expression. The lH2p86 site modulates 
early expression and may be required for activating late transcription (Rodems et al.
1998). Early genes are also involved in gene regulation. pUL34 represses the expression 
o f  the immediate early gene US3 (Biegalke et al. 2004; LaPierre and Biegalke 2001) by 
binding a transcriptional repression element in the genes promoter comparable with the 
cr.s o f  MIEP (LaPierre and Biegalke 2001).
Few H C M V  genes are considered true late genes; transcription o f  true late genes are 
observed only after onset o f  HCM V DNA synthesis. The UL94 gene product is a 
tegum ent protein that associates with pp28 (ppUL99) (Liu et al. 2009). UL94 is a true 
late gene which is controlled by a promoter with a negative response element (NRE) and 
a positive response element (PRE) (W ing et al. 1998; W;ing et al. 1996). During the early 
phase o f  infection. 1 K2p86 and cellular p53 interact with the NRE to prev ent expression 
(W ing et al. 1998). At late times the PRE is dom inant driving expression o f  the gene. 
Another true late gene. UL99. also contains repressor elements which modulate gene 
expression (Kerry et al. 1997).
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UL44. a D N A  polymerase processivity factor, has three distinct transcription start sites 
which produce three functionally different proteins with differing kinetics (Isonuira et al. 
2007). The proximal and distal start sites produce proteins with early kinetics which are 
essential for v iral D N A  replication ( lw ayam a et al. 1994). Expression o f  the proximal 
and distal gene products are under control o f  TA TA  elements (Isomura et al. 2008). the 
middle start site produces a protein with true late kinetics (Isom ura et al. 2007). This 
gene product does not influence DNA synthesis but instead increases viral protein 
synthesis. The middle start site is controlled by a non-canonical T A T A  element (Isomura 
et al. 2008).
1.3.4 Genome M aturation And Virion Morphogenesis
Viral DN A synthesis begins as early as 15 h p.i. with progeny virus released 48 h after 
DN A synthesis (W ang et al. 2008). HCM V utilises six core herpesvirus genes for DNA 
replication: UL54. UL44. UL57. UL105. UL70 and UL102 (reviewed in (Pari 2008)).
The replication machinery forms at sub-nuclear locations defined by UL1 12-113 gene 
products producing linear genomes linked together in concatemers (M cVoy et al. 1998). 
Concurrent with DNA replication the capsid is assembled. The 5 capsid components 
form around the assembly protein precursor (pAP) creating the procapsid (Gibson et al. 
1990). pAP is then digested by the maturational protease PR to form the mature form o f  
the assembly protein (AP) (Baum et al. 1993). pAP is sufficient to provide for the 
formation o f  procapsids. hut PR is required for the incorporation o f  the viral genome into 
the nucleocapsid (Baum et al. 1993). In addition, the nuclear localisation o f  pAP and PR
is essential for virus production (N guyen et al. 2008). The encapsidation machinery, 
which consists o f  ten core proteins, recognises the concatemeric template via conserved 
p a d  and p a c2  e lem ents within the terminal a  sequence (Bogner et al. 1998; Penfold and 
M ocarski 1997). The terminase com plex threads the genom e into the capsid by 
interacting with the portal protein pUL104, and then cleaves at the p a c  sequence at the 
end o f  the genom e (Dittmer et al. 2005).
Follow ing the encapsidation o f  the genome, the nucleocapsid then buds from the nucleus. 
N uclear egress is not completely understood but is thought to consist o f  envelopm ent step 
and de-envelopm ent steps (Azzeh et al. 2006; Cam ozzi et al. 2008). Primary 
envelopm ent delivers the nucleocapsid through a remodelled nuclear lamina (Camozzi et 
al. 2008) to the perinuclear space which is then followed by a de-envelopm ent step which 
releases the nucleocapsid to the cytoplasm. The nucleocapsid is then transported to the 
cytoplasmic assem bly site (Das et al. 2007). The cytoplasmic assembly site is a structure 
consisting o f  Golgi apparatus. Trans-Golgi network and early endosomes where final 
tegum entation and secondary envelopm ent occurs (Das et al. 2007; Hom m an-Loudiyi et 
al. 2003; Sanchez et al. 2000b). While some tegum ent proteins associate with the 
nucleocapsid in the nucleus, a majority o f  them associate in the cytoplasm (Azzeh et al. 
2006; Liu et al. 2009; Sanchez et al. 2000a). Final envelopm ent occurs in an assembly 
com plex com prised o f  concentric rings o f  Golgi, trans-Golgi network (TGN) and early 
endosom es organelles (Das et al. 2007). The tegum ent proteins pp28 and pp 150 and the 
m em brane glycoprotein gO are involved in promoting the envelopm ent process (Jiang et 
al. 2008; Sanchez et al. 2000a; Sanchez et al. 2000b). Following envelopment, the virus 
particle is released from the cell by exocytosis.
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N IE Ps follow the same method o f  tegumentation and envelopm ent (Irmiere and Gibson 
1983). However, instead o f  mature nucleocapsids leaving the nucleus procapsids, still 
with pA P associated, leave the nucleus and are subsequently enveloped (Irmiere and 
G ibson 1985b). In addition to infectious virions and NIEPs, dense bodies are also 
released from the cells (Craighead et al. 1972). Dense bodies are accumulations o f  
tegum ent proteins, which are enveloped in the cytoplasm  and released.
A majority o f  the experiments studying the maturation o f  the virus have been performed 
in hum an fibroblasts. The situation is likely to be far m ore dynamic in vivo; substantial 
differences are likely to be seen as studies are performed on other cell types.
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1.4 PATHOGENESIS, LATENCY AND REACTIVATION
1.4.1 Pathogenesis
Initial infection occurs in the mucosal epithelial following direct contact with virus from 
infectious secretions from another individual (G erna et al. 2004). Infected individuals 
secrete virus in saliva, urine, breast milk, cervical secretions and semen (Zanghellini et al.
1999). Following infection, a systemic phase which distributes virus in the host can last 
for several m onths (Revello et al. 1998). HCM V replicates in a wide range o f  host cells 
including epithelial, endothelial and haematopoietic cells (HPC) (Sinzger et al. 1995; 
W ang et al. 2008) with myeloid-lineage haematopoietic  cells important for life-long 
persistence (Hahn et al. 1998). D issemination through the host is thought to be mediated 
by HPC and m ore differentiated myeloid cell type (Sinzger et al. 1995). Epithelial cells 
are the site o f  virus production and shedding into secretions (Sinzger et al. 1995), 
replication in the salivary glands and kidney tubule ductal epithelial respectively results 
in the shedding in saliva and urine (Heieren et al. 1988).
1.4.2 Latency And Reactivation
Following the primary phase o f  infection, a lifelong latent infection is established. 
Classically, latency has been characterised as the m aintenance o f  the viral genome 
without the production o f  cell free virus. However, in HCM V lifelong infection is 
associated with frequent reactivation o f  virus replication (Zanghellini et al. 1999). While
28
long-term low-level persistent replication may be involved, it is likely that a latent 
H C M V  reservoir is constantly reactivating lytic replication. Reactivation is quickly 
controlled by the cellular imm une response in im m unocom petent individuals but causes 
disease in im m unocom prom ised individuals. Haematopoietic cells (HPC) have been 
identified as a m ajor latent reservoir o f  H C M V  (Hahn et al. 1998; Taylor-W iedem an et 
al. 1991). C D 3 4 + HPC, resident in the bone m arrow  constantly renew the short-lived 
m onocyte  population (Katz et al. 1985; M etcalf  1989). HC M V  D N A  can be detected in 
myeloid precursor cells from healthy seropositive individuals indicating that they are an 
important latent reservoir o f  virus in vivo  (Hahn et al. 1998; M endelson et al. 1996).
Little is known about the initiation o f  latent infection o f  HPC. However, recently 
G oodrum  and colleagues (2007) identified the UL138 O RF as promoting latent infection 
o f  HPCs. They discovered that while low-passage clinical isolates o f  H C M V  would 
establish latent infection o f  HPC in vitro , laboratory-adapted H C M V  strains, which lack 
the U L /b ' region, would establish productive infections. By using recombinant viruses 
UL138 was identified as required for H C M V  to establish latent infection.
During latency the H C M V  genome is maintained as a circular plasmid (Bolovan-Fritts et 
al. 1999). Repression o f  immediate early gene expression is controlled by the 
transcriptional repression o f  the M IEP by chromatin (Reeves et al. 2005a; Reeves et al. 
2005b). It has been problematic to detect expression from latent genomes, several 
putative latency-associated transcripts has been identified only for them to later be 
detected during productive infection o f  fibroblasts (Kondo et al. 1996; Lunetta and 
W iedem an 2000). The only true latency associated transcript identified so far is an anti­
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sense transcript from the UL81-82 region o f  the genome (UL81-82ast) (Bego et al. 2005). 
This transcript and its protein (pUL82as) can be detected in bone m arrow from 
seropositive healthy donors in the absence o f  immediate early gene expression(Bego et 
al. 2005). As this transcript runs anti-sense to the UL82 O R F, which encodes the viral 
transactivator pp71, it is postulated that either UL81-82ast or pUL82as may affect the 
expression o f  pp71 thus affecting immediate early expression. This function may have a 
role in the control o f  latent infection.
Reactivation from latent infection causes disease. Reactivation occurs in mature cells but 
not in the BM  resident or peripheral blood circulating progenitors. Maturation o f  CD 34+ 
HPC to mature dendritic cells (DC) or monocyte-derived macrophages leads to the 
acetylation o f  histones bound to the MIEP allowing transcription and expression o f  
immediate early genes (Reeves et al. 2005b). Allogenic stimulation o f  naturally infected 
PB M C s leads to viral replication and production o f  virus from monocyte-derived 
m acrophages (Soderberg-N aucler et al. 1997). These studies suggest that virus 
reactivation is the result o f  chrom atin remodelling o f  the M IEP during cell differentiation 
which results in the induction o f  immediate early gene expression
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1.5 IMMUNE RESPONSE AND MODULATION
1.5.1 Immune Response
H C M V  infection is controlled by a combination o f  the innate and adaptive arms o f  the 
im m une response working together. However, Natural killer (NK) cells are clearly 
crucial in controlling cytom egalovirus infections in m ouse and man. Individuals with 
defects in their NK response are rare, but do exhibit greatly enhanced sensitivity to 
H C M V  (Biron et al. 1989; G um a et al. 2004). Deletion o f  N K  cells renders mice 
vulnerable to M C M V  pathology, while deletion o f  N K  resistance functions compromises 
its virulence (Bukowski et al. 1984; Jonjic et al. 2008). In allogeneic bone marrow 
transplant recipients, the rapid expansion o f  functional NK  cells can be detected w ithin 
days following HCM V infection (Hokland et al. 1988). The protective potential o f  the 
adaptive im m une response has primarily focussed on cytotoxic T cells, yet HCM V- 
specific antibody can also elicit therapeutic benefit (Lilleri et al. 2009; Reusser et al.
1991; Stone et al. 2006; Tu et al. 2006). C D 4+ and C D 8+ T cell response develop 
simultaneously, generally 10 days following detection o f  HCM V D N A  in the individuals 
blood (G am adia  et al. 2003; Lilleri et al. 2009). Adoptive transfer o f  HCM V-specific 
CD8^ T-cells transplant recipients is associated with therapeutic benefit (Cobbold et al. 
2005; Hakki et al. 2003; Manley et al. 2004; Peggs et al. 2002; Walter et al. 1995). 
HCM V-specific  C D 8+ T-cell responses to the tegum ent protein pp65 and the major 
imm ediate early protein, IE-1, are im m unodominant, however, responses to these 
epitopes are not present in all infected individuals (Borysiewicz et al. 1988; Kern et al. 
2000; Kondo et al. 2004). The H C M V-specific  C D 4+ T-cell response is also important
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for the control o f  infection (Harari et al. 2004a; Harari et al. 2002; Tamarit et al. 2004). 
IFN-y secreting C D 4+ T-cells are protective and prevent horizontal transmission from 
m other to foetus (Lilleri et al. 2007). Over 150 H C M V  ORF have been identified as 
CD4* or C D 8+ targets (Sylwester et al. 2005).
A s HCM V is cell-associated in the host and only cell-free in secretions, the antibody 
response may be important for the control o f  transmission. Sera from seropositive 
individuals has antibodies specific for envelope glycoproteins and tegum ent proteins, 
including neutralising antibodies against gB, gM :gN and gH:gL (M ach et al. 2000; 
Marshall et al. 1992; Shim am ura et al. 2006; Stinski 1976). The administration o f  high- 
titre hyperim m une globulin specific to HCM V reduced the risk o f  transplacental 
transmission (Nigro et al. 2005).
The immune response controls infection but has never been docum ented as being capable 
o f  clearing the virus. HCM V has an array o f  immune m odulating and subverting gene 
functions which have co-evolved with the immune response (Harari et al. 2004b). These 
im m une m odulation functions are required to provide for long term survival o f  the virus.
1.5.2 Downregulation O f MHC Class I
T cells recognise antigens via an interaction between their T cell receptor and the antigen- 
M H C class I com plex  on the target cell (reviewed in Smith-Garvin et al. 2009). HCM V 
infection induced the downregulation o f  M HC 1 on the cell surface and thereby inhibits 
C D 8 M H C -l-restricted cytotoxic T lymphocytes (Hengel et al. 1996; Warren et al.
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1994a). The accelerated downregulation o f  M HC class I is independent o f  132- 
microglobulin  (Beersm a et al. 1993). Four gene products are responsible for 
downregulating antigen presentation by MHC-I during H C M V  infection; US2, US3, US6 
and U S 1 1 (Noriega and Tortorella 2009). H C M V  U S 2 -1 1 deletion mutants do not 
downregulate M HC class I during infection, indeed MHC-1 is upregulated, yet 
expression o f  only one o f  the four genes will successfully downregulate M HC class I, 
indicating a redundancy o f  function (Hewitt et al. 2001; Jones and Sun 1997; Jones et al. 
1996; Noriega and Tortorella 2009; Wiertz et al. 1996).
US3 is a spliced IE gene that encodes an ER resident glycoprotein (Ahn et al. 1996; 
Misaghi et al. 2004) that binds directly to the M HC class I heavy chain immediately 
following synthesis preventing its egress to the Golgi apparatus (Jones et al. 1996). 
gpUS3 directly binds tapasin and inhibits tapasin-mediated peptide loading (Park et al. 
2004). gpUS3 is an IE protein that is expressed only transiently during the early stages o f  
infection.
Starting at early times continuing throughout infection US2 and U S 1 1 inhibit surface 
expression o f  M H C class I by degrading newly synthesised M H C class I heavy chains 
(Jones and Sun 1997; Story et al. 1999; Wiertz et al. 1996). US2 and U S 1 1 both target 
newly synthesised M HC class I to ubiquitination-dependant proteasome-mediated 
degradation (Sham u et al. 2001; Sham u et al. 1999; Story et al. 1999). The newly 
synthesised M HC class I heavy chains are dislocated from the ER to the cytosol, where 
they are degraded by the proteasome. U S 1 1 recruits Derlin-1, a protein which is involved 
in the degradation o f  misfolded ER proteins, to M HC class I (Lilley and Ploegh 2004). In
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contrast, gpU S6 binds to the transporter associated with antigen processing (TAP) in the 
lumen o f  the ER and inhibits the import o f  peptides epitopes into the ER (Ahn et al. 
1997). gpU S6 binds to TA P and prevents ATP binding and the conformational 
rearrangement induced by peptide binding (Hewitt et al. 2001). Inhibition o f  antigen 
presentation by M HC class 1 is likely to allow the virus to escape clearance by cytotoxic 
T cells.
1.5.3 Downregulation O f MHC Class II
Antigen presenting cells, including DCs and m acrophages present antigens to C D 4+ T 
cells via M HC class II. H C M V  also downnegulates M H C class II expression in antigen 
presenting cells (Lee et al. 2006). Tw o HCM V genes target both MHC-I and M H C -II:  
gpUS2 binds to H L A -D R a and HLA-DMct and promotes their degradation in the ER 
(Hegde and Johnson 2003; Tom azin et al. 1999) while gpUS3 binding to class II a /p  
com plexes preventing their association with the invariant chain (Hegde et al. 2002). The 
gpU S3-M H C-II complex moves from the ER to the Golgi apparatus bypassing the class 
II loading compartm ent, resulting in a reduction o f  peptide-loaded M HC class II 
com plexes on the cell surface. MHC-II transcription is also suppressed by HCM V 
infection causing the degradation o f  the cellular kinase JAK , which in turn inhibits a key 
transcription factor (CTIIA ) (Miller et al. 1998). cm vILlO  has also been shown to 
downregulate M HC class II expression on m acrophages(Kotenko et al. 2000; Redpath et 
al. 1999).
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1.5.4 Natural Killer Cell Evasion
Natural Killer cell function is regulated by a balance o f  activating and inhibitory signals 
received from potential targets (fig 1.5). The default situation is clearly for the NK cells 
not to be activated. In line with Klaus K arre 's  missing se lf  hypothesis, NK cells receive a 
strong inhibitory signal from receptor recognition o f  se lf  M H C -1 molecules. HCM V 
downregulation o f  endogenous MHC-1 has the potential to render HCM V-infected cells 
vulnerable to NK attack (table 1.2). The sequence o f  H C M V  strain AD  169 revealed that 
an O R F (later designated U L 18) was a MHC-I hom ologue gpU L l 8 (Beck and Barrell 
1988). The gpUL18 is expressed on the cell surface in com plex with p2-microglobulin 
and endogenous peptide (Browne et al. 1990; Fahnestock et al. 1995). Two differentially 
g lycosylated forms o f  gpUL18 have been described; an Endo H sensitive form and a 
highly-glycosylated Endo H resistant form (Griffin et al. 2005). An early study 
supported the hypothesis that gpUL18 was an N K  cell evasion function, albeit by an 
erroneous m echanism  (Reyburn et al. 1997). Its role becam e m ore contentious when 
U L 1 8 was reported to stimulate NK cell-mediated cytolysis (Leong et al. 1998). gpULl 8 
has been shown to bind the NK  cell receptor LIR-1 (Chapm an et al. 1999; Cosm an et al. 
1997); LIR-1 is an inhibitory' N K  receptor which normally binds M HC class I NK cells; 
LIR-1 binds gpUL18 with 1000 fold higher affinity than to M HC class I (Chapman et al.
1999). The conflict with respect to U L 18 function was resolved when it was shown to 
inhibit cytotoxicity mediated by LIR-1+ NK cells while activating LIR -L  populations 
(Prod’hom m e et al. 2007). The activation o f  LIR-1+ N K  cell cytotoxicity implies that 
gpUL18 interacts with an unidentified NK cell activating receptor.
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Figure 1.5. Activating and inhibitory' interactions between NK cells and target cells
The interaction between NK cell receptors and their ligands on target cells. Activating 
ligands are in green and inhibitory receptors are shown in blue. Reproduced from (Vivier 
et al. 2008).
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Table 1.2. HCMV genes implicated in NK cell modulation
HCMV gene Comment Acts on inhibitory 
receptor
UL18 MHC-1 homologue L1R1 (ILT2)
UL40 Upregulates HLA-E CD 94/N K G 2A
HCMV gene Comment Acts on activating 
receptor
UL16 Sequesters M1CB, ULBP1-2 N K G 2D
UL83 Direct binding N K p30
m iR -U L l 12 Suppresses M ICB N K G 2D
UL141 Sequesters CD  155 DN AM -1, CD96
UL142 Acts on M ICA N K G 2D
Adapted from (W ilkinson et al. 2008).
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The first H C M V  gene unequivocally demonstrated to elicit protection against NK cell 
recognition was UL40. HLA-E is a non-classical M HC molecule which is also expressed 
a trimeric com plex  with B-2m and a restricted group o f  peptides, normally derived from 
the leader sequences o f  classical MHC-1 molecules. Maturation and cell surface 
expression is dependent on acquisition o f  this endogenous peptide in a TAP-dependent 
manner. W hen expressed on the cell surface, HLA-E is then available to be recognised 
by the N K  cell inhibitory N K  receptor C D 94/N K G 2A  (Braud et al. 1998). With the 
inhibition o f  TA P  by US6, surface expression o f  H LA -E is downregulated (Tomasec et 
al. 2000). A peptide derived from the leader sequence o f  U L40 is secreted into the ER 
independently o f  TAP to both rescue and enhance surface expression o f  HLA-E. and to 
elicit protection against N K  cells (Tomasec et al. 2000; W ang et al. 2002).
The ligands for the activating receptor N K G 2D  are upregulated in response to stress 
(Groh et al. 1996). CD 94/N K G 2D  recognises seven ligands; M ICA, M ICB, ULBP 
(UL16 binding protein) 1-5 (Bacon et al. 2004; Groh et al. 1996; Kubin et al. 2001). 
H C M V  infection, notably IE1 and IE2 functions, activate the expression o fN K G 2 D  
ligands (N K G 2D L s) during the early phase o f  infection (Venkataram an et al. 2007). 
UL16 encodes a protein expressed at early times, accum ulates during infection and binds 
to M ICB. ULBP-1 and ULBP-2 retaining them in the ER (Cosm an et al. 2001; Dunn et 
al. 2003; Welte et al. 2003). By sequestering N K G 2D L s in the ER, gpUL16 prevents 
their expression on the cell surface. In support o f  UL16, UL142 acts to suppress 
expression o f  full length alleles o f  M ICA and ULBP3 (Wills et al. 2005, Wills personal 
comm unication).
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The major tegum ent protein pp65 (ppUL83) inhibits the N K  cell activating receptor 
N K p30 by binding directly with the receptor (Arnon et al. 2005). This interaction leads 
to disruption o f  NKp30-induced signalling by disrupting the interaction between NKp30 
and CD3^. The dissociation o f  CD3^ leads to reduced killing by the NK cell.
It is expected that more NK evasion functions will be discovered as research into HCM V 
progresses. The use o f  clinical isolates and different cell types will likely provide novel 
N K  m odulatory  genes.
1.5.5 The UL141 ORF Of HCMV
UL141 was identified as a potent NK evasion gene by Tom asec and colleagues (Tomasec 
et al. 2005) and is the object o f  this study. It was identified as a NK evasion gene during 
a systematic screen o f  the U L /b ' region o f  Toledo strain HCM V. UL141 expression 
protected target cells from lysis by 67%  o f  N K  cell clones tested (Tomasec et al. 2005).
It was determined that gpUL141 was downregulating the cell surface expression o f  
C D 1 55. a ligand for the NK  cell activating receptor DNAM-1 (see fig 1.6) (as described 
in section 1.6.6). gpUL141 specifically downregulates C D  155, it does not downregulate 
cell surface expression o f  the other identified DNAM-1 ligand, nectin-2. gpUL141 
prevents the maturation o f  the fully-matured cell surface form o f  CD155, retaining it 
within the cell in an immature form (Tomasec et al. 2005). The immature intracellular 
form o f  CD 155 has different glycosylation than the mature cell surface form (Bernhardt
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et al. 1994). Soluble CD  155 is able to block the interaction between CD 155-specific 
m onoclonal antibodies and CD  155 implying that there is direct interaction between 
CD155 and gpUL141.
The UL141 O R F was first described during the identification o f  the 15 kb U L/b ' region 
in the low passage clinical isolate Toledo H C M V  (Cha et al. 1996). It was predicted to 
encode an immunoglobulin-like protein (Novotny et al. 2001), however, the originally 
described sequence contained a frame shift (Dolan et al. 2004). The updated sequence 
encoded for an immunoglobulin-like protein predicted to contain a signal peptide, 
hydrophobic transm em brane dom ain and an immunoglobulin-like p-sandwich domain 
(fig 1.7). W hile absent in laboratory strain o f  H C M V , the sequence o f  UL141 is highly 
conserved between clinical isolates with between 97-100%  identity at both the nucleotide 
and amino acid level (M a et al. 2006). The UL141 protein has 50%  homology to another 
H C M V  ORF, UL14 (Davison et al. 2003), which, together, comprise the UL14 gene 
family (fig 1.2). The function o f  UL14 protein is currently unknown, but it does not 
dow nregulate CD155 (Tomasec et al. 2005).
UL141 protein (gpUL141) is detected 24 hour post infection with protein levels 
increasing during infection (Tomasec et al. 2005). gpUL141 is a glycoprotein with three 
predicted glycosylation sites which is detected as a doublet with apparent molecular 
masses o f  37 and 40 kDa. Digestion with Endo H or PNGase produced a 34 kDa 
product, similar to the predicted molecular mass (Tom asec et al. 2005). The sensitivity to 
digestion by Endo H implies that gpUL141 is resident in the endoplasmic reticulum.
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Killing
gpUL141
Figure 1.6. Downregulation of cell surface CD 155 protects cells from NK cell 
mediated lysis
A) In the absence o f  gpUL141 expression, fully mature CD 155 is expressed on the cell 
surface where it can interact with DNAM-1 on N K  cells. This interaction triggers NK 
cell to lyse the target cell. B) When gpUL141 is expressed, it retains CD 155 within the 
cell preventing the surface expression o f  CD 155 and the interaction with DNAM-1. This 
protects the cell from N K  cell-mediated lysis.
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Figure 1.7. Predicted structure of gpUL141
gpUL141 is predicted to contain a Ig-like p sandwich domain at residue 15-114 in the 
luminal domain, a hydrophobic transmembrane domain and a short cytoplasmic domain. 
Adapted from Tomasec (2005).
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At the beginning o f  this study it w as unknow n if  gpUL141 had any additional role during 
H C M V  infection. In addition to being a NK ligand, CD  155 is involved in a wide range 
o f  cellu lar function (as discussed in section 1.6) and it is possible that gpUL141 may 
m odulate these as well. A s a result o f  technical lim itation it has previously not been 
possib le to d irectly  or indirectly visualise the interaction and localisation o f  CD 155 and 
gpU L141. These issues will be addressed in this study.
1.5.6 O ther Methods O f Immune Evasion
H C M V  expresses three G protein-coupled receptor hom ologues, one o f  which is a 
functional chem okine receptor (Chee et al. 1990b). gpU S28 binds m ultiple CC 
chem okines, it has highest affinity for fractalkine yet is able to bind RA N TES (Released 
upon A ctivation, Norm al T-cell Expressed and Secreted), MCP-1 (M onocyte 
C hem oattractant Protein 1) and M IP -la  and p (m acrophage inflam m atory protein) (Gao 
and M urphy 1994; Kledal et al. 1998; Kuhn et al. 1995). Follow ing interaction with 
chem okines, gpU S28 signals by m odulating the activity  o f  the transcription factors 
N FA T  (nuclear factor o f  activated T-cells) and CR EB  (cA M P response elem ent) 
(B illstrom  et al. 1998; M cLean et al. 2004). W hile gpU S28 signalling has been 
im plicated in cell m igration (S treblow  et al. 1999), continuous internalisation o f  
chem okines by gpU S28 has also been dem onstrated  to result in a reduction o f  
ex tracellu lar chem okine concentration (Bodaghi et al. 1998). H CM V  also a small soluble 
secreted R A N TE S binding protein, pUL21 A, w hich acts as a decoy receptor (W ang et al. 
2004a). pUL21 A and pU S28 m ay w ork in harness to suppress chem okine function.
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U L 146 is a highly variable O R F (B radley et al. 2008) w hich encodes for a potent a  
chem okine. term ed vCXC-1 (Penfold  et al. 1999). This is a fully functional chem okine 
w hich can induce chem otaxis and degranulation o f  neutrophils. H CM V  also encodes a 
hom ologue o f  interleukin 10 (IL-10), term ed cm vlL -10  (K otenko et al. 2000; Lockridge 
et al. 2000). cm vlL -10  functions in a sim ilar m anner as its hum an hom ologue and has 
been show n to inhibit interferon release by dendritic cells and cytokine release by 
m onocytes (C hang et al. 2009; N achtw ey and Spencer 2008; Spencer et al. 2002).
H C M V  encode tw o im m unoglobulin  G Fc receptors, R L 1 1 and U L 1 19, w hich are present 
on the p lasm a m em brane o f  infected cells and on the envelope o f  the virions (A talay et al. 
2002; Lilley et al. 2001; X u et al. 1989). These receptors bind the constant Fc region o f  
IgG m olecules. A process called antibody bipolar b inding is thought to protect the virus 
from  the com plem ent pathw ay (Frank and Friedm an 1989). A ntibody bipolar binding is 
w hen the Fc receptor binds the Fc region o f  an im m unoglobulin  m olecule w hile the Fab 
region binds to its antigen on the virion. This process has been show n to resist 
com plem ent-m ediated  neutralisation and antibody-m ediated  cellu lar cytotoxicity in HSV 
(D ubin  et al. 1991; Frank and Friedm an 1989).
H C M V  also controls the com plem ent pathw ay by upregulating the host regulators o f  
com plem ent activation CD 55 and CD 46 (Spiller et al. 1996). Host regulators o f  
com plem ent activation suppress the activation o f  C3 convertase on virus-infected cells 
providing a m echanism  to protect H C M V -infected cells from  com plem ent m ediated lysis. 
This technique is also utilised in the virions; CD55 and another com plem ent control 
protein. C D 59. are incorporated into the virion envelope (Spear et al. 1995).
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pp65 also m odulates the interferon response. It inhibits the transcrip tion factors N F -kB 
and IRF-1 inhibiting pro-inflam m atory responses (B row ne and Shenk 2003) and 
dow nregulating  IRF3 (interferon regulatory factor 3) (A bate et al. 2004).
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1.6 PROPERTIES AND FUNCTIONS OF THE NECTIN AND NECTIN-LIKE
FAMILY
1.6.1 Nectin And Nectin-Like Family
The nectin and nectin-like (necl) m olecules are a fam ily o f  im m unoglobulin-like cell 
adhesion m olecules (Takai et al. 2008b). M em bers o f  the fam ily are involved in cell-cell 
adhesion, polarisation, d ifferentiation, m ovem ent and proliferation (Takai et al. 2008a). 
N ectins are prim arily involved in the regulation o f  various types o f  cell-cell contacts 
including A dherin Junctions (A J) and the form ation o f  tight junctions (TJ) (K uram itsu et 
al. 2008; Takahashi et al. 1999) (table 1.3). N eels have m ore diverse functions including 
m ediating interactions betw een axons and glial cells, regulation o f  cell m ovem ent and 
proliferation (see table 1.3) (B oles et al. 2005; Ikeda et al. 2004; K akunaga et al. 2005; 
Spiegel et al. 2007). The fam ily consists o f  four nectins (n ec tin -1, -2. -3 and -4) and five 
nectin-like m olecules (n ec l-l, -2, -3, -4 and necl-5/C D 155) w hich are ubiquitously 
expressed. All m em bers share the sam e general structure o f  three extracellu lar 
im m unoglobulin-like loops, a transm em brane dom ain and a cytoplasm ic dom ain (Takai 
et al. 2008a).
The first m em ber o f  the nectin and necl fam ily to be characterised was C D 155; this was 
due to its im portant function as the cellular receptor for poliovirus (PV R ) although it can 
also be called necl-5, or Tage4 (B ernhardt et al. 1994; M endelsohn et al. 1989). 
Subsequently , n ec tin -1 and nectin-2 were show n to be related to CD 155 (hence their
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Table 1.3. The Nectin and Nectin-like (Necl) Family
Name Alternative
Nomenclature
Function Reference
N e c tin -1 PRR-1, HVEC Cell-Cell adhesion 
Receptor for a-herpesviruses 
entry
(G eraghty et al. 
1998)
N ectin-2 PRR-2, HVEC Cell-Cell adhesion 
Receptor for a-herpesviruses 
entry
(Aoki et al. 
1997; W arner 
et al. 1998)
N ectin-3 PRR-3 Cell-Cell adhesion (Satoh-
H orikaw a et al. 
2000)
N ectin-4 PRR-4 Cell-C ell adhesion (Reym ond et 
al. 2001)
N ecl-l TSLL1. SynCAM 3 N eural tissue-specific ce ll­
cell adhesions.
(K akunaga et 
al. 2005; 
M aurel et al. 
2007)
Necl-2 IGSF4, RA175, 
SglG SF, TSLC1, 
SynC A M l
Cell-Cell adhesion m olecule 
localised to the basolateral 
m em brane in epithelial cells
(Shingai et al. 
2003)
N ecl-3 SynC A M 2 Neural tissue-specific  ce ll­
cell adhesions
(Pellissier et al. 
2007)
N ecl-4 TSLL2. SynCA M 4 Neural tissue-specific  ce ll­
cell adhesions. M ediates 
m yelination.
(M aurel et al. 
2007; Spiegel 
et al. 2007)
CD  155 N ecl-5, Tage4, PVR Poliovirus receptor. Ligand 
for activating NK receptor 
DN A M -1.
(Ikeda et al. 
2003;
M endelsohn et 
al. 1989)
47
initial nam es poliovirus receptor related (PR R )-l and -2), and w ere dem onstrated to be 
co-receptors for alphaherpesviruses (G eraghty et al. 1998; M artinez and Spear 2001). 
N ectins and necls are predom inantly  adhesion m olecules that form  stable interactions 
w ith m em bers o f  the nectin fam ily, although som e exceptions interact w ith other 
im m unoglobulin-like m olecules. C haracteristically , nectins and necls are expressed as 
c/.v-homodimers on the plasm a m em brane (Tachibana et al. 2000), and these hom odim ers 
participate in hom ophilic /ram -in te rac tions to their partners on an adjacent cell; all 
nectins, necl-l and -2 bind in this fashion. H eterophilic trans-interactions form when the 
nectin or necl bind to another fam ily m em ber on another cell, all nectins and necls 
d isplay lim ited heterophilic binding capabilities (fig 1.8). The dom ains o f  nectins bind 
uncooperatively  in a zipper-like m ultiply bonded system  (Tsukasaki et al. 2007).
The cytoplasm ic regions o f  nectins associate w ith afadin and tc tex -l(M andai et al. 1997; 
M ueller et al. 2002). A fadin is an actin filam ent-binding protein w hich via the interaction 
betw een actin and the cytoplasm ic dom ain o f  nectins connects A Js to the cytoplasm ic 
cy toskeleton (M andai et al. 1997). N ectins and necls are differentiated by their ability to 
bind afadin; nectins interact directly with afadin w hile necls do not (Ikeda et al. 1999; 
M andai et al. 1997). Tctex-1. a com ponent o f  the dynein m icrotubule m otor com plex, 
interacts w ith the cytoplasm ic dom ain o f  CD 155 and targets CD  155 containing vesicles 
to the m icrotubule netw ork (O hka et al. 2004).
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Nectin-4 CD96 DNAM-1
Nectin-2Nectin-1 Nectin-3Necl-4
CRTAMNecl-2Necl-3 Necl-1
Figure 1.8. Interactions between Nectins and Necls.
N ectins, necls and o ther im m unoglobulin  fam ily m em bers form heterophilic trans-dim ers 
(straight lines) o r H om ophilic trans-dim ers (curved arrow s). C ross denotes no 
interaction. Q uestion m ark denotes interaction not determ ined. A dapted from (Takai et 
al. 2008b).
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1.6.2 Nectins And Cell-Cell Adhesion
N ectins have a m ajor role in the form ation o f  adherens junctions (Takahashi et al. 1999). 
Together w ith m em bers o f  the cadherin fam ily o f  cell adhesion m olecules, nectins form 
cell-cell contacts connected to the actin cytoskeleton (Tachibana et al. 2000). W hile 
nectins and cadherins localise at AJs, necls do not. N ectin-nectin  interaction initiates the 
form ation o f  AJs. Follow ing the nectin interaction, cadherins are recruited to the site o f  
cell-cell contact (Takahashi et al. 1999). Once the cadherins are incorporated into the AJ. 
the cytoplasm ic tail o f  cadherin binds the F-actin binding proteins a-catenin, a-actinin 
and vincilin  which anchor the cadherins to the actin cytoskeleton (Tachibana et al. 2000).
An im portant com ponent o f  the AJ is the integrin civp3, w hich m odulates the stability o f  
the cell-cell contact (Sakam oto et al. 2006; Sakam oto et al. 2008). Nectin-1 and -2 
physically  associate with integrin a v p 3 in cis (Sakam oto et al. 2008). This interaction is 
essential for AJ form ation and for dow nstream  nectin signalling.
A series o f  signalling reactions occur follow ing nectin /raw s-interactions that result in the 
dynam ic sequential rem odelling o f  the actin cytoskeleton (fig 1.9). Follow ing nectin- 
nectin interaction the tyrosine kinase Src is recruited and activated in an integrin av p 3- 
dependant m anner (Fukuyam a et al. 2005). Src then activates the small G protein R apl 
through the adapter proteins Crk and C3G (the guanine nucleotide exchange factor for 
R a p l) (Fukuyam a et al. 2005). Src also phosphorylates FRG (the guanine nucleotide 
exchange factor for Cdc42) and Vav2 (the guanine nucleotide exchange factor for Rac)
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Figure 1.9. Nectin-dependant intracellular signalling.
Hetero- o r hom ophilic rra/w-interaction o f  nectins leads to the reorganisation o f  the actin 
cytoskeleton. Reproduced from (Fukuyama et al. 2005).
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(Fukuhara et al. 2004; K aw akatsu et al. 2005). A ctivated R ap l activates phosphorylated 
FRG w hich activates Cdc42. Cdc42 then activates phosphorylated Vav2 which induces 
activation o f  Rac (Fukuhara et al. 2004). The activation o f  Rac and Cdc42 induces the 
form ation o f  filopodia and lam ellipodia (Takahashi et al. 2008). W hile these protrusions 
are generally associated with cell m ovem ent they increase the num ber o f  cell-cell 
contacts and reduces the intercell distance enhancing cell-cell adhesion (V asioukhin et al. 
2000).
1.6.3 CD155
The CD  155 gene contains 7 introns (K oike et al. 1990) w ith alternate splicing producing 
four recognised variants o f  CD 155; a . p, y and 6 (K oike et al. 1990). CD  155a and 8 are 
transm em brane proteins w hile C D 155p and y are secreted (B aury et al. 2003). Little is 
know n about the function o f  the alternatively spliced form s o f  C D  155. Soluble CD 155 is 
expressed in that form  (not produced by proteolysis), is present in hum an serum  at 
nanom olar concentrations and can com pete with m em brane-bound CD 155 to inhibit 
poliovirus entry (B aury et al. 2003). The CD 155 core prom oter is approxim ately 280bp 
long and contains binding sites for G lil,  Gli3. AP2 and nuclear respiratory factor (N RF)- 
1; these transcrip tion factors have all been show n to bind the prom oter to enhance 
expression  (Solecki et al. 2000; Solecki et al. 1999; Solecki et al. 2002). CD 155 
expression has been show n to be controlled by sonic hedgehog (SH H ), SHH is a 
m orphogen that is involved in the developm ent o f  m any structures during developm ent 
(Solecki et al. 2002). The transcription factors im plicated in CD  155 expression also have
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a role in em bryogenesis, consistent with CD 155 having an im portant role during 
developm ent (Solecki et al. 2002). Indeed, a focussed study has dem onstrated C D 155 is 
im portant in the developm ent o f  the rat liver (Erickson et al. 2006).
CD 155 alone is sufficient to act as the cellular receptor for poliovirus (K oike et al. 1990) 
(H ogle 2002; M endelsohn et al. 1989). Follow ing binding, CD  155 induction o f  tyrosine 
k inases and SH P-2 signalling is required to prom ote caveola endocytosis (B randenburg et 
al. 2007; C oyne et al. 2007). In neuronal cells, the retrograde transport o f  the endosom es 
to the nucleus is dependant on CD 155 interaction w ith the dynein-light chain Tctex-1 
(O hka et al. 2004). W hile the m ouse hom ologue o f  CD 155 (originally  term ed Tage4, 
now  standardised to necl-5) has a high level o f  structural and functional identity to hum an 
CD  155. it does not allow  poliovirus entry (B aury et al. 2001; Ravens et al. 2003). The 
poliovirus b inding capabilities o f  CD 155 is restricted to prim ates (Suzuki 2006). 
H ow ever, the expression o f  hum an C D 155 in m ouse cells is sufficient to confer 
poliovirus susceptibility (K oike et al. 1990). CD 155 also acts as a cellular receptor for 
viruses other than poliovirus, including porcine psuedorabies virus and bovine 
herpesvirus 1 (G eraghty et al. 1998).
1.6.4 CD 155 And Cell Movement.
U nlike nectins, CD  155 localises to the leading edge o f  m oving cells where it associates 
w ith the p latelet-derived grow th factor (PD G F) receptor and w ith integrin ay p 3 (Am ano 
et al. 2008; Ikeda et al. 2004; M inam i et al. 2007a). C D 155 has an im portant role in the
dynam ics o f  the leading edge. S tim ulation o f  CD 155 enhances cell m igration (O da et al.
2004). C D 155 enhances PD G F-induced and avp3-induced signalling (K akunaga et al. 
2004; M inam i et al. 2007a). CD  155, PD GF receptor and civP3 integrin can each form 
heterodim ers with either o f  the o ther tw o m olecules; C D 155:PD G F receptor, CD 155: 
a v p 3 in tegrin  and PD GF receptor:avP3 integrin can all be form ed (A m ano et al. 2008).
C D 155 and a vP3 integrin also co-localise at focal com plexes (A m ano et al. 2008; 
N agam atsu  et al. 2008). Focal com plexes are im m ature cell-ex tracellu lar m atrix 
adhesion sites that form  at the leading edge. As the focal com plexes m ature into focal 
adhesions CD  155 disassociates leaving a \  P3 integrin in the focal adhesion (B allestrem  et 
al. 2001; N agam atsu  et al. 2008).
Follow ing PD G F-induced cell m ovem ent, actin cytoskeleton reorganisation is regulated 
by C dc42, Rac and Rho (N agam atsu  et al. 2008; Sato et al. 2005). Cdc42 and Rac induce 
the form ation o f  cytoplasm ic protrusions, w hile Rho negatively regulates this process. 
PD G F receptor signalling leads to the dow nregulation o f  cell-surface PD GF receptor by 
endocytosis (A m ano et al. 2008). This leads to the inactivation o f  R apl and the 
activation o f  Rho kinase, which dissociates CD 155 from  focal com plexes. The PDGF 
receptor is then  re-recruited to the leading edge to start a new  cycle o f  signalling.
An integral part o f  directional cell m ovem ent is the reorganisation o f  the m icrotubule 
netw ork. The association o f  the cytoplasm ic dom ain o f  C D 155 with the tc te x l , a 
com ponent o f  the m icrotubule m otor com plex dynein, m ay supply a connection betw een 
the leading edge and m icrotubule netw ork (M ueller et al. 2002).
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1.6.5 CD155 In Contact Inhibition Of Movement And Proliferation
W hen cells com e into contact with each other m ovem ent and proliferation cease. The 
loss o f  contact inhibition is frequently associated w ith cancerous and transform ed cells. 
CD  155 has an im portant function in both contact inhibition and the loss o f  contact 
inhibition (M inam i et al. 2007b; Sloan et al. 2004; Sloan et al. 2005).
As C D 155 is concentrated at the leading edge o f  m oving cells m eaning that initial 
interaction is m ediated by CD 155 and nectin-3 (Fujito  et al. 2005; Ikeda et al. 2003). The 
initiation o f  contact also occurs w hen two independently  m oving cells m eet; afadin in the 
leading edges recruits nectin-3 to the site o f  contact (M inam i et al. 2007b; Sato et al.
2004). The initial binding o f  CD  155 with nectin-3 is a transient interaction that leads to 
the dow nregulation o f  C D 155 in a clatharin dependant m anner. Nectin-3 rem ains at the 
cell surface form ing stable interactions with o ther nectins initiating the form ation o f  AJs 
(Sato et al. 2004; Satoh-H orikaw a et al. 2000). The dow nregulation o f  C D 155 disrupts 
the C D 155-PD G F receptor- a v p 3 integrin com plex resulting in a reduction in cell 
m ovem ent (A m ano et al. 2008; Fujito et al. 2005). This together with the initiation o f  AJ 
form ation causes the cell to arrest.
CD  155 is also involved in the inhibition o f  proliferation follow ing contact (Fujito et al.
2005). C D 155 regulates cell proliferation by enhancing grow th factor-induced activation 
o f  signalling pathw ays including Ras, R af and ERK (K akunaga et al. 2004). 
D ow nregulation o f  C D 155 follow ing interaction w ith nectin-3 prevents the enhancem ent 
o f  these pathw ays, reducing cell proliferation. The cytoplasm ic tail o f  CD 155 interacts 
w ith sprouty2, a negative regulator o f  grow th (K ajita  et al. 2007). W hen C D 155 is
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expressed on the cell surface the interaction betw een CD 155 and sprouty2 prevents the 
phosphorylation o f  sprouty2. Follow ing the dow nregulation o f  C D 155, sprouty2 is 
released and phosphorylated by Src. Phosphorylated sprouty2 inhibits PD G F-induced 
Ras w hich in turn inhibits cell proliferation.
C ancerous cells lose contact inhibition leading to excessive proliferation and invasion.
An upregulation o f  CD  155 is a com m on feature o f  m any prim ary tum ours and 
transform ed cell lines (M asson et al. 2001; Sloan et al. 2004). U pregulation o f  C D 155 
can m ake cell lines m etastatic and knock dow n o f  CD  155 can inhibit cancer developm ent 
(Sloan et al. 2005). The loss o f  contact inhibition can partly be explained by the 
upregulation o f  CD  155 in cancerous cells. The rate o f  de novo  CD  155 synthesis is 
greater than the rate o f  internalisation leading to a net increase o f  C D 155 on the cell 
surface (M inam i et al. 2007b). W ith the continuous high level cell surface expression o f  
CD  155 there is no inhibition o f  m ovem ent or proliferation signals resulting in a loss o f  
contact inhibition.
1.6.6 CD155 In Immune Responses
In addition to its other roles. CD  155 also interacts w ith the im m une system  (M aier et al. 
2007). CD 155 interacts with DNAM-1 (C D 226) (B ottino et al. 2003; Tahara-H anaoka et 
al. 2004) and C D 96 (Tactile) (Fuchs et al. 2004; Seth et al. 2007) on im m une cells 
triggering responses (Fuchs and C olonna 2006) (fig 1.5).
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DNAM -1 is a transm em brane im m unoglobulin-like adhesion m olecule that was first 
identified as a T cell-specific activation m arker (originally called TLiSA -1) (Burns et al. 
1985) then subsequently  identified as a m arker o f  platelet activity as well (term ed PTA-1) 
(Scott et al. 1989). DNAM-1 is expressed on N K  cells, m onocytes, T cells and a sub-set 
o f  B cells (Shibuya et al. 1996). The expression o f  DNAM -1 on m onocytes and T cells 
can be m odulated by cytokines via the transcription factors AP-1 and Ets-1 (Jian et al. 
2006). DNAM -1 binds CD  155 and nectin-2 (B ottino et al. 2003; Pende et al. 2005a; 
Tahara-H anaoka et al. 2004) triggering N K  cell cytotoxicity  and enhances cytotoxic T 
lym phocytes cytotoxicity  (Shibuya et al. 1996). Follow ing ligation, the cytoplasm ic tail 
o f  DNAM -1 is phosphorylated by the protein kinase C (Shibuya et al. 1998) activating 
the tyrosine kinase Fyn (Shibuya et al. 1996) and recruiting the actin binding proteins 
protein 4 .1G and hum an discs large (R alston et al. 2004). Subsequent dow nstream  
DNAM -1 signalling  is dependent on the physical association o f  DNAM-1 with the 
integrin LFA-1 in lipid rafts (R alston et al. 2004; Shibuya et al. 2003; Shirakaw a et al.
2006).
M any cancerous cell lines and prim ary tum ours constitu tively  over express CD155 which 
can be killed by N K  cells (Tahara-H anaoka et al. 2006). N K  cells have been show  to kill 
ovarian  carcinom a cells, neuroblastom a cells, m yeloid leukaem ias and lym phoblastic 
leukaem ias m ediated CD 155-D N A M -1 interaction (C arlsten et al. 2007; Castriconi et al. 
2004; Pende et al. 2005b). This interaction is likely part o f  im m unosurveillance for 
tum ours. DNAM -1 is also involved in the d ifferentiation o f  T h l T cells (D ardalhon et al.
2005) and m ay protect against Fas ligand induced apoptosis (Tao et al. 2005).
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The CD 155-D N A M -1 interaction m ay also enhance the m etastasis o f  cancerous cells 
(M orim oto et al. 2008). A n interaction betw een C D 155 on the cancerous cells and 
DNAM -1 on platelets results in the arrest o f  the cancerous cells in pulm onary vessels and 
subsequent entry into tissue (M orim oto et al. 2008). D epletion o f  platelets reduced the 
rate o f  m etastasis into the lungs.
C D 155 also interacts w ith CD 96 (Fuchs et al. 2004). CD 96 w as first identified as a T 
cell activation antigen and originally called Tactile (T  cell activation, increased late 
expression) (W ang et al. 1992). It is an Im m unoglobulin superfam ily m em ber with 
hom ology to both CD 155 and DNAM1 (Shibuya et al. 1996; W ang et al. 1992). CD 96 is 
expressed on T cells and N K  cells and binds CD 155, but not nectin-2. Ligation o f  CD96 
w ith CD 155 enhances N K  cell-m ediated cytotoxicity. H ow ever, CD 96 does not directly 
enhance killing, rather it increase the stability o f  the cell-cell contact (Fuchs et al. 2004). 
The increased stability o f  the cell-cell interaction allow s for more efficient killing. Little 
is know n about the intracellular signalling induced by ligation o f  CD 96. The cytoplasm ic 
tail contains a putative im m une receptor tyrosine-based inhibitor receptor (ITIM ), 
how ever, ligation o f  CD 96 enhances rather then inhibits N K  cell cytotoxicity (Fuchs et 
al. 2004).
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1.7 AIMS
Interest in UL141 has focused on its role in suppressing cell surface expression o f  the 
pow erful NK cell activating ligand CD 155. H ow ever, CD 155 has im portant roles in 
regulating cell m otility , grow th and in intercellular signalling. The dow nregulation o f  
CD  155 by UL141 has the potential to im pact significantly on the biology o f  the host cell. 
This study sought to gain a greater appreciation o f  the role played by UL141 during 
productive H C M V  infection. To this end I had the fo llow ing aim s:
1) To characterise the effects o f  gpUL141 expression on cell adhesion and motility.
2) To investigate the physical relationship betw een CD 155 and gpUL141
3) To determ ine w hether gpUL141 is a com ponent o f  the H C M V  virion
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2 MATERIALS AND METHODS
2.1 SOLUTIONS
A m picillin  stock
A m picillin  (S igm a-A ldrich, Poole, UK ) w as dissolved in water at 
50m g/m l and stored at -20°C.
C hloram phenicol stock
C hloram phenicol (S igm a-A ldrich) was dissolved in ethanol at 
12.5mg/ml and stored at -20°C.
0 .1%  Crystal vio let solution
0.1%  (w /v) Crystal violet (BD H  ltd. Poole, UK) was dissolved in 
phosphate buffered solution (PB S) and filtered through a 0.2pm  
filter.
D A B C O
2%  (w /v) l,4-D iazabicyclo[2 ,2 ,2]octane (D A B C O ) (Sigm a-A ldrich) 
and 10% PBS in glycerol (F isher Scientific, Loughborough, UK)
D N A  loading buffer
30%  glycerol in de-ionised w ater w ith 0.25%  (w/v) brom ophenol 
blue (S igm a-A ldrich) in 0.25%  (w /v) xylene cyanol FF (Sigm a- 
A ldrich).
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Freezing m ixture
90%  foetal c a lf  serum  (FCS) and 10% (v/v) dim ethyl sulphoxide 
(D M SO ) (S igm a-A ldrich)
IPTG Stock
23.8m g Isopropyl P -D -l-th iogalactopyranoside (IPT G ) (M elford, 
Ipsw ich) dissolved in 1ml w ater to generate a lOOmM stock solution.
K anam ycin stock
K anam ycin (Roche, M annheim , G erm any) w as dissolved in w ater at 
50m g/m l and stored at -20°C.
Luria Bertani (LB) agar
As for LB broth but with 1.5% (w /v) agar (F isher Scientific) added 
before autoclaving. A ntibiotics w ere added before setting in plates.
LB broth
1% (w /v) tryptone, 1% (w /v) sodium  chloride (S igm a-A ldrich) 0.5%  
yeast extract (S igm a-A ldrich) dissolved in w ater then autoclaved.
LB sucrose selection plates
1% (w /v) tryptone, 0.5%  (w /v) yeast extract (S igm a-A ldrich), 5% 
(w /v) sucrose 1.5% (w /v) agar (S igm a-A ldrich) dissolved in w ater 
then autoclaved. 1:1000 chloram phenicol stock, 1:500 X-gal stock 
and 1:500 IPTG stock w ere added before setting in plates.
20%  N P40 5%  deoxycolate stock
20%  (v/v) N P-40 alternative (C albiochem , California, USA) and 5% 
(w /v) sodium  deoxycholate (S igm a-A ldrich) dissolved in sodium 
phosphate buffer.
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PBS
One PBS tablet (O xoid, Ham pshire, UK) w as dissolved per 100ml 
w ater to generate buffer containing 8% (w /v) sodium  chloride, 0.2%  
(w /v) potassium  chloride, 1.15% (w/v) disodium  hydrogen 
phosphate and 0.2%  (w /v) potassium  dihydrogen phosphate at 
pH7.3.
PBST
PBS with 0.1%  Tw een-20 (F isher Scientific)
10% SDS stock
10% (w/v) sodium  dodecyl sulphate (SD S) (Fisher Scientific) 
dissolved in sodium  phosphate buffer 
SD SPA G E sam ple buffer
0.225M  tris(hydroxym ethyl)am inom ethan (Tris)-C l, pH 6.8, 50%  
(v/v) glycerol, 5%  (w /v) SDS, 0 .05%  (w /v) brom ophenol blue,
50m M  dithiothreitol (S igm a-A ldrich) and 1% (v/v) 2- 
m ercaptoethanol (S igm a-A ldrich) were m ade to 10ml with water. 
Sem i-dry transfer buffer
48m M  Tris, 39m M  glycine (S igm a-A ldrich), 1.3mM SDS and 200ml 
m ethanol m ade up to 11 with w ater.
35%  Sodium -tartrate buffer
35%  (w/v) sodium  tartrate (S igm a-A ldrich) dissolved in sodium  
phosphate buffer.
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15% Sodium -tartrate/ 30%  glycerol buffer
15% (w/v) sodium  tartrate dissolved in 30%  (v/v) glycerol and 
sodium  phosphate buffer.
Sodium  phosphate buffer
4.8g sodium  dihydrogen phosphate (BD H  Ltd, Poole, UK) was 
dissolved in 11 w ater to generate a 0.04M  solution. 5.7g disodium  
hydrogen phosphate (S igm a-A ldrich) was d issolved in 11 w ater to 
produce a 0.04M  solution. The solutions w ere m ixed to produce a 
buffer with final concentrations o f  7.6m M  sodium  dihydrogen 
phosphate and 0.032M  disodium  hydrogen phosphate.
TA E (50x)
242g Tris base, 57.1m l glacial acetic acid (F isher scientific) and 
100ml 0.5M  ethylenediam inetetraacetic acid (ED TA ), pH 8.0 were 
m ixed with w ater in a final volum e o f  11.
0.7%  TA E agarose gel
0.7g agarose (Invitrogen) dissolved in 100ml TAE buffer by heating, 
then poured into a m ould and left to set at room  tem perature.
Tris B uffer
10ml o f  1M Tris-Cl pH 7.4 w as m ixed w ith 2ml 0.5M  EDTA, pH8.0 
w ith w ater added to a final volum e o f  11.
1M Tris-Cl
121.1 g Tris base was dissolved in 11 w ater and adjusted to desired 
pH with hydrogen chloride.
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0.5% Triton X-100
0.5%  (v/v) T riton X-100 (Sigm a-A ldrich) w as dissolved in water.
X-gal stock
5-brom o-4-chloro-3-indoyl-p-D -galactopyranoside (X -gal) (M elford, 
Ipswich) w as dissolved in N ,N -dim ethyl form am ide (D M F) (Sigm a- 
A ldrich) to generate a 40m g/m l stock solution. A liquots were stored 
at -20°C.
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2.2 CELL CULTURE
2.2.1 Cells
H um an foreskin foetal fibroblasts (H FFF) (kindly supplied by D r G. Farrar, Porton 
D ow n) w ere im m ortalised with hum an telom erase reverse transcrip tase by S Llewellyn- 
Lacey as described in M cSharry et a l  (2001). H FFF w ere m aintained in 175cm2 tissue 
culture flasks in DM EM -10. 293 cells (kindly provided by F G raham , M cM aster 
U niversity), 293 cells stably expressing gpU L 141G FP and G FP (293-U L141G FP and 
293-G FP, kindly provided by D r P Tom asec (Tom asec et al. 2005), 293-TR Ex cells 
(Invitrogen). hum an Caucasian glioblastom a-astrocytom a U373 (kindly provided by Dr 
M. W ills, C am bridge U niversity), and U373 cell lines stably expressing CD 155Y FP 
(kindly provided by Prof. G W ilkinson) were m aintained in 175cm2 tissue culture flasks.
All cell lines w ere grown in incubators at 37°C in 5%  CCE-
2.2.2 Passage O f Cell Lines
C onfluent m onolayers o f  adherent cells were passaged by rem oving m edium , washing 
with PBS then incubating the m onolayer w ith an appropriate volum e o f  trypsin/ED TA  
(Invitrogen) until the cells detached. An equal volum e o f  fresh D M EM -10 was then 
added to inhibit the trypsin and the cells were split betw een 1:2 and 1:5 with fresh
D M EM -10 and added to a 175cm2 tissue culture flask.
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2.2.3 Transfection Of DNA
2.2.3.1 Transfection With Effectene
Cells w ere transfected w ith Effectene transfection reagent (Q iagen, Sussex, UK) 
according to the m anufactu rer's  protocols. This technique gave high transfection 
efficiency for 293 and U373 cells (greater than 80%  efficiency) but was less efficient 
transfecting fibroblasts (less than 10% efficiency). P lasm ids used for transfections are 
described in table 2.1. Cells seeded at 40 to 80%  confluency in 6 well tissue culture plates 
w ere used for transfection. 0 .4pg  o f  DNA w as diluted in EC buffer to a total volum e o f  
lOOpl then 3.2pl o f  enhancer was added. Follow ing b rie f  m ixing and incubation at room 
tem perature for 5 m inutes, lOpl o f  Effectene transfection reagent w as added. The DNA- 
Effectene reagent m ixture was incubated for a further 5 m inutes then m ixed with fresh 
D M EM -10 and added to the cells. The cells were then incubated for three days at 37°C 
for three days then used in the appropriate assay.
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Table 2.1. Transfection vectors
Name Background Generated by Official
Designation
pE Y FP-N l n/a C lontech (C alifornia, USA) pAL 839
pEC FP-N  1 n/a C lontech (C alifornia, USA) pAL 295
pC D 155Y FP pAL 839 D. Cochrane pA L 880
pC D 155C FP pAL 295 D. Cochrane pAL 881
pUL141 YFP pAL 839 D. Cochrane pAL 882
pU L 141C FP pAL 295 D. Cochrane pAL 883
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2.2.3.2 Transfection With Nucleofector
For h igher efficiency o f  fibroblast transfection A m axa basic N ucleofector kit for primary 
m am m alian fibroblasts (Lonza, C ologne, G erm any) w as used according to the 
m anufactu rer's  protocol. Recently passaged fibroblasts at approxim ately 80-90%  
confluency w ere detached from the grow th substrate with trypsin and resuspended in 
fresh D M E M -10. 1 x 106 cells per transfection w ere then centrifuged at 90g for 10 
m inutes at room  tem perature then resuspended in lOOpl per transfection o f  N ucleofector 
solution. 1 OOpl o f  the cell suspension w as m ixed w ith 2pg o f  D N A  and added to a 
N ucleofector cuvette. The cuvette was then place in a N ucleofector II device and 
electroporated  on program  TO 16. Follow ing electroporation the cuvette w as rem oved 
from  the device and free pre-w arm ed m edia w as added to the cell suspension then 
transferred  to a six well tissue culture plate. The cells w ere then incubated for three days 
at 37°C for three days then used in the appropriate assay.
2.2.4 Lentivirus Vector Delivery To Human Fibroblasts
C onfluent fibroblasts in 12 well tissue culture plates were infected w ith one o f  five 
lentiviral vectors expressing CD 155 specific shR N A s (Sigm a) or w ith a lentiviral vector 
expressing scram ble RNA (Sigm a) for 20 hours in a m inim al volum e o f  D M EM -10 with 
8pg hexadim ethrine brom ide at M OIs o f  1, 5 and 10. The virus w as then rem oved from 
the cells and fresh m edia was added. A fter incubation for 3 days the m edia was replaced 
w ith fresh D M EM -10 containing 2.5m g/m l purom ycin (S igm a-A ldrich). The lentivirus-
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infected fibroblasts were m onitored daily w ith fresh D M EM -10 purom ycin added every 
three days. D uring recovery the cell lines were expanded from  one well o f  a 12 well 
tissue culture plate to a 25cm “ tissue culture flask. They were then assayed for CD 155 
expression by FA CS then cryopreserved.
2.2.S Cryopreserv ation Of Cell Lines
A dherent cells in log phase grow th were treated w ith a m inim al volum e to cover the 
m onolayer, e,g 1ml for a 25cm 2 flask o f  trypsin/E D T A  for 5 m inutes at room tem perature 
until the cells detached from  the tissue culture flask. The cell were recovered by 
centrifugation at 400g for 5 m inutes then resuspended in freezing m ixture (90% FCS 
10% D M SO ). 1 ml aliquots were transferred to cryovials and placed in a N algene 5100 
cryo 1°C freezing container (M erck, W est D rayton, UK) containing isopropanol at room 
tem perature. The freezing container was stored at -70°C overnight then the cryovials 
w ere transferred to liquid nitrogen for storage.
To resurrect cells from  liquid nitrogen storage, they w ere rapidly thaw ed, resuspended in 
DM EM  containing 50%  (v/v) FCS the centrifuged at 400g for 5 m inutes. The cells were 
resuspended in D M EM -10 then centrifuged at 400g for 5 m inutes. The cells were then 
resuspended in D M EM -10 and transferred to a 25cm 2 tissue culture flask and incubated at 
37°C.
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2.2.6 Cell Counting
A 1 Ojil aliquot o f  cells was diluted 1:1 with Trypan blue (S igm a-A ldrich) and counted on 
a glass haem ocytom eter (S igm a-A ldrich) under w hite light. V iable cells were identified 
by the exclusion o f  Trypan blue. Cells w ere counted in the four outer grid regions o f  the 
haem ocytom eter and the num ber o f  cells per ml was determ ined using the following 
equation:
N um ber o f  cells/m l = [(Total num ber o f  cells counted) x 104 x 2] / 4
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2.3 VIRUSES
2.3.1 Propagation Of HCMV
H C M V  strain M erlin, strain A D I69, H C M V U L32G FP and HCM VAUL141 were all 
grow n in fibroblasts. HFFFs were cultured in 175cm“ tissue culture flasks until they 
reached 70%  confluence. They were then infected with virus at a MOI o f  0.1 in 5ml o f  
D M EM  and rocked for 4 hours at 37°C. A fter the incubation the m edia was replaced 
with 25m l o f  fresh 10% FCS D M EM  and incubated at 37°C. The cells were m onitored 
for cytopathic effects (cpe) daily and the m edia w as renew ed weekly. W hen extensive 
cpe was apparent through the m onolayer, m edia w as rem oved to storage at -70°C and 
fresh m edia w as added to the cells. D uring the follow ing days, the growth m edia 
continued to be replaced and stored every tw o days until the infected cells disintegrate.
To prepare H CM V virions the aliquots o f  supernatant w ere defrosted and cell debris was 
rem oved by centrifugation at 600g for 10 m inutes. The supernatant was pooled and then 
spun at 23000g for 2 hours to pellet the virus. Follow ing centrifugation the supernatant 
was discarded and the pellet was resuspended in DM EM . To reduce aggregation o f  the 
viral particles the resuspended pellet was aspirated repeatedly through a 21G needle. The 
resuspended virus pellet was then frozen at -70°C in lOOpl aliquots.
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2.3.2 Propagation Of Recombinant Adenovirus (Rad) Stocks
RAd stocks were propagated in 293 cells. RAd viruses used are show n in table 2.2 along 
with their form al designations in the laboratory. 293 cells were grow n to 70% 
confluency in a 175cm “ tissue culture flask, infected with virus at a moi o f  0.1 in a 
m inim al volum e o f  m edia then incubated overnight in a rocking incubator at 37°C. The 
follow ing day the virus w as rem oved and replaced with fresh DM EM -10. Cells were 
m onitored for cpe and the m edia was replaced as needed. W hen 100% o f  cells exhibited 
cpe, they w ere detached from  the flask by gentle tapping and resuspended in DM EM . 
Infected cells w ere recovered by centrifugation at 900g for 5 m inutes and the cell pellet 
resuspended in PBS. A rklone P w as then added to the cells at a 1:1 ratio and m ixed 
vigorously before centrifugation at 900g for 5 m inutes. The aqueous phase containing 
the virus w as rem oved, aliquoted and stored at -70°C.
72
Table 2.2. Recombinant Viruses
Name Background Generated by Official
Designation
RAd
RAd control Ad Easy P. Tom asec RAd 592
R A dG FP Ad Easy P. Tom asec RAd 502
RAdUL141 A dEasy P. Tom asec RAd 587
RA dU L141G FP AdEasy P. Tom asec RAd 522
R A dC D l 55m Ch AdZ B. M cSharry RAd 1225
RA dU L141C FP AdZ D. Cochrane RAd 1281
H C M V
H C M V U L32G FP M erlin R. Stanton RC M V  1172
HCM VAUL141 M erlin V. P rod 'H om m e RC M V  1149
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2.3.3 Titration Of Virus Stocks
H CM V  and RA d virus stocks were titrated using a lim ited dilution assay. Confluent 
H FFFs (for H CM V titration) or 293 cells (for RAd titration) w ere trypsinised and added 
to 24 well tissue culture plates (H CM V ) or 96 well plate (R A d) and allow ed to adhere 
overnight. Cells w ere plated to 80%  confluency. Serial d ilutions betw een 10'2 and 10 '10 
o f  the virus stocks w ere m ade in D M EM -10 and 1ml (H C M V ) or lOOpl (RA d) o f  each 
dilution w as added to 10 wells. Follow ing incubation for 24 hours, all m edia was 
replaced. The cells were m onitored for cpe and the m edia w as replaced as necessary. 
A fter 4 w eeks for HCM V, or 10 days for RAd, cpe w as m arked in each well. The virus 
titre w as calculated as tissue culture infectious dose (TC ID 50) using the Reed-M uench 
form ula:
TC ID 5o=/o£/fldilution (%  infection at next d ilution above 50%  - 50_____________________ }
(%  infection dilution above 50%  - %  infection dilution below  50% )
TC ID 50 units w ere converted into pfu/m l for convenience using the accepted conversion 
factor o f  1 T C ID 50 = 0.7 infectious units (D avis 1990).
2.3.4 HCMV purification
HCM V virus particle w ere purified by ultracentrifugation over a continuous sodium 
tartrate gradient. HCM V w as grow n as described in section 2.3.1 and the clarified 
supernatant was recovered by centrifugation for 2 hours at 4°C then the pellet was
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resuspended in sodium  phosphate buffer. The gradients were m ade in ultra clear 
u ltracentrifuge tubes (Beckm an C oulter, California, USA) by com bining 4ml 35%  
sodium -tartrate and 5ml 15% sodium  tartrate/30%  glycerol in a gradient m ixer. The 
resuspended pellet was then layered over the gradients and balanced to lOOmg. The 
gradients w ere then centrifuged for 45 m inutes at 4°C. Follow ing centrifugation the virus 
particle band w as rem oved from the gradient with a 20G needle, w ashed in sodium 
phosphate buffer at for 1 hour at 4°C then resuspended in lOOpl sodium  phosphate buffer 
and stored at -80°C. For flow  cytom etry experim ents the virus was first inactivated by 
irradiated with a 22 TBq caesium -137 source for 24 hours.
2.3.5 Fractionation of HCMV
Purified H CM V  particles were separated into detergent soluble and insoluble fractions 
using a procedure adapted from  (A dair et al. 2002). Purified virions were incubated at 
4°C with 1% Triton X-100 for 30 m inutes. The insoluble com ponent was recovered by 
centrifugation at 18000g for 30 m inutes, then resuspended in sodium  phosphate buffer. 
Both fractions were stored at -70°C before use in w estern blotting.
An alternative detergent extraction buffer (W ang et al. 2004c) was also used to 
fractionate the virions. Purified virions were incubated with 1% N P-40 and 0.5%  
deoxycholate for 30 m inutes at room tem perature. A t 5 m inute intervals the sam ple was 
vigorously m ixed to ensure separation o f  the viral envelope. A fter the incubation the 
insoluble fraction was recovered by centrifugation at 18000g for 30 m inutes before being
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resuspended in sodium  phosphate buffer. Both fractions were stored at -70°C before use 
in w estern blotting.
2.3.6 Infection Of Cells For Assays
RA d w ere routinely delivered to HFFF, U373 cells and 293 cells, while HCM V 
infections w ere done in H FFF cells. Table 2.2 lists the viruses used as well as their 
official laboratory designations. C onfluent 175cm 2 tissue culture flasks o f  the 
appropriate cell line were trypsinised, resuspended in D M EM -10, seeded into 25cm 2 
tissue culture flasks or 6 well tissue culture plates then incubated overnight at 37°C.
W hen the cells had reach 70-80%  confluency the m edia w as rem oved and an appropriate 
volum e o f  virus was added in a m inim al volum e. The cells were then incubated for 2-4 
hours in a rocking incubator at 37°C. The inoculum  was then rem oved and replaced with 
fresh pre-w arm ed D M EM -10 then incubated for three days at 37°C before use in the 
relevant experim ent.
M ultiplicity o f  infection for RAd infections w ere 50, 100 and 150 pfu/cell and for HCM V 
was 5 and 10 pfu/cell. RA ds were titred on perm issive 293 cells, which express high 
level o f  the Coxsackie adenovirus receptor (CA R ). HFFFs express extrem ely low levels 
o f  CA R and are -1 0  fold less susceptible to RAd infection. In order to provide for 
efficient virus delivery, it is necessary to use 10 fold m ore virus. All virus infections
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included an independent negative control; RAd control for RA d infections and m ock 
infection (m edia only) control for H CM V infections.
77
2.4 MOLECULAR BIOLOGY
2.4.1 PCR
PCR reactions were carried out using Expand high fidelity PCR system  (Roche) with Ipl 
o f  the m anufacturers supplied buffer, 0.5pl dN TP (lO m M ) and 0.5pl o f  each prim er 
(lOOpm ol/ml) (m ade to order from Invitrogen). The follow ing therm ocycling reaction 
was used:
95°C for 2 m inutes 
95°C for 30 seconds
58°C for 30 seconds 35 cycles
72°C for 90 seconds
2.4.2 Agarose Gel Electrophoresis
Separation o f  DNA fragm ents by size was perform ed by electrophoresis in 0.7%  w/v 
agarose TA E gel. DNA sam ples were m ixed with D N A  loading buffer then transferred 
into wells. The gel was then run at 75 V for approxim ately 1 hour, depending on 
resolution required. The gel w as then stained w ith ethidium  brom ide buffer for ten 
m inutes, w ashed with w ater then visualised under UV light in an Autochem i system 
(U V P Bioim aging system s, C am bridge, UK).
78
2.4.3 Isolation Of DNA From Agarose Gel
D N A  w as isolated from agarose gels using a G FX  PCR D N A  and Gel Band Purification 
Kit (G E  healthcare, Buckingham shire, UK) follow ing the m anufacturers protocol. The 
kit w orks on the principle that DN A will bind to a glass fibre m atrix in high salt 
concentration w hile protein and salt contam inants do not. The DN A is eluted from the 
glass fibre m atrix colum n by w ashing with a low  salt concentration buffer.
2.4.4 Plasmid DNA Minipreps
Small scale plasm id preparations were perform ed using a QIA prep Spin M iniprep Kit 
(Q iagen). The kit is based on alkaline lysis o f  bacterial cells followed by the binding o f  
D N A  onto a silica colum n in the presence o f  high salt concentration. Bacteria containing 
the plasm id o f  interest were cultured in 5ml o f  LB overnight then recovered by 
centrifugation at lOOOOg for 5 m inutes. The bacteria w ere resuspended in 250pl o f 
m anufactu rer's  PI buffer then o f  then lysed in buffer P2 (250pl). A fter 5 m inutes the 
neutralisation buffer N3 (350pl) w as added to allow  denatured DN A to reanneal; 
bacterial cell debris and precipitated chrom osom al D N A  w as then cleared by 
centrifugation at 18000g for 10 minutes. The supernatant w as then decanted into a silica 
colum n, w hich was then centrifuged at 18000g for 60 seconds. The colum n was washed 
w ith the m anufacturers ' buffer PB then the DN A w as eluted from the colum n in 50pl Tris 
buffer. D N A  w as stored at -20°C until required.
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2.4.5 Plasmid Purification By Maxiprep
Large scale plasm id purification was perform ed using Q IA filter Plasm id M axi Kit 
(Q iagen). The principles o f  the kit are sim ilar to those o f  the m iniprep kit described 
above. The protocol is based on the alkaline lysis o f  bacteria cells followed by the 
b inding o f  plasm id DN A to an anion exchange resin under low  salt conditions. RNA and 
protein contam inants are w ashed from  the resin under m edium  salt concentration while 
the plasm id D N A  is eluted w ith high salt buffer. The D N A  is then desalted by 
isopropanol precipitation.
A starter culture o f  5ml o f  LB m edium  w as inoculated with the bacteria containing the 
p lasm id o f  interest. A fter 8 hours o f  incubation at 37°C with vigorous shaking. 25ml o f  
LB m edium  w as inoculated with 25pl o f  the starter culture. This m ain culture was then 
incubated overnight at 37°C with vigorous shaking. The bacteria cells w ere then 
harvested by centrifugation at 6000g for 15 m inutes at 4°C then resuspended in 4ml o f  
the m anufacturers PI buffer. The cells were then lysed by the addition o f  an equal 
volum e o f  the m anufactu rer's  P2 buffer then incubated at room  tem perature for 5 
m inutes. The lysate was then neutralised by the addition o f  P3 buffer (4m l), and cleared 
by passing through a filter cartridge into the resin colum n. Once the lysate has entered 
the resin by gravity flow  it w as washed tw ice w ith 10ml o f  the m anufacturers QC buffer 
under gravity flow . The DN A is then eluted from  the resin w ith 5ml o f  the 
m anufactu rer's  QF buffer and then precipitated by m ixing w ith 3.5ml isopropanol and
80
centrifuging at 15000rpm for 30 m in at 4°C. The precipitated DNA w as then washed 
tw ice with 70%  ethanol, allow ed to air dry then redissolved in Tris buffer. To determ ine 
the yield o f  the m axiprep purification the DNA concentration w as determ ined by UV 
spectrophotom etry at 260nm  and by analysis on an agarose gel.
2.4.6 Restriction Enzyme Digestion
R estriction enzym es used in this study were B a m \\\  (Prom ega, W isconsin, USA), A gel, 
(N EB , M assachusetts, USA) and N m d lll  (N EB , M assachusetts, USA). All digestions 
w ere carried out according to the m anufacturers’ instructions. Reactions consisted o f  
D N A  tem plate, 5pl lOx reaction buffer (N EB ) and de-ionised w ater to a total volum e o f  
50pl. R estriction enzym e digests were incubated for 2-16 hours at 37°C. Follow ing 
digestion, D N A  fragm ents were separated by agarose gel electrophoresis (section 2.4.2) 
and purified by GFX PCR DN A and Gel Band Purification Kit (GE lifesciences) (section 
2.4.3).
2.4.7 DNA Ligation
To clone DN A sequences, linearised vector and insert were m ixed with 1 pi T4 DNA 
ligase enzym e and 1 pi 10 x ligase buffer (N EB ) in a total volum e o f  lOpl. The reaction 
w as incubated for 1 hour at 16°C. A fter the incubation, the DN A was purified by GFX
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PCR D N A  and Gel Band Purification K it or ethanol/sodium  acetate precipitation then 
used to transform  bacteria.
2.4.8 Ethanol/Sodium Acetate Precipitation Of DNA
Ligation reactions and restriction nuclease d igestion products w ere purified by 
ethanol/sodium  acetate precipitation. 10% (v/v) sodium  acetate (Invitrogen) was added 
to the sam ple in a total volum e o f  lOpl. 250pl o f  ethanol w as added and the sam ple was 
centrifuged at 18000g for 30 m inutes. The supernatant was rem oved and the pellet 
w ashed tw ice in 70%  (v/v) ethanol. The purified D N A  w as then resuspended in an 
appropriate volum e o f  Tris buffer or water.
2.4.9 Transformation oiE.co/i
Plasm ids w ere transform ed into the electrocom petent E .coli TOPIO (Invitrogen) by 
electroporation. Briefly, lp l DN A was m ixed with an aliquot o f  E.coli TOPIO and 
incubated at 4°C for 15 m inutes then transferred to a 0.2cm  electroporation cuvette. The 
bacteria w ere then electroporated at 2.5kV using an electroporator (B ioRad Gene Pulser). 
The bacteria we then allow ed to recover in LB for 2 hour at 37°C. A fter recovery, the 
bacteria w ere plated on selective LB agar plates and incubated overnight at 37°C.
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2.4.10 Glycerol Stock
E. coli contain ing plasm ids o f  interest w ere stored as glycerol stocks. 500pl o f  an 
overnight bacteria culture was m ixed with 500pl o f  80%  (v/v) glycerol in a cryovial and 
stored at -70°C.
2.4.11 DNA Sequencing
Inserts w ere sequenced using BigDye 3.1 term inator cycle sequencing kit (PerkinElm er, 
B oston, U SA ) and dideoxy term inator cycle sequencing. The reaction m ixture consisted 
o f  D N A  sam ple, 4pl reaction m ix, Ip l sequencing prim er (see table 2.3 for prim er 
sequences) in a total volum e o f  lOpl. The follow ing therm al cycling conditions were 
used:
95°C for 30 seconds
50°C for 15 seconds 25 cycles
60°C for 4 m inutes
Follow ing the therm ocycling reaction, the products were precipitated by sodium  
acetate/ethanol precipitation and the sequencing products separated on an ABI model 377 
sequencer (A pplied B iosystem s, Foster City, U SA ) by a dedicated technician at Central 
B iotechnology Services (C ard iff U niversity)
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Table 2.3. PCR prim er sequences
N am e Sequence N otes Produced by
CD 155
5prim e
C A TG A A G C TTA G C TG C T
C G G A G C A A C TG G C A T
H in d lll  site added Inv
(Pa
trogen 
sley, UK)
CD 155
3prim e
G A TC A C C G G TG C C C TT G
T G C C C TC T G TC TG TG G A
A g e l  site added Inv
(Pa
trogen 
sley, UK)
CD 155
seq l
T TC G G G TTG C G C G T A G A
G G A
CD 155 sequencing prim er Inv
(Pa
trogen 
sley. UK)
C D I5 5
seq2
A T TG G A G C A C G A C C A T
GG
CD 155 sequencing prim er Inv
(Pa
trogen 
sley, UK)
CD155
seq3
C A G A A G G TC C A G C TC A
C TG G
CD 155 sequencing prim er Inv
(Pa
trogen 
sley, UK)
UL141
5prim e
C A TG A A G C TTA G A TC A T
G T G C C G C C G G G A G TC G
H in d lll  site added Inv
(Pa
trogen 
sley, UK)
UL141
3prim e
G A TG G A T C C A G C C TC TT
C A TC TTTC TA A C A C C
B am H I  site added Inv
(Pa
trogen 
sley, UK)
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2.4.12 Cloning Using The AdZ Vector.
The Ad recom binant RA dU L141C FP was produced in a novel vector system  that exploits 
D N A recom bineering technology (Stanton et al. 2008). The A dZ vector consists o f  the 
entire genom e o f  a replication-deficient Ad5 vector inserted into a single copy 
prokaryotic BAC (bacterial artificial chrom osom e) plasm id (fig 2.1). Dual selectable 
m arkers (am picillin  resistance and sucrose sensitivity) w ithin an H CM V  m ajor IE 
prom oter expression cassette are present in the E l locus. The A dZ vector is m aintained 
in E. coli SW 102, w hich carries an integrated copy o f  the lam bda red genes. The red 
genes prom ote DN A recom bination betw een short arm s o f  hom ology, and their 
expression can be transiently induced by heat-shock. The transgene, generated with short 
arm s o f  hom ology (usually by PCR) overlapping the H C M V  IE prom oter expression 
cassette, is transform ed directly into E. coli SW 102 as linear DNA. Expression o f  the red 
genes is induced; enabling the transgene to be inserted under the control o f  the IE 
prom oter by hom ologous recom bination (recom bineering). R ecom binants are selected by 
loss o f  the dual selectable m arkers, and the resultant BAC transfected into 293 cells to 
produce the recom binant virus.
2.4.13 PCR
The U L141C FP ORF was am plified from pU L 141C FP using prim ers with 80 nucleotide 
5 ' hom ology to the A dZ vector. The reaction was perform ed using Expand Hi-Fi
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BAC Plasmid Origin of Replication 
Chloramphenicol Resistance 
l-Scel expression cassette X :
P a rt (35227) y  /
1-SceJ (35214)
Ad5 genome 1-460
t-Seel (43708) w
Pui i (4 3 6 « })\ CMV Promoter containing 2 tet operators 
\  i Amp 
■ : LacZa
-* sacB
CMV IE PolyA
Ad5 genome 3520-35,938
F igure  2.1. A dZ  vector m ap.
The AdZ vector contains the Ad5 vector deleted for E l and E3 regions in a single copy 
vector. It contains a selection cassette encoding ampicillin resistance, lacZa  and sacB  
(sucrose sensitivity) between the CMV prom oter and the CM V IE PolyA. Inserts are 
generated with arms o f  homology to the promoter and PolyA replacing the selection 
cassette. Adapted from (Stanton et al. 2008).
86
polym erase (R oche) in the m anufactures buffer (containing M g), 50 pm ol prim er and 
nucleotides. The reaction conditions were as described in section 2.4.1.
The sequences o f  the prim ers used w ere (arm s o f  hom ology in norm al text, UL141 
specific sequence in bold):
5 ' UL141 prim er
5 'A A C C G T C A G A T C G C C T G G A G A C G C C A T C C A C G C T G T T T T G A C C T C C A T A G A
A G A C A C C G G G A C C G A T C C A G C C T G G A T C C A T G T G C C G C C G G G A G T C G -3’
3 ' UL141 Prim er
G G C G TG  AC A C G TTT A TTG  AGT AGG ATT AC AG A G T AT AAC AT AG AGT AT AATA 
T A G A G T A T A C A A T A G T G A C G T G G G A T C C T T A C T T G T A C A G C T C G T C C A
Follow ing the reaction the product was gel purified using GFX PCR DN A and Gel Band 
Purification K it (G E lifesciences) as described in section 2.4.3.
2.4.14 Transformation of Bacteria
An overnight starter culture o f  SW 102 bacteria contain ing the AdZ vector was grown in 
5ml o f  LB containing am picillin  and chloram penicol at 32°C. 0.5ml o f  the starter culture 
w as then inoculated into 25ml LB containing am picillin  then incubated at 32°C in a 
shacking incubator. The absorbance at 600nm  was m onitored until it reached a value o f  
0.6. A t this point the culture was transferred to a w ater bath and incubated at 42°C for 15
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m inutes to induce the lam bda red genes. The culture w as then transferred  to ice and 
cooled for 15 m inutes then centrifuged for 5 m inutes at 0°C. The bacteria cells were 
resuspended in ice-cold w ater and centrifuged again. Follow ing the final centrifugation 
the pellet w as resuspended in a m inim al volum e o f  w ater and transferred to Eppendorf 
tubes in 25pl aliquots. 3pl o f  the purified PCR product w as added then the bacteria and 
PCR product transferred to a pre-chilled 0.2cm  cuvette and electroporated at 2.5kV. The 
electroporated bacteria w ere transferred into 5ml LB, incubated for 4 hours to allow  for 
recovery. A 50pl aliquot w as plated on L-agar sucrose containing sucrose and X-gal, and 
incubated for 48 hours at 32°C. Follow ing incubation, w hite colonies that grew  in the 
presence o f  sucrose w ere selected for screening.
2.4.15 Preparation of BAC DNA
The standard m iniprep protocol (described in section 2.4.4) does not produce sufficient 
A dZ DNA; this is because the vector is based on a single copy BAC vector. To 
m axim ise D N A  yields, a m odified m iniprep spin (Q iagen) protocol was used. A white 
colony from  the sucrose selection plate was selected and grow n overnight in 5ml 
chloram phenicol LB at 32°C in a shacking incubator. The bacteria cells were recoverred 
by centrifugation at 18000g for 5 m inutes then resuspended in 250pl buffer P I . 250pl 
buffer P2 w as then added to lyse the cells. A fter 5 m inutes, 250pl buffer N3 was added 
to neutralise the lysis reaction. This solution w as centrifuged at 18000g for 10 m inutes, 
the supernatant transferred to a fresh Eppendorf tube and D N A  precipitated by the 
addition o f  750pl 70%  isopropanol. Follow ing centrifugation at 18000g for 10 m inutes
the D N A  was washed w ith 70%  (v/v) ethanol, air dried and finally resuspended in 30pl o f 
buffer EB.
To test w hether the desired recom bination event had occurred, the vector DNA was 
digested w ith Bam H l (Prom ega). 8pl o f  m iniprep purified plasm id DNA was incubated 
at 37°C for one hour with Ipl o f  the recom m ended buffer and lp l Bam H l (NEB). The 
entire reaction w as then separated on an agarose gel as described in section 2.4.2. The 
A dZ vector produces seven bands w hen digested w ith B am H l, how ever two are from in 
the selection cassette. I f  these bands, 2.5kbp and 1.7kbp, are not present then 
recom bination has occurred.
2.4.16 Sequencing
The sequencing reaction consists o f  5pl DN A , lp l prim er (3 .2pm ol/p l) and 4pl BigDye
3.1 (Perkin-E lm er). The sequence o f  the prim ers used were; 5 ’- 
A A T G T C G T A A C A A C T C C G -3 ' and 5 ’-A C C T G A T G G T G A T A A G A A G -3\ The 
reaction conditions were as follows:
95°C for 5m inutes 
95°C for 30 seconds
55°C for 10 seconds 100 cycles
60°C for 4 m inutes
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The reaction products w ere cleaned using Perform a D TR colum ns (EdgeBio, M aryland, 
U SA ) according to m anufactu rer's  instructions. Briefly, the product is added to the 
colum n and centrifuged. The gel filtration m atrix rem oves dye term inators and salts 
purifying the PCR products. The products were then sequenced as described in section 
2.4.11.
2.4.17 Maxiprep
N ucleoB ond BacM A X  100 kit (C lontech) was used for large scale purification o f  AdZ 
vector DN A. This kit is based on a m odified alkaline/SD S lysis procedure followed by 
potassium  acetate precipitation o f  chrom osom al DN A . Plasm id is first bound to an anion 
exchange resin, which is then w ashed then the plasm id D N A  is eluted. A single bacterial 
colony was inoculated into a 5ml starter culture and incubated for 6 hours at 32°C in a 
shaking incubator. The starter culture was then diluted into 250m l LB and incubated 
overnight at 32°C. The bacteria were harvested by centrifugation at 5000g for 15 
m inutes at 4°C then resuspended in 24ml o f  buffer SI (C lontech). 24ml o f  the 
m anufacturers buffer S2 is then added to lyse the cells. A fter three minutes, pre-cooled 
buffer S3 is added to the cells to neutralise the reaction. The bacteria suspension was 
then clarified by centrifugation at 12000g for 15 m inutes at 4°C then by filtration. The 
cleared lysate was then loaded onto an equilibrated N ucleoB ond column containing the 
anion exchange resin. The colum n was then w ashed tw ice w ith 18ml o f the 
m anufactu rer’s buffer N3 then the DNA was eluted by the addition o f 15ml buffer N5 
pre-heated to 50°C to the colum n. The plasm id DN A was then precipitated with
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isopropanol washed with 70%  (v/v) ethanol then resuspended in lOOpl lOmM Tris pH8.5. 
D N A  concentration was m easure by absorbance at 260nm .
2.4.18 Generation of RAd Virus
RAd w ere generated by transfecting the AdZ vector into 293TR Ex cells using Polyfect 
(Q iagen). 293TR Ex cells w ere seeded in a 25cm 2 tissue culture flask and incubated 
overnight at 37°C. 4pg  o f  the A dZ BAC D N A  was diluted to lOOpl with DM EM , then 
40pl o f  Polyfect reagent added and the sam ple incubated 10 m inutes. The volum e was 
m ade up to 1ml with D M E M -10 before the transfection m ix was added directly to 
293TR Ex cells. A fter 24 hours at 37°C, the m edia was rem oved, discarded and 
replenished with fresh D M E M -10. Cells were m onitored for cpe, and stocks m ade from 
resulting virus 2.3.2 and 2.3.3.
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2.5 WESTERN BLOTTING
Proteins separated by SD SPA G E were detected by w estern blotting. Pre-set 10% Nupage 
N ovex acrylam ide gels were used in conjunction with the N upage electrophoresis 
equipm ent (Invitrogen). M OPS or M ES buffer w as used for electrophoresis, depending 
on the required resolution. To prepare cell extracts, m onolayers were w ashed once with 
PBS, rem oved from the tissue culture flask by m echanical scraping and resuspended in 
10 ml PBS. Cells w ere centrifuged at 400g for 5 m inutes, washed again in 10 ml fresh 
PBS Before being resuspended in lOOpl SD SPA G E sam ple buffer. To prepare virus 
sam ples, irradiated purified H C M V  virions (described in section 2.3.4) or detergent 
treated virion fractions (described in section 2 .3.5) w ere diluted 1:4 in 4xSD SPA G E 
sam ple buffer.
Sam ples were then denatured at 99°C for 10 m inutes before loading 7-10pl o f  the 
sam ples into the wells o f  the acrylam ide gel, a longside a 5pl sam ple o f  N ovex sharp 
standard pre-stained m arkers (Invitrogen). Proteins w ere separated by SD SPA G E at 
150V for 1-2 hours, depending on the resolution required and running buffer used. 
Proteins were transferred to nitrocellulose m em brane (G E Biosciences, UK) by sem i-dry 
transfer. B lotting paper and nitrocellulose m em brane were pre-soaked in transfer buffer 
then layered onto the transfer apparatus (TransferB lot SD, BioRad, Heucules, California, 
U SA ) w ith a sheet o f  blotting paper on the negative electrode, then the nitrocellulose on 
top. The gel w as then rem oved from  the electrophoresis equipm ent and layered over the 
nitrocellulose m em brane. A final sheet o f  blotting paper w as layered on top o f  the gel.
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A fter ensuring that all air bubbles w ere rem oved the transfer apparatus w as assem bled 
and the proteins were transferred by sem i-dry transfer for 1 hour at 10V.
Follow ing the transfer the nitrocellulose m em brane was rem oved from  the transfer 
apparatus. The position o f  the pre-stained m arkers w ere m arked on the m em brane using 
an A ntigen-A ntibody (m ouse) Pen (A lpha D iagnostics, U SA ) before the m em brane was 
blocked w ith 5%  (w/v) m ilk pow der/PB ST for 1 hour at room  tem perature or overnight at 
4°C . A fter the incubation the blot was washed for 30 m inutes with an appropriate 
volum e o f  PB ST, the PBST being replaced three tim es then an appropriate dilution o f  
prim ary antibody in 5%  (w /v) m ilk pow der/PB ST w as added to the m em brane for 1 hour 
at room  tem perature or overnight at 4°C. Table 2.4 show s the prim ary antibodies and the 
d ilu tions used. The blot w as then washed with PBST as above, then goat anti-m ouse 
horse-radish peroxidase conjugated m onoclonal antibody (B ioRad) diluted 1:1000 in 5% 
(w /v) milk pow der/PB ST added to the blot and incubated for 1 hour at room  tem perature. 
Blots were w ashed a final tim e in PBST before incubation with the horse-radish 
peroxidase chem ilum inescent substrate (Therm o Scientific, W altham , M assachusetts, 
U SA) for 5 m inutes. The blots w ere analysed with Chem idoc chem ilum enescence 
im aging system  (UVP, C am bridge).
To re-probe a blot they were washed three tim es in PBST then incubated with ReStore 
(Pierce, R ockford, USA) for 2 hours before being w ashed a further three tim es in PBST. 
The stripped blots were re-blocked with in 5% (w /v) milk pow der/PB ST for 1 hour at 
room  tem perature or overnight at 4°C then the staining was carried out as described 
above.
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Table 2.4. Primary antibodies used for western blots
Antibody Dilution Isotype Company
a-C D 155 1 5000 M ouse IgG l A beam  (Cam bridge, UK)
a-gB 1 5000 M ouse IgG l A beam  (Cam bridge, UK)
a-lE-1 1 6000 M ouse IgG2a Chem icon (M assachusetts, USA)
a-pp65 1 6000 M ouse IgG l Abeam  (Cam bridge, UK)
a-U L 14 1 2000 M ouse IgG l In house
a-U L141 1 10000 M ouse IgG l Tom asec et al (2005)
a-U L 99 1 5000 M ouse IgG2a A beam  (Cam bridge, UK)
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2.5.1 Deglycosidase Treatment
To deglycosylate proteins, sam ples w ere digested with either endoglycosidase H (Endo
H) or peptide N -glycosidase F (PN G ase) (NEB). Cells or purified virions were 
resuspended in denaturing buffer (N EB) to a total volum e o f  90pl and incubated at 99°C 
for 10 m inutes. The sam ple w as then split into three aliquots for Endo H digestion, 
PN G ase digestion and a control aliquot processed w ithout enzym e. For Endo H, 1 pi (500 
U nits) enzym e and 5pl buffer G5 (N EB) were added to a total volum e o f  50pl. For 
PN G ase. Ip l (500 U nits) PN G ase enzym e, 5pl o f  the supplied N P40 solution and 5pl o f  
the buffer G7 w as added to a total volum e o f  50pl. For the control aliquot, 5pl o f  buffer 
G5 w as added the PBS added to a total volum e o f  50pl. All sam ples were then incubated 
overnight at 37°C. A fter the incubation the sam ples were m ixed with SD SPA G E sample 
buffer and blotted as described above.
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2.6 MICROSCOPY
2.6.1 Preparation Of Cells
For m icroscopy experim ents, cells were grow n on sterilised coverslips placed in 6 well 
tissue culture plates, either transfected (as described in section 2.2.2) or infected with 
RA ds or HCM V (as described in section 2.3.6) and incubated for three days at 37°C. The 
coverslips were rem oved from the tissue culture dish, w ashed w ith PBS and where 
appropriate im m unofluorescence perform ed (Section 2.6.2) then m ounted on m icroscope 
slides w ith D A B C O  to preserve fluorescence signal. The slides were then imaged 
directly  under phase and fluorescent light using a Leica DM  IRBE (Leica). For live cell 
im aging, cells w ere cultured directly on m icroscope slides (N unc Flask on Slide) then 
im aged directly.
For confocal m icroscopy the slides were fixed by im m ersion in a 1:1 m ixture o f  acetone 
and m ethanol for 30 seconds then m ounted onto m icroscope slides. The slides were 
im aged on a Leica SP5 confocal m icroscope (Leica) with the follow ing settings. 
S tim ulation w ith argon laser. CFP em ission 465-505 nm , YFP em ission 525-600 nm.
A F 549 em ission 605-700 nm. M icroscope im ages w ere obtained using OpenLab 
(Im provision, Coventry, UK) or Leica LAS AF softw are (Leica) then analysed with 
A dobe Photoshop CS2 (A dobe, California, USA).
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2.6.2 Immunofluorescence
Cells, w ashed in PBS, were fixed on coverslips with 4%  paraform aldehyde in PBS for 20 
m inutes at room tem perature. Paraform aldehyde was rem oved by w ashing the coverslips 
three tim es w ith PBS, then incubated with 1:200 dilution o f  m ouse anti-calnexin 
m onoclonal antibody (C hem icon, M assachusetts, USA) for 1 hour at 37°C in a 
hum idified cham ber. The coverslips were then w ashed three tim es in PBS then incubated 
w ith a 1:500 dilution o f  A F549-conjugated goat anti-m ouse IgG m onoclonal antibody 
(Invitrogen) for 1 hour at 37°C in a hum idified cham ber. Follow ing a final round o f  
w ashes the coverslips were m ounted onto m icroscope slides and im aged by confocal 
m icroscopy.
2.7 FACS
2.7.1 Cell Staining Protocol
Prim ary and secondary antibodies used in FA CS analysis are detailed in table 2.5. 
B etw een 5x105 and Ixl O6 cells w ere added per FACS tubes and washed in 3ml o f  
0 .2% B SA -PB S at 400g for 5 m inutes. Cells were then incubated with the prim ary 
antibody in 150pl 0.2% BSA -PB S for 30 m inutes at 4°C in the dark, washed in
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Table 2.5. Antibodies used for FACS experiments
Antibody Dilution Isotype Company
Prim ary A ntibodies
a-C D 155 1:500 M ouse IgG l Abeam  (Cam bridge, UK)
a-gB 1:50 M ouse IgG l A beam  (Cam bridge, UK)
a-pp65 1:50 M ouse IgG l Abeam  (Cam bridge, UK)
a-UL141 1:50 M ouse IgG l Tom asec et a l (2005)
a-U L 99 1:50 M ouse IgG2a Abeam  (Cam bridge, UK)
M ouse IgG l M ouse IgG l Sigm a-A ldrich (M issouri, USA)
M ouse lgG 2a M ouse IgG2a Sigm a-A ldrich (M issouri, USA)
Secondary A ntibodies
A lexa Fluor 647 F(ab’)2 
fragm ent o f  goat anti­
m ouse IgG ( H +L)
1:400 Goat IgG Invitrogen (Paisley, UK)
A lexa Fluor 488 F (ab’)2 
fragm ent o f  goat anti­
m ouse IgG ( H +L)
1:400 Goat IgG Invitrogen (Paisley, UK)
A lexa Fluor 594 F (ab ')2  
fragm ent o f  goat anti­
m ouse IgG ( H +L)
1:400 Goat IgG Invitrogen (Paisley, UK)
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0.2% B SA -PB S and incubated w ith an isotype specific fluorochrom e conjugated 
secondary antibody at an appropriate dilution in 150pl 0 .2% B SA -PB S for 30 m inutes at 
4°C in the dark. Cells were w ashed in 0.2% BSA -PB S then resuspended in 300pl 
0 .2% B SA -PB S before analysing by flow  cytom etry. FACS analysis was perform ed 
using a FA C SC alibur (BD , N ew  Jersey, USA) and CellQ uest Pro software (BD).
2.7.2 Virus Staining Protocol
See table 2.5 for antibodies and dilutions used. Irradiated purified H CM V virions were 
w ashed in 200pl 0 .2% B SA -PB S and centrifuged at 18000g for 20 m inutes. V irions were 
resuspended in lOpl 0 .2% B SA -PB S containing the prim ary unconjugated antibody for 30 
m inutes at 4°C in the dark, washed with 3ml 0.2% B SA -PB S and resuspended with an 
isotype-specific, fluorochrom e-conjugated secondary antibody (in lOpl 0.2% BSA -PB S) 
for 30 m inutes at 4°C in the dark. Cells were w ashed in 0.2% BSA -PB S then resuspended 
in 300pl 0.2% BSA -PB S before analysing by flow  cytom etry. FACS analysis was 
perform ed using a FA C SC alibur and CellQ uest Pro software.
For experim ents using purified virions and fibroblasts the follow ing procedure was 
followed. Fibroblasts w ere infected with R A dC D 155m C h or the same vector lacking an 
insert (RA d-control). A fter three days the m edia w as rem oved and the cells were washed 
in PBS. H C M V U L32G FP was added to the cells at a moi o f  10 and incubated at 4°C on a 
rocking platform  for 4 hours. A fter the incubation, the inoculate was rem oved, the cells 
were w ashed with PBS then incubated with 4%  paraform aldehyde. The cells were then
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incubated w ith trypsin/ED TA  (Invitrogen) until the cells detached. The cells were 
resuspended in 0.2%  (w /v)B SA -PB S, centrifuged at 400g for 5 m inutes at 4°C then 
resuspended in 400pl 0.2%  (w /v)B SA -PBS. FACS analysis w as perform ed using a 
FA C SC alibur and CellQ uest Pro software.
2.8 ADHESION ASSAY
C ells w ere seeded in a  96 well tissue culture dish (2 x l0 5 cells/w ell) then incubated at 
37°C. A t various tim es after addition o f  cells (tim e-points defined in figure legends) 
triplicate w ells were washed gently w ith PBS, fixed with m ethanol then washed again 
with PBS. At the end o f  the tim e course all PBS w as rem oved and the fixed cells were 
stained w ith 0.1%  crystal violet for 30 min, w ashed three tim es in w ater then dissolved 
with 0.5%  Triton x-100 overnight. A bsorbance at 550nm  w as used as a m easurem ent o f  
the num ber o f  adherent cells, and analysed using G raphpad Prism.
A m odified protocol was also used. The adhesion assay w as perform ed as described 
above, except the stained cells were dissolved in 33%  acetic acid for 30 min. The acetic 
acid dissolved the staining quicker, reducing the possibility  o f  evaporation or incom plete 
d issolving. A bsorbance at 550nm  was m easured and analysed using Graphpad Prism 
(G raphpad, California, USA).
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2.9 IN  VITRO SCRATCH ASSAY
Cells w ere seeded in a 60m m  tissue culture dish then incubated overnight. The follow ing 
day an area o f  the tissue culture dish was denuded by scoring a plastic tip across the 
surface creating an approxim ately 1mm wound in the confluent m onolayer. The lid was 
replaced and sealed with Parafilm .
T im e-lapse m icroscopy was perform ed with a Leica DM  IRBE inverted m icroscope 
(Leica) in an incubator set to 37°C. Images were taken every 5 m inutes for 16 hours 
using Im provision O penLab 3 (Im provision) then converted into m ovies using Apple 
Q uickT im e (A pple, California, USA).
To quantify the assay im ages taken each hour w ere analysed by three different 
techniques: m anual m easurem ent o f  area, m anual m easurem ent o f  distance and autom atic 
m easurem ent o f  area.
1) M anual m easurem ent o f  area
The leading edges o f  the m onolayer were defined m anually and the area o f  the wound 
was calculated using Im provision O penLab 3 softw are giving a m easurem ent o f  area in 
pixels. This value was then converted to percentage o f  initial w ound area for 
com parison.
2) M anual m easurem ent o f  distance
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U sing Im provision O penLab 3 softw are the distance betw een the leading edges were 
m easured at three separate points per fram e. The average distance was calculated for 
each fram e then converted to a percentage o f  the initial w ound size.
3) A utom atic m easurem ent o f  area
Individual im ages were im ported into Adobe Photoshop CS2 (Adobe). The area o f  the 
w ound w as calculated using the colour selection tool to autom atically select the wound. 
This technique gave a value in pixels for each fram e; these values were converted into 
percentage o f  initial area for com parison w ith the other techniques.
2.10 NEUTRALISATION ASSAY
Fibroblasts from a confluent 175cm2 tissue culture flask w ere detached with trypsin, 
seeded in a 96 well tissue culture plate and incubated overnight to attach. Doubling 
d ilutions o f  antibodies and positive and negative hum an sera from  1:40 to 1:2560 were 
m ade in D M EM  and m ixed with 100 pfu o f  H C M V U L32G FP. A fter 30 m inutes 
incubation, the serial dilutions plus virus w ere added to the HFFF in the 96 well plate. 
The cells were incubated for 4 hours in a rocking incubator then the m edia was replaced 
w ith fresh D M E M -10. A fter three days the cells w ere imaged with an inverted 
fluorescent m icroscope for GFP fluorescence caused by infection with HCM VU L32GFP. 
G FP positive cells were counted for each well and analysed with G raphpad Prism 
softw are (G raphpad).
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3 THE EFFECT OF UL141 ON CELL ADHESION 
AND MIGRATION
UL141 w as initially defined to be an NK evasion function through its capacity to 
dow nregulate cell surface expression o f  CD 155, thus sequestering the ligand for DNAM - 
1 and CD 96. H ow ever, CD 155 also participates in intercellular connections through 
b inding to nectin-3 (Sato et al. 2004) and adhesion to the extracellu lar m atrix via its 
capacity to bind vitronectin (Lange et al. 2001). CD 155 locates both to focal com plexes 
and the leading edge o f  m igrating fibroblasts w here ligand stim ulation prom otes 
intracellular signalling to stim ulate m ovem ent (O da et al. 2004). CD 155 upregulation is 
an im portant step in the m etastasis o f  certain  cancers, including gliom as (Sloan et al. 
2005) and sarcom as (Sloan et al. 2004), due to the reduced adherence and prom otion o f  
m otility.
I was therefore interested in determ ining w hether H CM V  UL141-m ediated 
dow nregulation o f  CD 155 w ould impact on norm al cell process involved in intercellular 
com m unication, adhesion and m otility. Cell adhesion can be readily m easured in vitro  
sim ply by m easure the tim e taken for cells to settle and attach to surface o f  tissue culture 
dishes. To provide further insight into the possible consequence o f  UL141 expression on 
cell m otility, an in vitro  wound healing assay was perform ed. The assay involves 
artificially introducing a gap in a cell m onolayer and tracking the capacity o f  cells to 
repair this ‘w ound’. The assay thus m easures the capacity o f  cells to respond to their 
environm ent, then m igrate or proliferate to repair the dam age. In these studies, UL141
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w as analysed by expression in continuous 293 cells lines, and follow ing transient 
expression w hen delivered by using an Ad vector. A H C M V  UL141 deletion m utant 
becam e available in the later stages o f  the study, and w as then  included in experim ents.
3.1 EFFECT OF UL141 EXPRESSION ON THE ADHERENT PROPERTIES OF 
293 CELLS
A 293 continuous cell line expressing a U L 141 G FP fusion protein was instrumental in 
identifying the m echanism  by w hich UL141 m odulated N K  cell function (Tom asec et al. 
2005). By fluorescence m icroscopy, expression o f  the U L141G FP fusion protein was 
readily detected, although expression levels varied betw een cells. U L141G FP exhibited a 
restricted intracytoplasm ic distribution that in cells expressing particularly high levels 
looked like inclusion bodies (fig 3.1 A). In contrast GFP expressed alone has a more 
generalised distribution, not trafficking to a specific organelle (fig 3 .IB). Endogenous 
C D 155 expression could readily be detected on the surface o f  293-G FP control cells by 
flow  cytom etry, and w as efficiently dow nregulated in cells expressing U L141G FP (fig 
3.1C). This study reproduces and supports the findings o f  Tom asec et al (2005). It was 
apparent, how ever, that the 293 U L141G FP cell line proved relatively difficult to culture 
relative to 293-G FP cells, taking m uch longer to reach confluency.
104
A B
Isotype Control
293-UL141-GFP
293-GFP
/
A,
1 0 ’
CD155
F igure  3.1. D ow nregu lation  o f cell su rface CD 155 in 293 Cells.
Continuous 293 cell-line expressing UL 141 GFP or GFP and grown under selection with 
Geneticin. (A) Fluorescent image o f  293-UL141GFP cells. (B) Fluorescent image o f  
293-GFP cells. (C) Com parison o f  CD 155 cell surface expression on 293-UL141GFP and 
293-GFP cells. Cells were stained with anti-CD 155 monoclonal antibody then AF594 -  
tagged secondary goat anti-mouse antibody. Solid red is isotype control, black line is 
293-UL141GFP and green is 293-GFP.
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I w as interested in the poor growth properties o f  this cell line. The effect o f  UL 141 GFP 
expression on the capacity o f  cells to adhere to the substrate w as therefore studied using a 
crystal violet adherence assay. Cells rem oved from m onolayers, by m inim al treatm ent 
w ith trypsin, were allowed to adhere to the surface o f  96 well plates. At various 
tim epoints non-adherent cells were washed o ff  and the adherent cells were fixed with 
m ethanol. A t the end o f  the tim ecourse all w ells were stained with crystal violet then 
lysed in a solution containing Triton X-100 (m aterials and m ethods section 2.8). 
A bsorbance o f  the Triton x -100-crystal violet solution at 570nm  was interpreted to be a 
quantitative m easurem ent o f  the num ber o f  adherent cells. To m easure total cell num bers 
in each experim ent, wells were included where the non-adherent cells are not washed off. 
C om parison o f  the absorbance o f  these w ells dem onstrated that sim ilar num bers o f  cells 
w ere added initially.
Either 293-G FP cells or 293-U L141G FP cells (2 x l0 5 per well) were plated in triplicate, 
non adherent cells were washed o ff  and adherent cells were fixed at the tim e indicated in 
fig 3.2. Cell adhesion increased over tim e for both lines, yet 293-G FP cells clearly 
attached m ore efficiently than 293-U L141G FP cells (fig 3.2A). W hile the difference 
varied over tim e at all tim e points, 293-G FP cells exhibited m ore efficient adhesion (up 
to 3 fold at 2h). 293 UL 141 GFP cells adhered to  the grow th substrate at a slow er rate 
than 293-G FP cells.
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Figure  3.2. UL141 expression reduces 293 cell adhesion.
(A) A ssay measuring 293-UL141GFP or 293-GFP cell adherence to plastic substrate over 
time. Absorbance at 570nm was measured. Data shown is the average o f  three replicates 
with error bars representing standard deviation and representative o f  three independent 
experiments. (B) Assay m easuring 293-GFP, 293-UL141GFP or 293-UL14GFP cell 
adherence to plastic substrate over time. Data shown is the average o f  three replicates 
with error bars representing standard deviation and representative o f  three independent 
experiments.
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There are only two m em bers o f  the H C M V  UL14 gene fam ily: UL14 and UL141 
(D avison et al. 2003; Dolan et al. 2004). A lthough the function o f  UL14 has yet to be 
determ ined, like UL141, it encodes an Endo H -sensitive glycoprotein that traffics to the 
ER but it is known not to dow nregulate C D 155 (Tom asec et al. 2005, M. Arm strong,
PhD thesis). W hen repeating this assay, a 293 cell line stably expressing a UL14GFP 
fusion protein was included to com pare the relative effect o f  the U L14-fam ily m em bers 
on cell adhesion (fig 3.2B). U L14G FP expression also reduces 293 cell adherences when 
com pared to control 293-G FP cells. U L14G FP reduces cell adhesion to a sim ilar extent 
to U L 141G FP w ithout dow nregulating cell surface CD 155.
3.2 EFFECT OF UL141 EXPRESSION ON THE ADHESIVE PROPERTIES OF 
U373 CELLS
U373 cells are a hum an glioblastom a line sem i-perm issive for FtCMV, which were 
observed to express CD 155 on the cell surface (fig 3 .3A). Ad vectors provide for 
efficient transient expression o f  transgenes; an Ad vector encoding UL141 (RA dU L141) 
was available to this study (Tom asec, 2005). U pon expression o f  UL141 cell surface 
CD 155 is dow nregulated (fig 3.3A) com pared to the CD155 expression levels observed 
in RAd control infected U373 cells. A biphasic response w as observed, indicative o f  two 
populations o f  cells. One population in which there is efficient suppression o f  C D 155, 
and a second with partial dow nregulation.
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F igu re  3.3. The effect o f UL141 on U373 cell adhesion.
(A) Cell surface expression o f  CD 155 on U373 cells infected with RAdUL141 (black 
line) or a control vector (RAd Control, blue line). Cells stained with m ouse anti-CD 155 
m onoclonal or isotype control (red) then stained with goat anti-mouse AF594 were 
analysed by flow cytometry. (B) U373 cells infected with RAd Control ( T ) ,  RAdUL141 
(♦) or m ock infected ( T ) were used in a crystal violet adhesion assay. Error bars are the 
standard deviation between three replicates.
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U373 cells were infected w ith RA d UL141, RAd control and m ock infected. The control 
Ad vector was based in the sam e vector background (A dEA SY -1), contained the HCM V 
m ajor IE prom oter and SV40 polyadenylation sequence, but lacked a transgene insert. 
Throughout this study, the control Ad vector used will be o f  equivalent construction to 
the adenovirus recom binant under test. Three days post infection the adherence o f  the 
cells on cell culture plastic was studied (fig 3.3C). M ock infected U373 cells and cells 
infected with an em pty vector both adhere to the plastic grow th substrate at the same rate. 
There is a slight deficit in adhesion in cells infected with RAd-UL141 at one hour; 
how ever, this difference does not persist during the rest o f  the experim ent. W hen 
expressed in the context o f  an Ad vector, UL141 did not substantially alter the capacity o f  
U373 cells to adhere to the susbstrate.
3.2.1 Effect of Overexpression of CD 155 on the Adhesive Properties of U373 Cells
To determ ine the role o f  CD 155 in the initiation o f  adhesion o f  U373 cells, U373 cell- 
lines stably expressing a CD 155C FP fusion protein were created. U373 cells were 
transfected with the plasm id pAL881, then plated 24 hours late on 100mm diam eter 
tissue culture dishes at a range o f  low cell densities, by sequential 10 ten-fold dilutions. 
G eneticin-resistant cell colonies were selected, a panel o f  10 expanded. Tw o clones, 
U373-A 6 and U 373-A 3, expressed higher levels o f  cell-surface CD 155 than the parental 
cells w hen m easured by flow  cytom etry (fig 3.4A). These cell-lines were used in an 
adhesion assay to see if  increased expression o f  CD155 could affect U373 cells adhesion.
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F igure  3.4. E ctopic expression of CD155 increases adhesion  of U373 cells.
Continuous U373 cell lines expressing CD155CFP were analysed in an adhesion assay. 
(A) Cell surface expression o f  CD 155 on the parental U373 cells (solid red) and two 
transfected cell lines U373-A6 (Black line) and U373-A3 (blue line). Cells stained with 
an anti-CD 155 mAh or an isotype control were analysed by  flow cytometry. (B) The 
three cell lines were used in an adhesion assay as described previously. Cells were 
washed and fixed at thirty m inute intervals. Data shown is the mean o f  three replicates 
with the error bars showing the standard deviation.
I l l
D uring the first hour no difference was apparent, but as the tim e course proceeded, the 
tw o C D 155C FP cell lines consistently  exhibited greater adherence (fig 3.4B). U373 cells 
express a relatively low  am ount o f  CD 155 as m easured by FACS.
UL141 dow nregulation o f  cell-surface endogenous CD 155 did not score in the adhesion 
assay (fig 3.3), yet it is clear that CD 155 can influence U373 cells adhesion. It is possible 
that UL141 w as not expressed efficiently enough in U373 cells to significantly impair 
adhesion, or that the endogenous CD 155 levels did not reach a threshold level o f  
expression to be a rate-lim iting factor. The over-expressing cell lines potentially could be 
used to aid functional studies.
3.3 EFFECT OF UL141 EXPRESSION ON THE ADHERENT PROPERTIES OF 
HUMAN FIBROBLASTS
H um an fibroblasts support a fully productive infection with both low and high passage 
H CM V  strains, and exhibit strong adherence to plastic grow th substrate. In contrast, 293 
cells adhere weakly to the plastic and fail to support productive H C M V  infection. W hilst 
I w ished to study the effect o f  UL141 influence on fibroblasts adhesion, continuous cell 
lines cannot readily be established in this cell type. An Ad vector was therefore used to 
deliver and express UL141 in HFFFs. The capacity  o f  the recom binant RA d-U LI41 to 
dow nregulate cell surface expression o f  CD 155 in this experim ental system  was 
established in a FACS experim ent. HFFF cells w ere infected for three days prior with 
RA d-U L141, RAd-control or m ock infected. W hile RAd-UL141 efficiently
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dow nregulated CD 155 relative to m ock-infected and cells infected w ith the control vector 
(fig 3.5A).
The cells were then trypsanised and used in a crystal violet adherence assay as described. 
The cell num ber control w ells had equal absorbencies (data not shown). There was no 
consistent difference in adherence betw een m ock-infected cells and RAd-control infected 
fibroblasts across the tim e course (fig 3.5B) show ing that infection with the vector did 
not substantially  alter the adherence o f  the cells. RAd-UL141 cells followed the same 
dynam ics as the control cells but with m uch low er adherence. At all tim e points RAd- 
UL141 had approxim ately h a lf  the absorbance o f  either the m ock-infected cells or the 
RA d-control infected cells. This data shows that UL141 expression alter the rate o f  
adherence o f  HFFF cells
3.4 EFFECT OF UL141 EXPRESSION ON ADHERENCE DURING HCMV 
INFECTION
Expression o f  UL141 alters the ability o f  H FFFs to adhere to the grow th substrate. A 
recom binant HCM V virus with a deletion in UL141 (H CM V A U L141) was used to study 
w hether the UL141-dependant reduction o f  adherence occurs during HCM V infection. 
HCM VAUL141 has lost the capacity to dow nregulate CD 155 and nectin 2, plus infected 
cells are m ore vulnerable to NK cell attack than those infected with the parental virus
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F igure  3.5. E xpression o f UL141 reduces adhesion  o f h um an  fib rob lasts
HFFF were m ock infected or infected with RAdUL141 or RAd control. (A) Three days 
p.i. cells stained with anti-CD 155 mAb or isotype control were analysed by flow 
cytometry. (B) Assay measuring cell adherence to plastic substrate over time. Data 
shown is the mean o f  three independent replicates with error bars showing standard 
deviation.
114
(P rod’hom m e, personal com m unication). HFFFs were infected w ith the parental HCM V 
strain M erlin, HCM VAUL141 virus or m ock infected for three days then used in an 
adhesion assay using a slightly m odified technique (described in section 2.8.1).
Infection with either strain M erlin or the AUL141 virus resulted in greatly reduced 
adherence o f  cells com pared to the m ock-infected controls (fig 3.6). The adherence o f 
HCM VAUL141 infected fibroblasts was com parable to that o f  strain M erlin-infected 
cells at all tim e points. H CM V infection alters m any aspects o f  cell binding including the 
destruction o f  focal adhesions (S tanton et al. 2007) and the dow nregulation o f  integrins 
(W arren et al. 1994c), the effect o f  UL141 on cell adhesion was not detectable against a 
background o f  other m ajor changes to adhesion m olecules in infected cells.
3.5 ESTABLISHMENT OF AN IN  VITRO  WOUND HEALING ASSAY
To investigate the effect o f  UL141 expression on cell m igration an in vitro  wound healing 
assay w as perform ed. A linear gap is first introduced into a confluent m onolayer using a 
plastic tip; the cells are then im aged in real tim e to track the repair o f  the wound. This 
assay provides a m easure o f  the rate cell m igration to repair the lesion in the m onolayer.
To ensure an accurate and objective assessm ent o f  scratch closure three m easurem ent 
techniques were used to com pare the sam e im ages follow ing the m igration o f  a 293- 
UL141 cell m onolayer: distance m easurem ent, m anual area m easurem ent and autom atic 
area m easurem ent (fig 3.7). For the first technique, the distance between the two leading
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Figure 3.6. Effect of UL141 expression on cell adhesion during HCMV infection
Human fibroblasts were infected with M erlin strain HCM V, HCM VAUL141or mock 
infected. Data shown is the mean o f  three independent replicates with error bars showing 
standard deviation.
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F igu re  3.7. C om parison  o f techniques fo r m easu rem en t o f sc ra tch  assay w ound size.
A  m onolayer o f 293-UL141GFP cells was w ounded with a plastic tip then incubated for 
12 hours at 37°C. Images were taken at 0,1,5,10 and 12 hours post wounding. The size 
o f  the void in the m onolayer was measured either by ( ▼) m easurem ent o f  the distance 
betw een leading edges, (♦) automatic calculation o f  area by Adobe Photoshop or by 
(•)m anual area calculation. All values are expressed as percentage o f initial wound size 
to standardise values.
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edges w as m easured at each tim e point. For m anual area m easurem ent the perim eter o f  
the wound w as defined m anually on screen for each fram e then the area was calculated 
using Im provision O penLab softw are. Autom atic area m easurem ent used Adobe 
Photoshop CS2 softw are to calculate the area o f  the wound. A fter conversion to 
percentage m easurem ents, the initial scratch being set at 100%, the three techniques 
produced com parable results. The area m easurem ents varied by less than one percent at 
one hour post w ounding and by five percent at 12 hours post w ounding, whilst the 
distance m easurem ent gave consistently  lower values at each tim epoint studied. At one 
hour post w ounding distance m easurem ent was low er than autom atic area m easurem ent 
by 10% and at 12 hours post w ounding the difference was 25%. The variation in the 
distance m easurem ent technique is because the leading edges do not m ove uniformly 
w ith parts o f  the leading edges m oving faster than other. Area m easurem ent was 
therefore considered a m ore accurate assay. For all further wound assays Photoshop 
softw are w as used to quantify scratch assays as it is straightforw ard and potentially less 
subjective.
3.5.1 Effect Of UL141 On 293 Cell Migration In An in vitro Wound Healing Assay
To determ ine the effect if  UL141 expression altered cell m igration 293 cells expressing 
U L141G FP or GFP (fig 3.8A) were used in the in vitro  wound assay. A small area o f  a 
confluent m onolayer w as denuded with a plastic tip and was incubated at 37°C for 16 
hours. Im ages were acquired every five m inutes, w ith a subset selected at hourly 
intervals analysis quantitatively using A dobe Photoshop. The 293-G FP m onolayer 
closed at a relatively consistent rate, averaging 3.1%  / hour over the course o f  the
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experim ent (fig 3.8A and B and video 3.1). At 14 hours post w ounding the tw o leading 
edges have began to m ake contact and only small voids in the m onolayer remain.
293-U L141G FP cells exhibited  reproducible differences to the control cells (fig 3.8A). 
W ithin m inutes o f  w ounding, the area o f  the w ound increased, peaking at 1 h post 
w ounding w ith an increase o f  up to 30%  o f  the initial size. D irectly follow ing wounding 
the edges o f  the m onolayer detach from the substrate (video 3.2) and over the course o f 
an hour either reattaches to the substrate or settled on top o f  the m onolayer.
The expanded wound size rem ained stable for 4 hours then a phase o f  rapid closure 
follow ed. From  4 to 14 hours post w ounding the rate o f  closure was 9%  per hour, three 
tim es greater than closure in the control cells. The leading edges o f  293-U L141G FP 
begin to m eet at 14 hours post wounding. The total tim e to wound resolution for both 
cell lines is sim ilar; how ever, the dynam ics o f  closure are m arkedly different.
A lthough the assay w as set up to investigate cell m igration, no clear U L141G FP- 
m ediated effect on m otility could be deduced from  this assay. U L141G FP appeared to 
act to reduce cell:substrate adhesion, and as a consequence the m onolayer adjacent to the 
lesion detached. U nexpectedly, a m ore rapid peak rate o f  gap closure w as observed with 
the 293-U L141G FP cells. H ow ever, these cells w ere able to recruit displaced cells to the 
gap. Cell surface CD155 expression helped to protect the cell m onolayer from damage, 
but did not accelerate repair.
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Figure 3.8. E ffect o f UL141 on 293 cell m ig ra tion  in an in vitro w ound healing assay.
293-GFP or 293-UL141GFP cells were used in an in vitro  wound healing assay (A) 
Images at hourly intervals were analysed using Adobe Photoshop. Results are expressed 
as percentage o f  initial wound area Data shown is the average o f  three independent 
experiments, error bars are standard deviation. (B) Images from an individual 
experiment. Images are representative o f  three independent experiments.
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3.6 SUMMARY
The study consolidated previous findings from this laboratory, UL141 downregulated cell 
surface CD155 expression in transfected 293 cells, and in both U373 and human 
fibroblasts when expressed by using an Ad vector. C D 155, like the other m em bers o f  the 
nectins and nectin-like fam ily o f  proteins, has im portant adhesion properties. It was 
postulated by Tom asec et al (2005) that UL141 suppression o f  CD155 could have 
im plications for H C M V -infected cells distinct from  N K  cell evasion. This study provides 
the first dem onstration that UL141 can also affect the adhesive properties o f  cells.
UL141 m ediated dow nregulation o f  cell surface CD 155 in 293 cells and fibroblasts, but 
nor U373 cells, was observed to reduces cell:substrate adhesion. Productive HCM V 
infection w as dem onstrated to have a m ajor suppressive effect on cell substrate adhesion. 
H ow ever, experim ents w ith a H CM V deletion m utant show ed this to be a redundant 
function, the contribution m ade by UL141 could not detected in the context o f  lytic 
infection. In this context, it is dem onstrated that UL14 w hen expressed in isolation also 
inhibited celksubstrate adhesion.
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4 CHARACTERISATION OF THE INTERACTION 
BETWEEN gpUL141 AND CD155
The proposed model for U L 141-m ediated evasion o f  NK  recognition involves gpUL141 
form ing a stable com plex with de novo synthesised CD  155 and this com plex being 
retained in the ER. D irect im aging o f  this com plex by im m unofluorescence has proved 
problem atical. The only m A h available for CD 155 com patible with 
im m unohistochem istry w as only capable o f  detecting the fully m ature glycosylated form 
o f  the protein; CD 155 rem ains in an im m ature (Endo H -sensitive) form in the presence o f  
gpU L 141. W hilst gpUL141 w as readily detected, it was associated with inclusion bodies 
that co-localised w ith ER m arkers. Only the surface o f  these inclusion bodies could be 
stained, it w as not clear if  this was because gpUL141 was only on the surface or because 
the antibody could not penetrate into the inclusion. To enable to direct visualisation o f  
CD 155 and UL141, they w ere expressed with C-term inal fluorescent tags; variously 
yellow  fluorescent protein (YFP), cyan fluorescent protein (CFP) and m Cherry (mCh). 
This procedure allow ed co-expression o f  the tw o proteins to be follow ed sim ultaneously 
w ithout using antibodies and live cell im aging to be perform ed.
4.1 GENERATION OF CD155 AND gpUL141 FUSION CONSTRUCTS.
The cD N A  o f  UL141 was am plified by PCR, digested with restriction endonuclease and 
ligated into the plasm ids pECFP-N 1 and pEY FP-N 1. Insertion o f  the appropriate size into
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the vector w as established first by restriction nuclease d igestion  (fig 4.1 A ) then by DNA 
sequencing. Figure 4.2 show s plasm id m ap o f  pUL 141Y FP and pU L 141CFP.
O ccasionally , fluorescent tags are cleaved from fusion pro teins by cellular proteases, 
leaving GFP expressed in isolation. It is therefore prudent to check the expressed fusion 
protein is o f  the appropriate m olecular weight. Cell extracts were prepared from HFFFs 
transfected w ith pU L 141C FP or pUL141 YFP, and infected w ith strain M erlin infected 
(positive control) were used in a w estern blot (fig 4 . IB ). C yan fluorescent protein and 
yellow  fluorescent protein both have a m olecular w eight o f  27kDa; therefore the 
predicated w eight o f  both the gpU L 141C FP and gpUL141 YFP fusion proteins is 61kDa. 
On the w estern blot both proteins m igrated to 60 kDa, very close to the predicted size.
Sim ilarly, CD  155 sequence w as also am plified and inserted into the sam e plasm ids to 
generate pC D 155C FP or pC D 155Y FP (fig 4.2). Correct insertion was verified by 
restriction digestion (fig 4 .1C ) and sequencing. To ensure that these fusion proteins 
expressed CD  155 HFFF cells transfected with pC D 155Y FP were analysed by flow 
cytom etry (fig 4 .1D). T ransfection was m easured by the presence o f  YFP fluorescence 
and cell surface CD 155 expression was m easured by staining with anti-CD 155. 7% o f  
the fibroblasts had been transfected successfully, o f  these h a lf  had greater CD 155 levels 
than the untransfected cells show ing that pC D 155Y FP is causing an increase in CD 155 
expression.
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F igure  4.1. C onstruc tion  o f CD155 and  UL141 fluorescen t fusion p ro te ins
(A) The M erlin HCM V UL141 sequence was cloned into pEYFP-1 and pECFP-1 to 
create the constructs pUL141YFP and pUL141CFP. The plasm ids were digested with 
H in d lll  and Bam H I to confirm insertion. (B) gpUL141 expression in HFFF transfected 
with pUL141CFP or pUL141 YFP. gpUL141 expression was detected with the M550 
series o f  mAbs. (C) The CD 155 sequence was cloned into pEYFP-1 and pECFP-1 to 
create the constructs pCD155YFP and pCD155CFP. The plasm ids were digested with 
H in d lll  and A g e l  to confirm insertion. pCD155YFP and pCD155CFP were then 
transfected into HFFF cells to confirm CD 155 expression by flow cytometry. (D) 
pCD155YFP transfected HFFFs stained with anti-CD 155 and goat anti-mouse AF647 
fluorescent-conjugated secondary
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Figure 4.2. E xpression  p lasm id  m aps
Plasmid maps o f  the four expression vectors; pCD155YFP, pCD155CFP, pUL141YFP 
and pUL141CFP. The plasm ids have the following official laboratory designations 
pAL880, pAL881, pAL882 and pAL883.
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4.2 UL141 AND CD155 TRANSFECTION OF 293 CELLS
The plasm id constructs w ere tested first in 293 cells because these cells can be readily 
transfected at high efficiency. 293 cells were transfected singly w ith pUL141CFP (fig 
4 .3A ), pUL141 Y FP (fig 4 .3B ), pCD 155C FP (fig 4 .3C ) or pC D 155Y FP (fig 4.3D), and 
co-transfected w ith pC D 155C FP and pUL141 YFP (fig 4 .4A ) or with pCD 155Y FP and 
pU L141C FP (fig 4.4B). Three days post transfection the cells were fixed and imaged 
directly. CD155 appeared to be expressed on the cell surface (fig 4.3), although 
intracellular accum ulations w ere also observed. In 293 cells surface expression o f  
C D 155 appeared to localise strongly to regions o f  cell-cell contact. In contrast, 
gpUL141 w as exclusively intracellular w ith a  structured perinuclear distribution 
consistent w ith it trafficking to the ER (fig 4.3A  and B; Tom asec et al 2005). This is 
consistent with the 293 U L141G FP cells in chapter 3.
W hen CD  155 and gpUL141 are co-expressed in 293 cells gpUL141 retains the 
perinuclear staining observed in the single transfections (fig 4.4). U tilising the C D 155 
fusion protein it is possible to directly v isualise the im m ature CD 155 form retained 
w ithin the cell. C D 155 is dow nregulated from  the cell surface and is now  predom inantly 
intracellular. Intracellular CD 155 co-localises closely w ith gpUL141. The co-localisation 
is m ainly concentrated in the inclusion bodies with a diffuse area o f  staining surrounding 
the structures. CD 155 and gpUL141 are both present throughout the inclusion bodies. 
The dim ensions and quantity  o f  these structures are not constant and vary between cells. 
The close co-localisation throughout the cell suggests that gpUL141 is directly 
interacting CD  155 within the cell.
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Figure 4.3. Distribution of gpUL141 and CD155 in 293 cells.
293 cells were transiently transfected with expression plasmids expressing (A) gpUL141- 
CFP fusion protein (pUL141CFP), (B) gpUL141-YFP fusion protein (pUL141YFP), (C) 
CD 155-YFP (pCD155YFP) or (D) CD155-CFP fusion protein (pCD155CFP) using 
Effectene. Three days following transfection, cells were fixed and imaged directly at 
lOOx m agnification under oil immersion. Fluorescence was detected and analyzed with a 
Leica DM IRBE microscope with Improvision Openlab software.
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Figure 4.4. Co-localisation of gpUL141 and CD155 in 293 cells.
293 cells were transiently transfected with expression plasm ids expressing (A) CD 155- 
CFP fusion protein (pCD155CFP) and gpUL141-YFP fusion protein (pUL141YFP) or
(B) CD155-YFP (pCD155YFP) and gpUL141-CFP fusion protein (pUL141CFP), using 
Effectene. Three days following transfection, cells were fixed and imaged directly. 
Fluorescence was detected and analyzed with a Leica DM IRBE microscope with 
Improvision Openlab software.
128
4.3 gpUL141 AND CD155 TRANSFECTION OF HUMAN FIBROBLASTS
Follow ing the im aging in 293 cells, the experim ent w as repeated in hum an prim ary 
fibroblasts (H FFF cells). A lthough fibroblasts exhibited a m uch low er levels o f  
transfection by standard techniques, they are a m ore valid target cell to study as they can 
support full productive H C M V  infection. Initial experim ents used transfectene while 
latter experim ents w ere perform ed using nucleofection as it gave a higher rate o f  
transfection. Use o f  transfectene resulted in 4%  o f  fibroblasts transfected while 
nucleofection resulted in greater than 60%  efficiency.
R eassuringly, transfection with pC D 155Y FP (fig 4 .5A) or pCD 155CFP (fig 4.5B) 
resulted in identical expression profiles: localising predom inantly at the cell m em brane, 
w ith small intracellular concentrations. M ost noticeably, CD 155 was associated with 
*nanotubule'-like extrusions that are visible extending from  cells. A lthough in 293 cells 
CD 155 was clearly concentrated to cell-cell contacts, in H FFFs CD 155 this phenom enon 
w as m uch less pronounced (fig 4.5A ).
H FFFs transfected with either pUL141 YFP or pU L 141C FP w ere directly imaged. Both 
constructs produce proteins with the sam e distribution (fig 4.6). gpUL141 expressed in 
H FFFs exhibit an intracellular perinuclear distribution. The inclusion bodies observed in 
293 cells are not present in transfected HFFFs. Endogenous C D 155 present in the 
transfected fibroblasts will com plex with the UL141 fusion protein.
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Figure 4.5. Distribution of CD155 in transfected fibroblasts
HFFFs were transiently transfected with expression plasm ids expressing (A) CD155-YFP 
(pCD155YFP) or (B) CD155-CFP fusion protein (pCD155CFP) using Effectene. Three 
days following transfection, cells were fixed and imaged directly at lOOx magnification 
under oil immersion. Fluorescence was detected and analyzed with a Leica DMIRBE 
m icroscope with Improvision Openlab software.
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Figure 4.6. Distribution of UL141 in transfected Fibroblasts
HFFFs were transiently transfected with expression plasm ids expressing (A) gpUL141- 
YFP fusion protein (pUL141YFP) or (B) gpUL141-CFP fusion protein (pUL141CFP) 
using Nucleofector. Three days following transfection, cells were fixed and imaged 
directly at lOOx magnification under oil immersion. Fluorescence was detected and 
analyzed with a Leica DM IRBE microscope with Improvision Openlab software.
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N ext, HFFF w ere co-transfected  w ith the CD 155 and gpUL141 fusion proteins to 
visualise the interaction. pU L 141C FP and pCD 155Y FP (fig 4 .7A ) or pUL141 YFP and 
pC D 155C FP (fig 4 .7B ) w ere co-transfected into HFFF cells. The distribution o f  the 
UL141 fusion protein is altered in HFFFs overexpressing CD  155; it is still intracellular 
but the d istribution is m ore structured with several well defined inclusion bodies visible. 
CD  155 is now  retained w ith in  the cell and closely co-localises with gpUL141 including 
w ithin the inclusion bodies. A s observed in the 293 cells above, the inclusion bodies are 
an am algam  o f  gpUL141 and CD  155. The dow nregulation o f  cell surface CD 155 by 
gpUL141 is not absolute. It is dependant on the relative expression levels o f  both CD 155 
and gpU L 141. H ow ever, independent o f  CD 155 dow nregulation co-localisation o f  
gpUL141 and CD 155 is alw ays observed. CD 155 is observed distinct from gpUL141 but 
gpUL141 is alw ays observed co-localised w ith CD 155.
W hen CD  155 is incom pletely retained (fig 4.7) CD  155 displays an interm ediate 
phenotype w here it is partially cell surface and partially  intracellular. All intracellular 
CD  155 invariably co-localises w ith gpU L141, w hile cell surface CD 155 does not. The 
variable dow nregulation o f  cell surface CD 155 is in agreem ent with previous 
observations that gpUL141 dow nregulates cell surface CD 155 but does not com pletely 
eradicate surface expression (chapter 3).
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Figure 4.7
A -  CD 155YFP and UL141CFP
CD155-YFP UL141-CFP Merge
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B -  CD155CFP and UL141YFP
Figure 4.7. Co-localisation of gpUL141 and CD155 in HFFF.
HFFFs were transiently transfected with expression plasm ids expressing (A) CD155-YFP 
(pCD155YFP) and gpUL141-CFP fusion protein (pUL141CFP) or (B) CD155-CFP 
fusion protein (pCD155CFP) and gpUL141-YFP fUsion protein (pUL141YFP) using 
Nucleofector. Three days following transfection, cells were Fixed and imaged directly. 
Fluorescence was detected and analyzed with a Leica DM IRBE microscope with 
Improvision Openlab software.
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4.3.1 Confocal Imaging of gpUL141 and CD155 Transfection of Human 
Fibroblasts
To image the interaction betw een UL141 and CD155 in greater resolution confocal 
m icroscopy w as used. In transfected H FFFs U L141CFP exhibited the same diffuse 
perinuclear d istribution, but was observed to be granular w ith m any foci o f  intense 
fluorescence (fig 4 .8A ). Inclusion bodies were w ell-defined and varied in both size and 
shape. Intracellular CD  155 YFP also exhibited a m ore granular appearance within cell, 
and finely labelled the outline o f  the cell m em brane w ith the protein being m ore 
concentrated in som e regions (fig 4.8B).
In co-transfection experim ents, U L141C FP and CD  155YFP co-localised w ithin cells (fig 
4.8B). The two proteins exhibited a granular distribution w ith m any bodies o f  high 
fluorescence. The inclusion bodies, both large and small, consist o f  co-localised 
gpUL141 and CD 155. W hile not all CD 155 is intracellular, cell surface CD 155 is not 
associated with gpU L 141. This is likely to be breakthrough expression where C D 155 is 
able to reach the cell surface w ithout being retained by gpUL141.
To resolve the three-dim ension structure o f  the gpU L141-C D 155 inclusion bodies in 
H FFFs a series o f  images were taken along the z-axis at 1pm intervals (fig 4.9). CD 155 
and gpUL141 co-localise throughout the inclusion body. The inclusion bodies occur 
w ithin the cell not at the cell surface and consist o f  a hom ogeneous m ixture o f
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Figure 4.8. Confocal microscopy of CD155YFP and UL141CFP
HFFFs were transiently transfected with expression plasm ids expressing (A) gpUL141- 
CFP fusion protein (pUL141CFP), (B) CD155-YFP fusion protein (pCD155YFP) or (C) 
CD155-YFP (pCD155YFP) and gpUL141-CFP fusion protein (pUL141CFP) using 
Nucleofector. Three days following transfection, cells were fixed and imaged directly. 
Fluorescence was detected and analyzed with a Leica SP5 resonant scanning confocal 
m icroscope. Cyan Channel -  UL141-CFP, Yellow channel -  CD155-YFP.
Figure 4.9. Three dimensional co-localisation of CD155 and UL141.
HFFFs were transiently transfected with expression plasm ids expressing CD155-YFP 
(pCD155YFP) and gpUL141-CFP fusion proteins (pUL141CFP) using Nucleofector. 
Three days following transfection, cells were fixed and imaged directly. Fluorescence 
was detected and analyzed with a Leica SP5 resonant scanning confocal microscope. 
Serial images along the z-axis were taken at 1pm intervals. Yellow channel is 
CD 155YFP, cyan channel is UL141CFP and the double overlay is shown.
gpU L 141C FP and CD 155 YFP. In contrast to the im m unofluorescence staining, where 
gpUL141 w as only detected  on the outer surface o f  inclusion bodies, U L141CFP and 
CD 155 YFP w ere present th roughout the inclusion.
4.3.2 Intracellular localisation of CD155 and gpUL141
W hile gpUL141 w as show n previously (by im m unofluorescence) to be expressed in the 
ER (Tom asec et al. 2005), it w as not possible at that time to image the retained 
in tracellu lar form o f  CD 155 with antibodies. H FFFs transfected with pCD 155Y FP and 
pUL 141CFP w ere therefore stained for the ER m arker calnexin. Calnexin associated 
closely with CD 155 and gpUL141 (fig 4.10); indeed it was detected both in inclusion 
bodies and granular particles. There are occasional points o f  calnexin staining which do 
not correspond to CD 155 or gpUL141 but the m ajority does co-localise. The distribution 
o f  calnexin show  that the interaction betw een CD  155 and gpUL141 occurs in the 
endoplasm ic reticulum . The presence o f  large areas o f  calnexin staining corresponding 
w ith inclusion bodies suggest that the endoplasm ic reticulum  has been distended by the 
com plex form ation. The high level o f  calnexin co-localisation with the CD155-gpUL141 
com plex indicates that calnexin is also involved in the com plex. Calnexin is a chaperon 
protein that binds N -linked glycoprotein in the endoplasm ic reticulum. Both gpUL141 
and the im m ature ER -resident form  o f CD 155 have N-linked oligosaccharides so an 
interaction w ith calnexin is to be expected.
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Figure 4.10. Co-localisation of calnexin with gpUL141 and CD155.
HFFFs were transiently transfected with expression plasm ids expressing (A) gpUL141- 
CFP fusion protein (pUL141CFP), (B) CD155-YFP fusion protein (pCD155YFP) or (C) 
CD 155-YFP (pCD155YFP) and gpUL141-CFP fusion protein (pUL141CFP) using 
Nucleofector. Three days following transfection, cells were fixed, stained with the anti- 
calnexin monoclonal C8.B6 (Chemicon) with goat anti-mouse AF647 as the secondary 
m onoclonal then imaged directly. Fluorescence was detected and analyzed with a Leica 
SP5 resonant scanning confocal microscope. Images shown are o f  two separate cells, 
scale bar is 5pm. (A) CD 155YFP is shown in yellow, (B) gpUL141CFP is shown in 
cyan, (C) Calnexin staining is shown in red (D) overlay o f  yellow and cyan channels, (E) 
overlay o f  cyan and red channels (F) overlay o f  yellow and red channels (G) overlay o f  
all three channels.
5 pm
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4.4 Ad RECOMBINANTS ENCODING UL141 AND CD155 IN LIVE HUMAN
FIBROBLASTS
RAd expressing UL141 and CD 155 were created to overcom e the lim itations o f  
transfection. Fibroblasts transfect at low efficiency, even the higher efficiency 
N ucleofection technique does not transfect all cells. A dditionally , N ucleofection requires 
the cells to be in suspension during electroporation w hich is inappropriate for the study o f  
UL141. UL141 expression reduces the ability o f  H FFF to adhere (chapter 3), this system  
m ay be selecting against high expression o f  U L 141. RA d vectors overcom e these 
lim itations. RAd infections are m uch m ore controllable and reproducible, which m eans 
that 100% o f  cells can easily be infected. A dditionally , RAd infections are perform ed on 
pre-adhered cells w hich is ideal for the study o f  adhesion-m odifying factors. A RAd 
expressing UL141CFP (R A dU L141C FP) w as generated by recom bineering as described 
in m aterials and m ethods and used in concert w ith a RAd expressing CD 155m Cherry 
(R A dC D 155m C h) that had already been generated in the laboratory.
Initially, cells were infected individually w ith RA dCD 155m C h or with RAdUL141CFP. 
Reassuringly, both viruses produced distributions in agreem ent w ith the transfection 
studies. RA dU L141C FP infection produced fluorescence w ith intracellular distribution 
(fig 4.11 A). How ever, the distribution is m uch m ore diffuse and without the inclusion 
bodies observed previously in the transfection images. CD 155 had a cell surface 
d istribution (fig 4 .11B). The fluorescence is less even than w hen C D 155 is expressed 
follow ing transfection. There are intracellular
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Figure 4.11. Recombinant adenoviral vectors encoding CD155 and UL141.
HFFFs were infected with (A) RAdUL141CFP or (B) RAdCD155mCh incubated for 
three days then imaged directly.
concentrations o f  CD 155 visible which are likely CD 155 expressing  intracellular 
vesicles.
Interestingly, infection w ith R A dC D 155m C h had a m arked effect on the m orphology o f  
the fibroblasts. Cells overexpressing C D 155 appeared th inner and elongated com pared to 
uninfected fibroblasts. This change in m orphology is probably caused by an increase in 
cell adhesion caused by the overexpression o f  CD 155. A lso, these cells frequently had 
long thin protrusions w hich began at the cell m em brane and extended away from the cell.
In co-infection experim ents CD 155 is retained w ithin the cell and co-localises with 
gpUL141 (fig 4.12). As w ith the transfection system , inclusion bodies, consisting o f  both 
U L141CFP and CD 155m C h, are observed. H ow ever, the inclusion bodies are generally 
larger and less well defined than those observed previously. The suppression o f  CD 155 
from  the cell surface w as less efficient in RAd infected cells com pared to transfected 
cells. CD  155, w ithout gpU L141, was visible on the surface o f  RAd infected cells.
W hen UL141 is expressed in the presence o f  only endogenous CD 155 there was few to 
no inclusion bodies present. H ow ever w hen both UL141 and CD 155 are m assively 
overexpressed by RAd infection, the inclusion bodies w ere frequently observed and were 
generally larger. The variation in size is likely because o f  the variable expression levels 
o f  both proteins. This suggests that the inclusion bodies form by CD 155 com plexing 
with gpUL141 and not by gpUL141 alone. Previously, gpUL141 had been shown to 
form  large m ultim eric com plexes with itse lf (Mel A rm strong, PhD thesis) which had
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been hypothesised to be responsible for creating the bodies o f  high gpUL141 
concentration.
4.5 IMAGING CD155YFP IN HUMAN FIBROBLASTS DURING HCMV 
INFECTION
H aving established that gpUL141 and CD  155 co-localise w hen both proteins are 
expressed via transfection or RA d infection, it w as then im portant to study the 
d istribution o f  CD 155 during H C M V  infection. All studies described so far have 
excluded all other HCM V proteins to image the interaction betw een CD  155 and 
gpU L 141. H ow ever the situation is m ore com plex during HCM V infection. Recently, it 
has been identified that gpUL141 functions in concert w ith another, yet unidentified, 
H C M V  protein to suppress the cell surface expression o f  nectin-2 (Tom asec, personal 
com m unication).
Previous attem pts to visualise CD 155 during H CM V  infection used im m unofluoresence 
(Tom asec et al. 2005). As stated above, the im m ature intracellular form o f  C D 155 is not 
recognised by available antibodies. How ever, the C D 155 fluorescent fusion protein 
enables the direct visualisation o f  intracellular CD 155, so it is ideal for visualising 
CD  155 during HCM V infection. Fibroblasts w ere transfected with pC D 155Y FP, allowed 
to adhere that infected with HCM VAUL141 or the parental M erlin strain HCM V. After 
three days the cells w ere imaged directly.
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Figure 4.13. CD155 distribution in HCMV-infected fibroblasts
HFFF were transfected with pCD155YFP then infected with either (A) AUL141HCM V 
or (B) M erlin HCM V AUL141 HCMV then imaged after three days
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The HCM VAUL141 had been described  as losing the ability to suppress cell surface 
expression o f  CD  155 (P rod 'hom m e, personal com m unication) and this was confirm ed by 
the im ages (fig 4 .13A). In C D 155Y FP -expressing  fibroblasts infected with 
HCM V A U L141, CD 155 disp layed  the standard  cell surface fluorescence with no 
intracellular fluorescence. Indeed, as previously  described for laboratory strain which 
lack UL141 (Tom asec et al. 2005), cells appeared to have upregulated cell surface 
expression o f  CD 155.
C D 155Y FP-expressing fibroblasts infected w ith M erlin  strain H C M V  displayed 
dow nregulation o f  cell surface C D  155 with the characteristic inclusion bodies present 
(fig 4 .13B ). The inclusion bodies observed w ere generally sm aller than those observed 
previously. The dow nregulation  o f  CD 155 w as not as efficient as observed in both the 
transfection and RAd infection experim ents. Extensive cell surface CD 155 fluorescence 
is observed in addition to the intracellular fluorescence. This is to be expected as CD155 
is hugely overexpressed com pared to norm al cellu lar levels.
This show s direct visual evidence that CD  155 is dow nregulated  from  the cell surface and 
retained w ithin the cell during H CM V infection. D espite any other interactions involving 
gpUL141 that occur during H CM V infection, the interaction w ith CD 155 and form ation 
o f  inclusion bodies originally  observed in the transfection  system  are preserved during 
H C M V  infection.
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4.6 SUMMARY
W hen CD  155 is expressed in the presence o f  UL141 it is retained w ithin the cell as in an 
im m ature form . This im m ature form  is not recognised by anti-C D  155 m Abs, which, 
therefore, prevents the v isualisation  o f  the interaction betw een CD 155 and gpUL141. 
Fluorescent fusion proteins o f  both CD  155 and UL141 w ere generated to enable the 
direct visualisation and characterisation  o f  the interaction betw een CD155 and gpUL141. 
Initially, this was im portant to confirm  the findings o f  Tom asec and colleagues (2005), 
then used to further our understanding o f  the interaction. The fusion proteins had 
distributions consistent w ith previously published observations w hen expressed 
individually. W hen co-expressed, either by transfection or RAd infection, CD 155 was 
dow nregulated from the cell surface and retained w ithin the cell in agreem ent with 
Tom asec (2005). H ow ever, because o f  the fluorescent m oiety fused to CD155 it was 
possible to directly im age the im m ature in tracellu lar form  (see table 4.1 for summ ary o f  
fluorescence results). W hen co-expressed w ith UL141, CD 155 was intracellular and co ­
localised closely with gpUL141 in the ER. Large bodies o f  high fluorescence were often 
observed. These inclusion bodies w ere com prised evenly o f  both gpUL141 and CD 155.
A dditionally , I show  that the ER chaperone, calnexin , closely co-localises with CD 155 
and gpUL141 and is included in the inclusion bodies. A s both CD155 and gpUL141 are 
glycoproteins it is likely that calnexin interacts with both proteins.
The size and frequency o f  the inclusion bodies vary considerably . It appears that size and 
prevalence o f  these bodies depend on the relative expression levels o f  both proteins;
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w hen UL141 is expressed only in the presence o f  endogenous CD 155 (high gpUL141, 
low  C D 155) there were very few  inclusion bodies present, w hile w hen both proteins are 
expressed by RA d infection (high gpU L 141, high CD 155) the inclusion bodies are large 
and plentiful.
Finally, the distribution o f  CD  155 during H C M V  infection w as studied. Fibroblasts 
infected w ith HCM VAUL141 did not dow nregulate cell surface CD 155, while infection 
w ith the parental strain M erlin H C M V  did result in the dow nregulation o f  CD 155. As 
w ith the transfection and RA d infection experim ents, intracellular CD 155 accum ulated in 
inclusion bodies. This show s that despite the function o f  gpUL141 being m ore com plex 
during HCM V infection the interaction w ith CD  155 is m aintained.
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Table 4.1. Summary of Fluorescent imaging results
Cell
Type
Expression Method Expression
construct/virus
Expression Distribution
293
Cells
Effectene transfection pC D 155C FP C D 155C FP Cell Surface
pC D 155Y FP C D 155Y FP Cell Surface
pU L 141C FP U L141C FP Intracellular
pUL141 YFP U L 141 YFP Intracellular
pC D 155C FP, 
pUL141 YFP
C D 155CFP, 
UL 141 YFP
Intracellular, CD 155 
and UL141 co-localise
pC D 155Y FP ,
pU L 141C FP
CD 155 YFP, 
U L141CFP
Intracellular, CD 155 
and UL141 co-localise
HFFF N ucleofector
T ransfection
pC D 155C FP CD 155C FP Cell Surface
pC D 155Y FP C D 155Y FP Cell Surface
pU L 141C FP U L141CFP Intracellular
pUL141 YFP UL 141 YFP Intracellular
pC D 155C FP, 
pUL141 YFP
CD 155CFP, 
UL141 YFP
Intracellular, CD 155 
and UL141 co-localise
pC D 155Y FP ,
pU L 141C FP
CD 155 YFP, 
UL141CFP
Intracellular, CD 155 
and UL141 co-localise
N ucleofector 
transfection w ith anti- 
C alnexin
im m unofluorescence
pC D 155Y FP,
pU L 141C FP
CD 155Y FP,
U L141CFP
Intracellular, CD 155, 
UL141 and calnexin 
co-localise
RA d Infection R A dU L141C FP U L141C FP Intracellular
R A dC D 155m C h CD 155m C h Cell Surface
R A dU L141C FP, 
R A dC D l 55m Ch
U L141C FP, 
CD 155m C h
Intracellular, CD 155 
and UL141 co-localise
N ucleofector 
transfection w ith 
H CM V  infection
pC D 155Y FP, 
strain M erlin 
H CM V
C D 155Y FP Intracellular CD 155
pC D 155Y FP, 
AUL141 H CM V
C D 155Y FP Cell Surface CD 155
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5 CHARACTERISATION OF gpUL141 IN HCMV 
VIRUS PARTICLES
H C M V  disease can be associated  w ith the infection o f  an extrem ely w ide range o f  cell 
types in vivo , how ever in v itro  efficien t virus production is best achieved in prim ary 
hum an fibroblasts. Recent studies have revealed that to adapt to grow th in fibroblasts 
H C M V  clinical isolates reproducib ly  develop m utations in the UL 128-131A locus (Dolan 
et al. 2004; S inzger et al. 2000) and UL135 (S tanton et al, m anuscript in preparation). 
M utation in UL 128-131A is associated w ith loss o f  endothelial and m yeloid cell tropism  
(section 1.2.4). Interesting, UL141 is also often deleted from  the genom e o f  HCM V 
clinical isolates, although the selective pressure is clearly m uch less than for UL135 and 
UL 128-131A (D avison, personal com m unication).
A lthough gpUL141 is a H C M V -encoded transm em brane glycoprotein, it was not initially 
considered to be a strong candidate to be a virion protein. The protein was shown to be 
retained in the ER, w hich is not the site for virion production. A dditionally, UL141 has a 
recognised function in suppressing N K  cell recognition during productive infection. 
H ow ever, C D 155 is a recognised receptor for poliovirus and a range o f  herpesviruses 
(section 1.6.3). I f  gpUL141 w ere to be in the virion, it is possible that the interaction 
betw een gpUL141 and CD 155 could potentially  be involved during virus entry. M ost 
studies o f  H CM V virion glycoproteins have been perform ed using the laboratory strain 
AD 169 and Tow ne, w hich are both deleted in UL 141. I therefore set out to determ ine 
w hether gpUL141 w as a com ponent o f  virions.
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5.1 gpUL141 IS A COMPONENT OF MERLIN HCMV VIRUS PARTICLES
To study the com position  o f  H C M V  virions, it is necessary first to purify them  free from 
the cellu lar debris. Strains M erlin and A D  169 strain w ere cultured in HFFF cells, then 
purified by ultracentrifugation over a continuous glycerol-sodium  tartrate gradient. 
Follow ing centrifugation three bands are visible; N IEPs at the top, m ature virus particles 
in the m iddle and dense bodies at the bottom . The m ature virus particle band was 
rem oved from the gradients w ith a  large gauge needle then w ashed and resuspended in 
sodium  phosphate buffer. The presence o f  virus particles w as tested by blotting for the 
H C M V  envelope g lycoprotein  gB. O ccasionally  virion envelopes can be lost through 
osm otic shock, thus gB w as indicative that the virions w ere intact. To control for cellular 
protein contam ination the sam ples w ere probed for the m ajor im m ediate-early protein 
IE lp 7 2 , which is know n not incorporated into virions. Strain M erlin-infected HFFF 
extract, purified strain M erlin virions and purified strain AD 169 virions were all positive 
for gB (fig  5.1 A), w ith a 55 kD a band visib le in all three lanes. The m A b used for 
detection o f  gB recognises only the cleaved 55kD a transm em brane com ponent but not the 
extracellu lar com ponent or uncleaved precursor. The detection o f  the 72 kD a IE1 protein 
w as in strain M erlin-infected cell extracts, but in neither o f  the tw o purified virion 
preparations (fig 5 . IB ), w as evidence that the purified virus preparation are not 
contam inated with extraneous protein from infected cells.
150
CMV cell 
extract AD169 Merlin
50-
B
gB
IE-1
75-
35-
75-
50-
E
35-
UL141
CD155
UL14
Figure 5.1. gpUL141 but not gplJL14 or CD155 is a component of the Merlin 
HCMV virus particle.
Strain AD 169 HCMV and strain Merlin HCM V were purified by ultracentrifugation in a 
glycerol-tartrate gradient. Purified virus particles and the cell extract o f  HCMV infected 
HFFF were blotted with the (A) 2F12 mAb specific for the envelope glycoprotein gB, (B) 
8b 1.2 mAb to the immediate-early protein IE-1, (C) the gpUL 141-specific M550 mAbs, 
(D) 5 D 1 mAb to CD 155 and (E) mAbUL 14 specific for gpUL 14. Left margin, molecular 
sizes (in kDa).
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Having established that the purified  viruses w ere free o f  cellu lar contam ination, they 
w ere then blotted for gpUL141 (fig 5.1C). Strain M erlin-infected  cell extract was 
positive for gpUL141 w ith a double band visib le at 37 and 40 kDa. UL141 is encoded by 
UL /b ' sequence that is m issing from  all passaged strains o f  H C M V , strain AD 169 virions 
w ere therefore included as a negative control for non-specific antibody binding. Purified 
strain AD 169 virions w ere negative for stain ing w ith the gpUL141 mAb.
Purified strain M erlin v irions w ere positive for gpUL141 staining. gpUL141 stained as a 
doublet approxim ately  the sam e size as the gpUL141 staining in M erlin strain HCM V- 
infected cell extract. A dditionally , there is a selective concentration o f  gpUL141 in the 
virion, as w as observed also for gB. The gpUL141 staining o f  the purified strain M erlin 
virion is not because o f  contam ination  w ith cellu lar proteins as the strain M erlin virions 
stain negative for the in tracellu lar localised im m ediate early protein IE lp72 . Therefore, 
gpUL141 is a com ponent o f  the strain M erlin H C M V  virion.
gpUL141 and CD 155 co-localise w ithin infected cells w hen co-expressed, indicative o f  
the proteins being in a com plex (C hapter 4). To determ ine if  CD 155 is also incorporated 
into the virus the purified  virus w as blotted for CD 155 (Fig 5 .ID ). W hen blotted for 
C D 155, strain M erlin-infected HFFF d isplays bands at 75 and 50 kDa. However, both 
M erlin and A D I69 purified virus particles are negative for CD 155.
A lthough gpUL141 and CD  155 co-associate in fibroblasts, only gpUL141 was 
incorporated into the virion. The selective incorporation  o f  gpUL141 was consistent with 
it being an active process rather than non-specific  incorporation o f  infected cell
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glycoproteins. C ellu lar pro teins can detected in purified v irions, and it m ay be possible 
that m ore sensitive assays could  detect the presence o f  low  am ounts o f  C D 155 in the 
virion. H ow ever, there is no concentration  o f  CD  155 as there is for gpUL141 and gB. 
Therefore, CD  155 is not intentionally  incorporated  into the virion. The result also 
im plies that since gpUL141 in v irions m ay yet have the capacity  to bind CD 155 during 
the infection process.
gpU L14 is the only know n hom ologue to gpU L 141 . There are functional sim ilarities 
betw een the tw o proteins; w hen expressed from  an Ad vector gpU L14 can suppress NK 
cell function (W ilkinson, personal com m unication), and gpU L14 also reduces cell 
adhesion to the sam e extent as gpUL141 (C hapter 3.2). Because o f  the structural and 
functional sim ilarities, the purified  virus particles w ere then blotted for gpUL14. Strain 
M erlin-infected cell extract produced a band at 30 kDa, w hile both strains M erlin and 
AD 169 purified virions w ere negative. Both strains o f  H C M V  used encode UL14, 
express gpU L14 during productive infection but neither incorporates gpUL14 into their 
virions. This is further evidence that the incorporation o f  gpUL141 into the virion was 
selective.
5.2 LOCATION OF gpUL141 IN THE VIRION
H CM V virus particles consist o f  three parts: capsid, tegum ent and envelope (fig 1.3). 
G lycoproteins involved in virus attachm ent and entry are invariably associated with the
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envelope. If  gpUL141 is in the envelope, it m ay be on the outside surface o f  the virion 
and in a topologically  appropriate  location to be involved in virion attachm ent and entry
Purified strain M erlin virus particles w ere d issolved in T riton X -100 for one hour at 4°C. 
The precipitate w as centrifuged  and the soluble fraction w as extracted. Follow ing the re­
suspension o f  the insoluble precip itate  the tw o fractions, plus whole purified M erlin 
virions were exam ined on W estern blots using m A bs to the tegum ent protein pp65, the 
envelope glycoprotein  gB and gpUL141 (fig  5.2A). pp65 was only present in the 
insoluble fraction, consisten t w ith the tegum ent protein rem aining attached to capsids 
during the extraction process. gB w as present in both the soluble fraction and the 
insoluble fraction, indicating that the v irion envelope has not been com pletely dissolved. 
Parts o f  the envelope m ay rem ain  attached to  the tegum ent follow ing detergent treatm ent 
(Farrar and Oram  1984). If  the envelope w as com pletely dissolved gB w ould be only 
present in the soluble fraction. gpUL141 follow s the sam e pattern as gB; gpUL141 is 
present in both the insoluble and soluble fractions. A s the soluble fraction was free from 
tegum ent and capsid, this im plied that gpUL141 w as present in the envelope o f  the 
virion. H ow ever, because o f  the incom plete separation o f  the envelope from the 
tegum ent and capsid it w as not possible to rule that gpUL141 w as present only in the
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Figure 5.2. Detergent fractionation of the Merlin virion.
Purified strain Merlin virus particles were dissolved in either Triton x-100 (A) or 1% NP- 
40 and 0.5%  deoxycholoate (B). The insoluble portion was spun down and the soluble 
portion was removed. The pelleted insoluble portion o f the virus particles was 
resuspended. Purified M erlin virus and both the insoluble fraction and the soluble 
fraction were blotted for pp65, gB and UL141.
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envelope. Triton X-100 has reduced effectiveness at low  tem peratures, which may 
prevent com plete separation o f  the envelope (Roberts 2008).
The previous m ethod used Triton X -100, a non-ionic detergent. N on-ionic detergents are 
typically m ilder and less likely to denature proteins than ionic detergents. To enhance the 
separation o f  the m em brane, a m ixture o f  non-ionic and ionic detergents were used. 
Purified M erlin virus particles w ere dissolved in N P40, a  non-ionic detergent, and sodium 
deoxycholate, an ionic detergent, for one hour at room  tem perature (W ang et al. 2004c). 
The soluble fraction w as rem oved and the insoluble precipitate was redissolved in sodium  
phosphate buffer. Both fractions plus whole virus particles were blotted for pp65, gB and 
gpUL141 (fig 5.2B). pp65 is present only in the w hole virus particles and in the 
insoluble fraction (fig 5.2A ); thus show ing that the capsid and tegum ent have separated 
together into the insoluble fraction. gB is present in the soluble fraction and absent from 
the insoluble fraction (fig 5.2B). This show ed that the envelope has been successfully 
dissolved from the rest o f  the virus. It also show s that the inclusion o f  an ionic detergent 
has not denatured the virion envelope proteins. W hen the fractions are probed for 
gpUL141 (fig 5.2C), the protein was predom inantly present in the soluble fraction with a 
small am ount detected in the insoluble fraction. This result was also consistent with that 
gpUL141 being present in the envelope m em brane. The C-term inal tail o f  gpUL141 is 
predicted topologically to be inside the virion envelope. The fact that gpUL141 was also 
detected in the insoluble fraction suggests that a com ponent o f  the protein may interact 
w ith the tegum ent, to a greater degree than gB. N evertheless, gpUL141 was 
predom inantly  located in the H CM V  envelope, consistent w ith it being a transm em brane 
glycoprotein.
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5.3 GLYCOSYLATION OF VIRION gpUL141
For gpUL141 to be incorporated  in the v irus particle it m ust be trafficked from the ER to 
the cytoplasm ic assem bly site. Endo H selectively cleaves h igh-m annose asparagines- 
linked o ligosaccharides typically  associated with core oligosaccharide added to proteins 
the ER, but not processed com plex oligosaccharides. R em odelling o f  oligosaccharides 
occurs during protein traffick ing  through the Golgi apparatus, with high-m annose 
oligosaccharides being trim m ed and converted to com plex oligosaccharides. Cell- 
associated gpUL141 w as sensitive to Endo H digestion, which is consistent with 
im m unofluorescence studies show ing gpUL141 being ER resident. To be incorporated 
into virions, however, gpUL141 m ust exit the ER. To assess w hether gpUL141 is 
processed through the Golgi apparatus, the glycosylation status o f  gpUL141 from cells 
and virus particles w as exam ined. Strain M erlin  HCM V was purified by isopycnic 
gradient u ltracentrifugation then digested overnight w ith Endo H or with PNGase.
PN G ase deam inates asparagine to release all high-m annose and com plex 
oligosaccharides from  glycoproteins.
gB in strain M erlin virions and infected-cell extract display the sam e pattern o f  
glycosylation (fig 5.3A ), w hich is consistent w ith previously published results (M arshall 
et al. 1996; Strive et al. 2002a). gB is partially  sensitive to Endo H digestion but further 
sugar residues are released w hen digested by PN G ase. This is consistent with gB in both 
cells and virus particles being a hybrid m olecule consisting o f  both high m annose and 
com plex oligosaccharide side chains. To achieve partial protection against PNGase, gB 
presum ably has been exposed to enzym es in the Golgi apparatus.
157
gpUL141 in strain M erlin-infected cell extract m igrated by SD S-PA G E to produce a 
protein doublet w ith m olecular m ass estim ated to be 40 and 37 kD a (fig 5.3B).
Follow ing digestion by Endo H or by PN G ase, gpUL141 is deglycosylated to a 35kDa 
band. gpUL141 in infected cell extracts w as sensitive to Endo H, which is consistent 
with gpUL141 being as ER resident protein. gpUL141 present in purified M erlin virions 
appeared to co-m igrate w ith gpUL141 in cell extracts. PN G ase digestion o f  gpUL141 
from  purified virions yielded a single 34kD a product. Endo H digestion o f  gpUL141 
from  virions produced tw o m ajor products w ith apparent m olecular m asses o f  38 and 36 
kDa, w hile PN Gase digestion o f  cellu lar gpUL141 produced a single band at 34kDa. 
PN Gase treatm ent o f  virions and cell extracts generated a sim ilar size product; consistent 
with there being no obvious m odification o f  the protein backbone during incorporation o f  
gpUL141 into the virus particle. The slow er m igrating band in the virion is com pletely 
protected by Endo H, w hile the faster m igrating for is partially susceptible to digestion. 
This is consistent with tw o populations o f  gpUL141 being packaged. The fact they 
appear to reduce to a single size on PN G ase treatm ent indicated that they were different 
glyocoform s. O ne o f the glycoform s was processed to  a  com pletely Endo H-resistant 
form , w hile the other w as only partially protected; like gB corresponding to a hybrid 
glycoprotein. W hile the m ajority o f  gpUL141 in infected cells rem ained Endo H 
sensitive and ER -localised, a proportion appeared to transit through the Golgi apparatus 
to be selective incorporated into H CM V virions.
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F igure 5.3. G lycosylation  o f  UL141 in cells and virus particles.
Cell extract o f  HFFF infected with strain M erlin HCM V and purified strain Merlin 
HCM V virus particles were digested overnight with Endoglycosylase H (E), PNGase (P) 
or mock digested (C). The digested cell extracts and virus particles were then blotted 
with 2F12 m Ah specific for the envelope glycoprotein gB and the gpU Ll41-specific 
M 550 mAbs
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5.3.1 Timecourse of gpUL141 glycosylation
gpUL141 in strain M erlin v irions has a different pattern o f  g lycosylation from gpUL141 
in the ER. H C M V  has an exceptionally  slow  replication cycle in fibroblasts. Typically, 
de novo  virus production is first detected at 72h p.i., yet peak levels are not reached until 
120 h p.i.. In this laboratory, N K  assays are typically  perform ed at 72 h p.i., and thus that 
was the preferred tim e point to m onitor gpUL141 expression. A t 72h p.i., the function o f  
gpUL141 w as likely to be biased tow ards CD  155 retention rather than virus production. 
Since the com plex glycosylation pattern w as associated w ith virion production, I sought 
to fo llow  gpUL141 expression tem porarily  across a full cycle o f  productive infection. 
HFFF w ere infected w ith M erlin H CM V at a high M OI and cell extracts were collected at 
24 hour intervals. The cell extracts were then digested overnight with Endo H or PN G ase 
(fig 5.4). All sam ples w ere blotted for actin to control for protein levels (fig 5.4A). gB 
w as blotted to control for virus infection and digestion by Endo H and PN Gase (fig 
5.44B). gB is first detected at 3 days post infection with the sam e pattern o f  
glycosylation observed above. gpUL141 is first detected at day 2 and the protein 
accum ulates during the tim ecourse (fig 5.4C). gpUL141 is first detected as is a single 40 
kD a species (2 days p.i.). yet over the course o f  infection a faster m igrating species 
becom es m ore abundant. By 5 days p.i. the tw o form s o f  gpUL141 are expressed in 
sim ilar abundance. The Endo H and PN G ase digestion follow  the sam e pattern. At early 
tim epoints, Endo H and PN Gase digestion both produce a single product at about 34kDa 
w hile at later tim e points deglycosylation o f  gpUL141 produces a doublet with the 
apparent sizes 32 and 34 kDa. As this doublet is present in the undigested and PNGase
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Figure 5.4. UL141 glycosylation  during the course o f  H C M V  infection.
HFFF were infected with strain Merlin HCMV at a moi o f  5. Samples were taken at 0, 1, 
2, 3 ,4  and 5 days post infection. The cells extracts were mock digested (C) or digested 
with Endoglycosidase H (E) or PNGase (P). The digested extracts were blotted for gB, 
UL141 and actin.
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digested sam ples it due to a m odification (possibly proteolytic  processing) in the protein 
backbone o f  gpUL141 rather than a change in glycosylation.
5.3.2 Comparison of the glycosylation of gpUL141 from cells and virus particles
In the previous section small differences in the m igration o f  gpUL141 was observed 
betw een sam ples. It w as unclear w hether these differences w ere actual differences in 
m olecular w eight or a result o f  uneven m igration on nonadjacent tracks on the 
polyacrylam ide gel. To m inim ise gel effects and to enable m ore direct com parison o f  the 
digested form s o f  gpU L 141, a w estern blot was perform ed w ith  the sam ples grouped by 
glycosidase digestion m ethod (fig 5.5). The undigested products o f  the three sam ples all 
m igrate as a  doublet consisting o f  40 and 37 kD a products, albeit in different abundance. 
H ow ever, the pattern o f  Endo H digestion is d ifferent in each o f the three samples. 
gpUL141 from both H C M V -infected cell extracts (day 3 and 5) are sensitive to Endo H 
digestion. D igestion o f  gpUL141 in the 3 day p.i. cell extract produced a single band 
with an apparent m olecular w eight o f  34 kDa. A doublet, w ith  the apparent m olecular 
w eights o f  34 and 32 kDa. w as observed follow ing digestion o f  5 day p.i. cell extract. 
gpUL141 in virions exhibits a degree o f  resistance to Endo H, the 40 and 36 kDa species 
corresponds to the doublet observed in the undigested fraction. How ever, the apparent 
increase in the 36kD a form and appearance o f  low  abundance faster m igrating species 
indicated som e sensitivity to Endo H. PN G ase digestion produces a single 34 kDa band 
in both the day three post infection cell ex tract and the purified  virion, while PNGase 
digestion o f  day five cell extract produces a 34 and 33 kD a doublet.
Mock Digested 
Day 3 Virion Day 5
Endo H Digested 
Day 3 Virion Day 5
PNGase F Digested 
Day 3 Virion Day 5
35-
Figure 5.5. Comparison of glycosylation of early and late time point gpUL141 and 
virion gpUL141.
Cell extracts from fibroblasts infected with a high moi o f  strain Merlin HCMV were 
taken at three days post infection and five days post infection. Purified strain Merlin 
virions and the cell extracts were digested overnight with Endo H, PNGase or mock 
digested. The digested samples were then blotted for gpUL141.
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Taken together these results indicated that the tw o species observed during the early 
stages o f  H C M V  infection in fibroblasts w ere probably the result o f  two different 
glycosylated form s on the sam e gpU L 141 protein  backbone. Rem oval o f the 
o ligosaccharides by Endo H or PN G ase produces a  single product. However, the two 
predom inant species observed during the latter stage o f  infection (day 5) were produced 
follow ing the glycosylation o f  tw o different sized protein backbones. The nature and 
function o f  the additional processed form  o f  gpUL141 produced late in infection is 
currently  not know n, it w as not packaged into virions. A dditional low  abundance bands 
visible on w ith undigested sam ple (day 5), w ould also be consistent with it also being 
expressed as tw o glycoform s. gpU L 141 incorporated into the virion has a different 
glycosylation pattern than the m ost abundant form  o f  gpUL141 from  HCM V-infected 
cells; the v irion-associated gpUL141 being resistant to Endo H digestion. This shows 
that the virion-associated form  o f  gpUL141 does not accum ulate w ithin the cell; rather it 
m ust be processed then rapidly incorporated into the virion.
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5.4 NEUTRALISATION OF HCMV INFECTION WITH ANTI-GPUL141 
ANTIBODIES
UL141 is located on the envelope o f  H CM V virus particles. The possibility exists that 
gpUL141 could have a role in virus infection, possibly exploiting its interaction with 
CD 155. A s a com ponent o f  the virion envelope, gpUL141 also becom e a potential target 
for the hum oral im m une system . To investigate w hether gpUL141 is accessible on the 
surface o f  virion for antibody binding, a neutralisation assay w as perform ed.
As controls, HCM V seropositive (H S3) and seronegative (H S 1 1) hum an polyclonal 
antibodies w ere used to set param eters. Since gB is recognised to contain a num ber o f  
neutralising epitopes, a m A b to gB potentially  provided a positive control. I was 
fortunate to have access to  tw o g p U L l41 -specific m A bs (m 550.2 and m 550.3) and a 
strain M erlin reported virus encoding a U L32G FP fusion protein. Both gpUL141- 
specific m A bs were generated against a soluble form  o f  gpUL141 which only consists o f  
the extracellular dom ain. H C M V  was m ixed w ith doubling dilutions o f  serum or 
m onoclonal antibodies then the m ixture w as added to confluent fibroblasts in triplicate. 
A dditionally, virus w ithout any antibodies w as added to fibroblasts to control for initial 
virus levels. After 2 days the cells were exam ined and the num ber o f  green fluorescent 
cells were counted. H CM V  positive hum an sera neutralised the infection, while HCM V 
negative hum an serum did not. 50%  neutralisation occurred at a dilution greater than 
1:640 for positive serum  HS3 (fig 5.6). M A bs specific for gB neutralised the infection 
with 50%  neutralisation occurring at a d ilu tion betw een 1:80 and 1:160. M Abs specific
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Figure 5.6. Neutralisation of HCMV infection by human sera and HCMV specific 
monoclonal antibodies.
N eutralisation o f  HCMV infection o f  HCM V positive human serum (HS3), HCM V 
negative hum an serum (H S 11), two gpUL141 specific m Abs (m550.2 and m 550.3) and 
gB specific mAb. GFP positive cells were counted. Data shown is the mean o f  three 
replicates with the standard deviation.
for UL141 did not neutralise at any d ilu tion  used (fig 5.6). It is possible that the UL141- 
specific antibodies are b inding to the v irion but not enough to induce neutralisation. 
These results show  that U L141 -specific antibodies do not neutralise H CM V  infection. 
This could m ean that UL141 is not on the outside o f  the envelope and, therefore is not 
accessible to the antibodies. A lternatively , the UL141 antibodies m ay be binding to 
UL141 but are unable to  neutralise the infection.
5.5 FLOW CYTOMETRY ANALYSIS OF HCMV VIRIONS
In a further attem pt to detect gpUL141 on the surface o f  M erlin virus particles flow  
cytom etry was used. B russaard and colleagues (2000) have described the ability to detect 
fluorescence-labelled H C M V  virions by flow  cytom etry. How ever, the use o f  flow  
cytom etry to stain for H CM V  virion glycoproteins appears to be novel approach.
Initially. I needed to establish  that H C M V  virions could be detected by flow  cytom etry. 
Recom binant H CM V  virions encoding a U L32G FP fusion protein, U L32G FP-RCM V , 
were purified using ultracentrifugation then  inactivated by gam m a-irradiation (data not 
shown). U nstained purified U L32G FP-R C M V  virions w ere then analysed by flow 
cytom etry. Individual virus particle w ere observed by side and forw ard scatter (fig 
5.7A). The virus particles w ere also detected by G FP fluorescence, w hile untagged 
HCM V virions were negative for G FP fluorescence (fig 5.7B).
Having established that individual virus particles could be detected by flow  cytom etry, I 
then attem pted to detect envelope g lycopro teins by stain ing with specific antibodies. In
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addition to the gpU L 141-specific  m A b, antibodies specific to the envelope glycoprotein 
gB and the tegum ent protein  pp65 w ere also used. The virions were stained with gB as a 
positive control o f  the stain ing  procedure and pp65 stain ing w as included to ensure that 
the virion particles w here intact. Purified and gam m a-irradiated  U L32G FP-RC M V  virus 
particles and AD  169 virus particles were stained for gB, pp65 and gpUL141 then 
analysed by flow  cytom etry  (fig 5.7B). A lthough initial prelim inary results were 
encouraging (not show n), it becam e apparent that a high level o f  non-specific and auto 
fluorescence w as responsible for the signal. Both M erlin and AD 169 purified virions 
also stained positive for gpU L141. A s A D  169 lacks the UL141 ORF, it m ust be 
concluded that th is result is non-specific binding o f  the antibody to the virion.
The detection o f  envelope glycoproteins by flow  cytom etry could potentially be a 
pow erful technique for the study o f  H C M V  virions. The developm ent o f  this technique 
w as lim ited by tim e and available reagents. There are still several lim itations to 
overcom e before this technique could be used.
The m ajor issue that needs to be addressed is the high level o f  non-specific fluorescence. 
The size o f  a virus particle lim its the am ount o f  antigen available; it is clearly much 
sm aller than a eukaryotic cell. High concentrations o f  antibody m ay therefore be 
required to produce a detectable signal. H ow ever, high antibody concentrations 
contribute to the high levels o f  background fluorescence. The developm ent and use o f
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Figure 5.7. Flow cytometry analysis of purified HCMV virions
(A) Forward scatter and side scatter profile o f HCM VUL32GFP. (B) GFP fluorescence 
o f  purified HCM VUL32GFP virions (red), black line is untagged HCMV virions. (C) 
Purified strain M erlin and strain AD 169 virions were stained with monoclonal antibodies 
specific for gB, pp65 and gpUL141 or with mouse IgGl as isotype control (black lines) 
then stained with anti-m ouse Alexa Fluor AF488. The stained virions were then analysed 
by flow cytometry.
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high affinity  antibodies could  reduce the level o f  background staining. A dditionally, a 
m ore robust blocking procedure m ay also reduce the level o f  background fluorescence.
A nother factor that m ay contribu tes to the high level o f  non-specific fluorescence is the 
presence o f  H CM V Fc receptors in the virion; The H CM V  Fc receptor gpU L l 19 has 
been detected in the virion (V arnum  et al. 2004). To m inim ise any effect o f  virion Fc 
receptors, Fab fragm ents w ere used for secondary staining.
The integrity o f  the virion m ay also lim it the usefulness o f  this technique. The 
centrifugation and irradiation o f  the virus particles m ay expose the tegum ent which could 
underm ine the aim  o f  the experim ent. S taining for tegum ent proteins, such as pp65, 
w ould allow  disrupted viral particles to be excluded from  analysis. It w ould be worth 
investigating other m ethods to m inim ise the disruption o f  the virions. By not irradiating 
or by using less purified preparations o f  v irions, viral integrity may be preserved.
I f  these issues can not be resolved then this technique can not be used to study envelope 
glycoproteins. H ow ever, it m ay be useful for titration o f  viruses. Individual virus 
particles can be detected and counted (fig 5.7A ) w hich enables the ratio o f  particle to 
plaque form ing units to be determ ined in conjunction w ith cell culture m ethods. Once 
the ratio is established, rapid titration o f  virus w ould be possible by counting virus 
particles by flow  cytom etry.
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5.5.1 FACS-based virus adhesion assay
A possible role for virion gpUL141 could be to bind cell surface CD 155 and thereby 
prom ote attachm ent. W hile it did not prove possible to detect antibody bound to virus 
particles to cells by flow  cytom etry, the presence o f  the U L32G FP fusion protein was.
By utilising fluorescent virus particles, it w ould therefore be possible to m easure directly 
the am ount o f  virus bound to a cell. The initial strategy w as to investigate HCM V 
binding to HFFF com pared w ith the sam e cell w ith knocked-dow n CD 155 expression.
To this end, H FFFs w ere infected w ith five d ifferent M ission Lentiviral shRN A 
transduction particles (S igm a-A ldrich , Poole, UK). Each replication deficient lentivirus 
encodes a shR N A , consisting o f  a 21 base sense sequence, a 6 base loop then a 21 base 
anti-sense sequence, w hich is designed to target CD 155 using a proprietary algorithm  
(sigm a) (fig  5.8A for clones nam es and shR N A  sequences). Follow ing infection o f  
H FFFs at a moi o f  5, genom ic integration w as selected for by the addition o f  G 418 to the 
grow th m edium . CD 155 knockdow n w as observed in 1/5 stable cells lines established by 
lentivirus transduction (fig 5.8B). The grow th rate o f  this knock dow n cell line was 
significantly slow er than those expressing norm al levels o f  CD 155. Frozen stocks o f  this 
cell line w ere established, how ever, the knock dow n o fC D 155  expression was lost from 
resuscitated cells. D uring recovery from  frozen stocks there w ould have been strong 
selective pressure against the dow nregulation o f  CD 155.
An alternative strategy w as devised to m easure if  gpUL141 on the virion enhanced virus­
cell binding. Fibroblasts w ere infected w ith RA dC D 155m C h (or m ock infected) for three 
days before H C M V U L32G FP w as added at 4°C for three hours (fig 5.9A). Unattached 
virus w as washed o ff  then adherent virus and cells w ere fixed
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AClone ID Sequence
TRCN0000062908 CCGG G A G GT AT CC A T CT CT GGCT AT CT CG AG AT AGCC A 
GAG AT GG AT A C CT CTTTTT G
TR CN 0000062909 CC G G CT AA T GG GC A T GT CT CCT ATT CT CG AG AAT AGG A 
G A CA TG C CCA TTA G TTTTTG
TR CN 0000062910 CCG G CCC A G CT ATT CGG AGT CC AA ACTCG AGTTT GG ACT 
CCG A A T AG CT GG G TTTTT G
TR C N 0000062911 CCGG C AG A G CCC AC AG GCT AT AATT CT CG AG AATT AT A 
GCCT GT G G GCT CT GTTTTT G
TR C N 0000062912 CCGGCGG CA AG AATGTG ACCTG CAA CTCGA GTTG CA GG 
T C AC ATT CTT G C CG TTTTT G
|  HFFF 
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Figure 5.8. CD155 Knock-down in lentiviral transduced HFFF
(A) Five lentiviral vectors encoding shRNA designed to target CD 155 coding region 
were obtained from Sigm a-Aldrich (Poole, UK). Official clone names and shRNA 
sequences shown.
(B) Stable cell lines were produced by infecting HFFFs with a lentiviral vector at a moi 
o f  5 then selecting for genomic integration under G418 selection. CD 155 knock-down 
was determ ined by flow cytom etry using the D171 mAb specific for CD 155 (Abeam). O f 
the 5 cell lines tested, only TRCN 0000062909 produced CD 155 knock-down (green 
line).
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with paraform aldehyde, trypsanised  then analysed by flow  cytom etry. G FP fluorescence 
was m easured as an indicator o f  virus attachm ent to the cells. M ock-infected cells plus 
G FP M erlin and R A dC D 155m C h infected cells plus G FP M erlin displayed a small 
increase in G FP fluorescence (fig 5.9B i). W hen G FP and m C herry fluorescence was 
graphed, R A dC D 155m C h infected cells plus PBS displayed tw o populations (fig 5.9Cii); 
a m Cherry positive, GFP negative population o f  RAd infected cells and a second 
m C herry negative, GFP negative population o f  uninfected cells. However, 
R A dC D 155m C h infected cells plus GFP M erlin  displayed a third population (fig 5.9Ciii). 
This GFP positive population is unbound virus particles. The m Cherry population o f  
cells are negative for GFP fluorescence. I f  virion binding to cells w as detected then the 
m Cherry positive population w ould be shifted for GFP fluorescence. Taken together this 
show s that the shift in G FP fluorescence show n in fig 5.9Bi is caused by unbound virus 
particles and not because v irusicell binding w as detected. Flow  cytom etry may not be 
suited for this experim ent. It is possible that the virus is sheared from  the cells during the 
processing o f  the sam ples. This w ould m ean that it is not possible to detect viriomcell 
binding by flow  cytom etry.
Follow ing flow  cytom etry, attem pts w ere m ade to observe virions attaching to cells by 
direct m icroscopy. H ow ever, the G FP tagged virions w ere at the lim it o f  detection which 
prevented observation o f  the virions and cells. Both techniques could possibly be 
im proved by using excess virions. This w ould increase the level o f  fluorescent signal 
enhancing the ability to detect any viriom cell interaction.
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Figure 5.9. Effect of relative levels of CD155 on virion binding
(A) RA dCD 155m Ch infected HFFF were stained with anti-CD 155 and AF 488 then 
analysed by flow cytom etry, (i) CD 155 expression levels and (ii) m Cherry fluorescence.
( B ) ) RA dCD 155m Ch infected HFFF were incubated at 4°C with HCM VUL32GFP or 
PBS. A fter w ashing unbound virus cells were analysed by FACS, (i) GFP fluorescence 
(ii) dotplot showing m Cherry fluorescence against GFP fluorescence for RAdCD155mCh 
infected fibroblasts incubated with PBS. (ii) dotplot showing m Cherry fluorescence 
against GFP fluorescence for RA dCD 155m Ch infected fibroblasts incubated with 
HCM VUL32GFP.
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5.6 SUMMARY
I w anted to investigate the possib ility  o f  the presence o f  gpUL141 in the HCM V virion. 
gpUL141 is a transm em brane g lycoprotein  that w as detected in the envelope o f  strain 
M erlin H CM V  virions; in contrast, both C D  155 and gpU L14 w ere excluded. gpUL14, a 
fam ily m em ber o f  gpU L141, and has sim ilar b iological properties: it suppresses cell 
adhesion, is ER -resident and elicits pro tection  against N K  cell attack w hen expressed 
from  an A d vector. H ow ever, UL14 does not suppress CD  155 expression and is not a 
virion protein. The exclusion o f  CD  155 from  virions indicates selectivity in gpUL141 ’s 
incorporation and potentially  leaves it open for gpUL141 to bind CD 155 during cell 
entry. gpUL141 in purified virions was Endo H -resistant consistent w ith trafficking 
through the G olgi, w hereas cellu lar gpUL141 rem ained sensitive. D uring the later stages 
o f  infection a truncated form  o f  gpUL141 w as detected, consistent with proteolytic 
cleavage. W hile gpUL141 is present in the virion envelope, attem pts to neutralise 
H C M V  infection w ith gpU L 141-specific m Ab, gpUL141 on the virion surface with the 
same antibodies (by flow  cytom etry) or enhance H C M V  binding by over-expressing 
CD 155 were all negative. W hile gpUL141 is present in the virion envelope, it is not yet 
clear w hether it is accessib le to antibody or posses a function related to its known binding 
to CD155.
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6 DISCUSSION
6.1 UL141 ALTERS CELL ADHERENCE
H CM V  encodes a pow erful N K  evasion gene that is present in clinical isolates but lost 
from  the com m only used laboratory strains AD 169 and Tow ne. UL141 suppresses NK 
cell activation during productive infection by dow nregulating cell surface expression o f  
CD 155, a ligand for the activating N K  activating receptors DN A M -1, CD 96 and 
S1GLEC. H ow ever, CD 155 is a  constitu tively  expressed protein that has im portant 
cellular functions that appear superficially  to be quite distinct from  its role in N K  cell 
recognition: CD 155 has im portant roles in prom oting cell m igration, grow th cell:cell and 
celhm atrix  interactions. In m ost quiescent cells, CD  155 would be subject to post- 
translational dow nregulation follow ing binding o f  nectin 3 or be consum ed in functional 
protein:protein interactions. CD 155 becom es exposed on the surface w hen cells break 
free o f  their natural contacts w hen undergoing proliferation or m igration, both enhanced 
follow ing m alignant transform ation. C ertain virus infection can also produces changes 
com parable w ith transform ation (grow th stim ulation, cell cycle progression), break 
cellicell contacts and H C M V  appears to prom ote m onocytic m igration. Consequently, 
the normal biological properties o f  C D 155 do relate to its role in N K  recognition, its 
exposure on the cell surface is perceived by N K  cells as a ‘danger'’ signal. This study 
sought to determ ine for the first tim e how  dow nregulation o f  CD 155 impacted on the 
physiology o f  the infected cell.
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UL141 expression reduced the ability  o f  293 cells and H FFFs to adhere to the growth 
substrate (fig 3.2 and 3.5). In both cell lines CD 155 w as dow nregulated  from the cell 
surface follow ing the expression UL141 in isolation (fig 3.1 and 3.5). CD 155 enhances 
adhesion by binding to its ligands nectin-3 and the ECM  com ponent vitronectin (Ikeda et 
al. 2003; Lange et al. 2001). Follow ing ligand interaction, the internalisation o f  CD 155 
prom otes the form ation o f  focal com plexes (M inam i et al. 2007a). A dditionally, C D 155 
co-localises w ith, and enhances the signalling o f  ayfb  integrin with also enhances 
adhesion o f  cells. The dow nregulation o f  cell surface CD 155 by gpUL141 w ould disrupt 
the adhesion functions o f  CD 155. A dditionally , CD155 has an im portant role in the 
initiation o f  cell-cell contact and the form ation o f  AJs via an interaction w ith nectin-3. 
The form ation o f  cell-cell contacts likely stabilises newly adhered cells by providing 
additional contacts. This is another potential m echanism  by which UL141 affects cell 
adhesion by dow nregulating cell surface CD 155.
The dow nregulation o f  adhesion m olecules is a  com m on them e in HCM V infection. The 
virus dow nregulates a w ide range o f  adhesion m olecules including integrins, NCAM  
(neural cell adhesion m olecule, CD 56) and the Ig superfam ily m em ber Thy-1 (CD90) 
(B laheta et al. 2004; Leis et al. 2004; W arren et al. 1994b). H CM V disrupts the 
form ation o f  focal com plexes and dow nregulates four cellular proteins (focal adhesion 
kinase, H ic-5, paxillin, and alpha-actinin) involved in the form ation and m aintenance o f  
focal com plexes (Stanton et al. 2007). W hen H C M V -infected fibroblasts were tested in 
the adhesion assay, there w as a large reduction in cell adhesion. Deletion o f  UL141 from 
the virus genom e did not result in a detectable increase in the level infected cell 
adherence. Any UL141-dependant effect on adhesion is m asked is m asked during
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productive infection in fibroblasts by o ther effects. Interestingly, CD 155 is integral to the 
form ation o f  focal com plexes (M inam i et al. 2007a) so there m ay be a redundancy o f  
function in H CM V infection. A s long term  passaged laboratory strains o f  HCM V, such 
as AD  169, lack the U L /b ’ region w hich contains UL141 (C ha et al. 1996) it indicates that 
there are additional focal adhesion-d isrupting  functions encoded by HCM V. W hile 
UL141 does not reduce adherence during H C M V  infection in fibroblasts it may have a 
role in vivo. H CM V  infects a  w ide range o f  cells in vivo  and it is possible that the 
U L 141-dependant dow nregulation o f  CD 155 m ay affect the adherence o f  certain cell 
types. It w ould be o f  interest to study the effects o f  UL141 expression on a wide range o f  
cell types in order to elucidate an in vivo  function.
E levated levels o f  C D 155 expression  in cancerous cells correlates with enhanced 
m igration (Ikeda et al. 2004; M inam i et al. 2007b; Sloan et al. 2004) An in vitro  scratch 
assay w as used to assess the im pact o f  UL141 on cell m ovem ent (fig 3.8). W hile UL141 + 
cells took the sam e tim e to close the gap, the control cells did so at a more constant rate. 
Cells expressing gpUL141 displayed four d istinct phases: a period o f  expansion, a lag 
phase, a phase o f  rapid closure, then finally the rate o f  closure m atched that o f  the control 
cells.
W ithin seconds o f  w ounding, the leading edges o f  the 293-U L141G FP m onolayer 
detached from the substrate yet rem ain attached to the rest o f  the m onolayer. The 
floating cells then re-settle either back onto either the m onolayer or into the gap near their 
original location. This peeling o f  the m onolayer m ay sim ply be due to downregulation o f  
CD 155 causing reduced adherence.
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Follow ing the detachm ent o f  the leading edges o f  the m onolayer there then follows a 
phase w here the g p U L l4 1 -expressing cells do not close the gap. It is possible that this 
phase is caused by the reattachm ent o f  the leading edges. A lternatively, it may be that 
the gpUL 141-expressing cells are in a state o f  contact inhibition. The internalisation o f  
cell surface CD 155 is a powerful m echanism  for the inhibition o f  m ovem ent following 
contact (M inam i et al. 2007b). Intracellular signalling by cell surface CD 155 leads to the 
reorganisation o f  the cytoskeleton prom oting m ovem ent. Follow ing contact, CD155 is 
dow nregulated and the intracellular signals are ablated. Therefore w ithout CD 155 on the 
surface, the UL141 expressing cells w ould constantly  be in a state o f  contact inhibition, 
believing that they are in contact w ith other cells. A s CD155 internalisation is not the 
only contact inhibition m echanism  the cells eventually begin to move.
Once the cells begin to close the gap there is a period o f  increased m ovem ent com pared 
to the control cells. This m ay be a result o f  the detached regions o f  the m onolayer 
reattaching. R eattachm ent o f  cells w ould equate to a  reduction in the size o f  the void. 
Conversely, the reduced adherence caused by the dow nregulation o f  CD 155 could 
enhance cell m ovem ent.
In the final phase o f  w ound closure, both U L141-expressing and control cells close the 
gap at a sim ilar rate which lasts until both leading edges m ake contact. For the 293- 
UL141 cells this is m arkedly slow er than the previous phase. If  the previous phase was a 
result o f  the resettling o f  the detached m onolayer then this phase m arks the point where 
the reattachm ent is no longer a factor in the m ovem ent o f  the leading edge.
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It cannot be excluded that the U L 141-dependant effects described are a result o f  an 
interaction w ith another cell adhesion m olecule and not CD  155. How ever, Tom asec and 
colleagues (2005) perform ed an extensive survey on the effects o f  UL141 expression on a 
panel o f  adhesion m olecules and they identified CD  155 as the only cell adhesion 
m olecule dow nregulated by UL141 expressed in isolation. In attem pt to m im ic the 
phenotype o f  gpUL141 expressing cells CD  155 w as successfully dow nregulated by RNA 
interference induced by lentiviral vector. The dow nregulation was not tolerated in stable 
cell lines. The potential exists to rem ake and reselect the cell line for each experim ent. 
H ow ever, if  this strategy is pursued then there is no advantage in using a transducing 
vector. T ransient delivery o f  the interfering RN A , for exam ple by electroporation, would 
perhaps be m ore successful in reproducibly knocking dow n CD 155 expression. 
A lternatively, RAd vectors provide efficient transient expression and are com patible with 
RN A  interference. Three shR N A  designed to target CD 155 were introduced into the 
A dZ vector (M cSharry and W ilkinson, personal com m unication) but these constructs did 
not sufficiently suppress C D 155 expression. I f  this technology can be m ade to work then 
it w ould be a powerful tool to d issect the function o f  U L 141.
W hen m onocytes m igrate through a m onolayer o f  endothelial cells, CD226 disrupts AJs 
and binds to CD 155 on the endothelial cells; antibodies against either m olecule will arrest 
m igration (Reym ond et al. 2004). H CM V  is recognised to infect both m onocytes and 
endothelial cells; indeed it is possible that m onocyte m ay potentially acquire the virus 
during diapedesis through a layer o f  chronically  infected endothelial cells. The 
expression and effect o f  U L141, and additional H CM V -encoded function that impact on
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cell adhesion, on the integrity o f  endothelium  lining blood vessels w arrants investigation. 
It will also be im portant to study the effect o f  gpUL141 expression in endothelial cells on 
trans-endothelial cell m igration. In this context, i f  H CM V  UL141 efficiently 
dow nregulates CD 155 in endothelial cells theoretically  diapedesis should be inhibited. In 
m onocytes, C D 155 m ay also be required to  interact w ith nectin-3 from  the AJs to 
enhance m onocyte m igration. The H C M V  transcriptional cascade is regulated by 
m yeloid cell differentiation. In m onocytes H C M V  gene expression has been reported to 
be restricted essentially to IE genes, thus UL141 should not be expressed. Following 
differentiation into m acrophages, activation o f  UL141 expression and the concom itant 
dow nregulation o f  CD 155 m ay contribute to suppressed cell m igration in the target 
organ. W hile these questions can be addressed in in vitro  m odels o f  transendothelial cell 
m igration, there is currently a technical issue delivering fibroblast-adapted H CM V  strains 
to these cell types. A wild type M erlin BA C, repaired in RL13 and UL128, which has 
intact tropism  for endothelial cells is currently being created (Stanton, personal 
com m unication). W hen this BAC is available it w ould be interesting to look at 
transendothelial cell m igration with virus (± U L 1 4 1 ) in m onocytes and endothelial cells
UL141 is the only other m em ber o f  the U L14 fam ily, presum ably due to gene duplication 
during HCM V evolution, with the tw o genes diverging. Interestingly, rhesus CM V 
contains hom ologues o f  both genes w ith the rhesus UL141 hom ologue also being capable 
o f  dow nregulating C D 155 (A icheler, personal com m unication). The conservation o f 
these genes is rem arkable in that it appears not to be true o f  other HCM V NK  m odulators 
(U L 16, U L 18, U L 142). Like gpUL 141, gpU L 14 is an ER resident glycoprotein, however 
it does not dow nregulate CD 155 or the nectin  fam ily m em bers nectin-2 or nectin-3 (Mel
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A rm strong, PhD thesis). W hen expressed from  an A d vector gpU L14 can provide 
protection from  N K  cell recognition, how ever, U L14 has yet to be dem onstrated to 
function in the context o f  virus infection (P rod’hom m e, A rm strong, Tom asec & 
W ilkinson, personal com m unication). In order to com pare the tw o hom ologues, 293 cells 
stably expressing UL14 w as also included in adhesion assays. Cells expressing a 
gpU L14G FP fusion protein had a sim ilar level o f  adhesion reduction as cells expressing 
U L141G FP. This result w ould be consistent w ith a model in w hich gpUL14 also 
dow nregulates surface expression o f  an endogenous cellu lar adhesion m olecule, possibly 
also by retention in the ER. In v iew  o f  the potential for this function to be a ligand for an 
N K  activating receptor, there is clear m erit in identifying this protein. The cellular target 
for UL14 could be sought by system atic screen o f  all know n cellular adhesion, or by 
using biochem ical/proteom ic approaches.
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6.2 CO-LOCALISATION OF gpUL141 AND CD155 IN THE ENDOPLASMIC 
RETICULUM
CD 155 is retained w ith in  the cell in an im m ature 69kD a Endo H sensitive form in 
HC M V -infected cells (Tom asec et al. 2005). W hile this im m ature form was readily 
observed by w estern blot, the only available m A b com patible w ith im m unofluorescence 
could not detect im m ature intracellular CD  155. Expression o f  UL141 was associated 
w ith a loss o f  CD 155 staining. To address th is issue, plasm ids encoding fluorescent 
fusion proteins o f  CD155 and UL141 w ere generated. W hen transfected individually, 
CD155 was expressed on the cell surface w hile UL141 was expressed as an intracellular 
protein w ith large bodies o f  high concentration observed. These inclusion bodies varied 
in both size and shape (fig 4.5 and 4.6). gpUL141 has been described as form ing dim ers 
and high m olecular com plexes w ith itse lf (M el Arm strong, PhD thesis); therefore, these 
bodies are likely large m ultim eric UL141 com plexes. It is not clear w hether CD 155 has a 
role in form ation o f  these com plexes, as the endogenous cellular protein is present in all 
experim ents. W hile CD 155 RN A  knock dow n experim ents could provide further insight, 
even this approach w ould be associated w ith a level o f  residual expression.
The fluorescent fusion o f  CD 155 is dow nregulated from  the cell surface when UL141 is 
expressed. How ever, because o f  the fluorescent tag  connected to CD 155 it was possible 
to directly image the im m ature form w ithin the cell (fig 4.5 and 4.6). W hen expressed in 
the presence o f  gpU L141, CD 155 is intracellu lar w ith the same distribution as gpUL141. 
CD 155 co-localises closely w ith gpUL141 including in the inclusion bodies. CD 155 has 
not previously been detected in the inclusion bodies as the antibodies could not penetrate.
183
H ow ever by using fluorescent fusion proteins it w as possible to dem onstrate that CD 155 
is included in these bodies. By tak ing  serial sections along the z axis, I also dem onstrated 
that the inclusion bodies are com posed o f  a hom ogenous m ixture o f  CD 155Y FP and 
gpU L 141C FP (fig 4.7). The size and num ber o f  the inclusion bodies is highly variable; 
cells m ay have several sm aller bodies or occasionally  they will have few er large bodies.
It appears that the size o f  the bodies is dependant on the relative expression levels o f  the 
tw o proteins.
The dow nregulation o f  C D 155 by UL141 is not absolute; a  small level o f  cell surface 
C D 155 can be detected by flow  cytom etry  (fig 4.6) (Tom asec et al. 2005). This is 
verified by the use o f  the fluorescent fusion proteins. W hen fluorescent C D 155 and 
UL141 are co-expressed, there is often faint CD 155 fluorescence visible on the cell 
surface. This is breakthrough expression as the cell surface C D 155 is not localised with 
gpU L 141 .
Tom asec and colleagues hypothesised that because o f  the Endo H sensitivity o f  C D 155 
that the interaction betw een C D 155 and gpUL141 occurred in the ER (Tom asec et al. 
2005). H ow ever they did not produce any specific evidence to support this hypothesis. 
This hypothesis w as confirm ed by staining cells co-transfected w ith gpUL141 and 
CD 155 with the ER resident protein calnexin (fig 4.8). The interaction with CD 155 and 
gp\JL141 occurred exclusively w ithin the ER. Both the granular intracellular staining 
and the inclusion bodies co-localises closely w ith calnexin. Indeed, the co-localisation is 
so precise that it is likely that calnexin is involved in the interaction between CD155 and 
gpU L 141. Calnexin operates as a chaperon in the ER, ensuring the correct folding and
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glycosylation o f  g lycoproteins (review ed in H elenius and Aebi 2004). Considering the 
im m ature g lycosylation o f  CD 155 in the presence o f  gpUL141 (Tom asec et al. 2005), it 
is likely that gpUL141 is d isrupting  the calnexin-dependant glycosylation o f  CD 155. 
H ow ever, by being involved in the gpUL141 :CD155 interaction calnexin loses credence 
as an ER m arker. It m ay be transported  from  the ER w ith the g p U L l41 :CD 155 complex. 
It w ould be w orth w hile repeating th is experim ent w ith o ther ER m arkers to confirm  the 
ER localisation. Also, it w ould be o f  interest to study the co-localisation o f  other ER 
chaperones, such as calreticulin , to see i f  their d istribution is changed by UL141 
expression.
By infecting cells expressing fluorescent CD 155 w ith the UL141 deletion H C M V  or the 
parental virus it was possib le to observe CD  155 during infection. CD 155 w as down 
regulated in M erlin strain virus infected cells, but not in the UL141 deletion virus 
infected cells. CD 155 cell surface dow nregulation correlated with internal CD 155 
fluorescence, in agreem ent w ith the results discussed above. Large inclusion bodies were 
not observed, how ever som e cells display sm aller bodies. This supports the conclusion 
above that the bodies are dependant on expression  level. The large bodies observed 
during transient transfection are likely a result o f  the overexpression o f  both proteins. 
W hile during H CM V infection, UL141 expression is m uch lower therefore the inclusion 
bodies are smaller.
W hile I show  close association betw een CD  155 and gpU L141, direct interaction has not 
been shown. It is o f  im portance to indentify if  gpUL141 binds directly with CD 155 or if  
there are interm ediary m olecules involved in the interaction. Im m unoprecipitation was
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attem pted but w as fruitless; co-im m unoprecip ita tion  o f  CD 155 is recognised to be 
problem atic. A nother techn ique w hich could  potentially  determ ine if  direct binding 
occurs is to m ix epitope-labelled  soluble gpUL141 and soluble CD  155, then attem pt to 
pull dow n CD 155 using m A bs to  the epitope-tagged soluble gpU L 141. Unfortunately, 
there were technical problem s purify ing the soluble gpUL141 w hich prevented the 
experim ent from being perform ed.
It w as discovered late in the course o f  th is study that the recom binant HCMVAUL141 
loses the ability to dow nregulate nectin-2, as well as CD 155 (Tom asec and Prod’hom me, 
personal com m unication). H ow ever U L141, w hen expressed on its ow n only 
dow nregulates C D 155 and not nectin-2 (Tom asec et al. 2005). This im plies that UL141 
is w orking in concert w ith another H CM V  gene to dow nregulate nectin-2. M ost non- 
essential genes, including UL14, have been elim inated in the search for the partner 
(Tom asec and Sugrue, personal com m unication). Regardless o f  the identity o f  the 
binding partner, the distribution and interaction o f  CD 155 and gpUL141 is likely to be 
m ore com plex iti vivo  than the situation produced by the introduced expression o f  UL141 
and CD 155 fluorescent fusion proteins. Once the o ther H CM V com ponent is identified, 
further studies will be required to determ ine the relative distribution and interactions 
betw een CD 155, gpU L 141, nectin-2 and the o ther H C M V  protein. These studies w ould 
have to utilise fluorescent fusion proteins because, as previously discussed, there are 
problem s attem pting to perform  im m unofluorescence w ith CD 155 and gpUL141.
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6.3 gpUL141 IS A COMPONENT OF THE HCMV VIRION ENVELOPE
The envelope o f  H C M V  is a derived from  host m em brane. T ransm em brane HCM V 
glycoproteins are expressed on the envelope; the m ost studied are the m ajor glycoprotein 
com plexes gB, gH :gL:gO  and gM :gN  (discussed in section 1.2.4). H ow ever, a small 
num ber o f  other envelope glycoproteins have been identified including UL22A, UL33, 
UL41A, U L 1 19 and U L 128-U L 131A  (V arnum  et al. 2004; W ang and Shenk 2005b). As 
UL141 is a transm em brane glycoprotein , it has the potential to be incorporated into the 
virus particle. gpUL141 w as detected in purified  strain H C M V  virions. Cellular 
contam ination w as ruled out as the v irions w ere negative for intracellular proteins. The 
identification o f  gpUL141 in the virion is a  novel observation; previously gpUL141 was 
thought to only be an in tracellu lar protein.
Interestingly, C D 155 w as absent from  the virion. As dem onstrated in chapter 4, C D 155 
and gpUL141 closely co-localise w hen expressed together. There is little free gpUL141 
that does not co-localise w ith CD 155 in the transfected fibroblasts. How ever, late in 
infection increasing gpUL141 m ay no longer be saturated by binding CD 155 giving rise 
to free gpU L 141. The absence o f  CD 155 from  the virion also provides further evidence 
that the incorporation o f  gpUL141 is selective and not attributable to non-specific 
contam ination.
V irion particles are highly structured w ith the positioning o f  m ost proteins appearing to 
be highly regulated and related to their functional role during infection. gpUL141 is a 
transm em brane protein, and the envelope is the only m em brane in the virion. It was
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therefore perhaps to be expected  that gpUL141 w as present in the envelope fraction (fig 
5.2). A small level o f  gpUL141 w as detected in the capsid and tegum ent fraction. It is 
m ost unlikely that gpUL141 is also a com ponent o f  the tegum ent, rather the data would 
be consistent with gpUL141 being envelope-located  but w ith the internal dom ain o f  the 
protein having an interactions w ith the tegum ent, w hich results in the increased 
association o f  gpUL141 w ith the tegum ent during the separation process. Interactions 
betw een the tegum ent and envelope is a com m on feature o f  H C M V  proteins, such as the 
tegum ent protein pp28 w hich interacts w ith the envelope (Silva et al. 2003). Irmiere and 
G ibson (1983) have dem onstrated  that parts o f  the envelope can still be attached to the 
tegum ent follow ing extensive de-envelopm ent. As gB w as only present in the envelope 
fraction, it suggests that there w as good separation o f  the envelope from  the tegum ent and 
capsid.
O ne technique which could potentially  confirm  the location o f  gpUL141 in the virion is 
electron m icroscopy. By probing purified virions with gold-labelled antibodies it may be 
possible to visualise gpU L 141. H ow ever, because the label is on the end o f  the antibody 
it m eans that the label is adjacent to, not on, the epitope. Therefore, the location m ay not 
be revealed.
The topological orientation o f  HCM V envelope proteins is essential for their functions. 
The m ajor glycoproteins are arranged so that their glycosylated dom ains are facing out 
from the virus enabling interactions w ith cellu lar m olecules during attachm ent. 
Conversely, certain m olecules m ay be arranged to enable interactions with the tegum ent. 
These interactions are im portant for the secondary envelopm ent o f  the virion prior to
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egress from the cell. To define the topological orientation o f  gpUL141 in the virion flow  
cytom etry and neutralisation assays w ere perform ed using UL141 m A bs. These 
antibodies w ere generated against a  soluble form  o f  UL141 w hich consists o f  the Ig-like 
dom ain but does not have the transm em brane or cytoplasm ic dom ain (Tom asec et al. 
2005). U nfortunately, neither technique provided definite results. In both assays binding 
o f  the UL141 antibody to virus particles were not detected. This could m ean that the Ig- 
like dom ain o f  gpUL141 is contained w ith in  the virion, although this would represent a 
topological challenge during envelopm ent. It is m ore likely that the Ig-like dom ain o f  
gpUL141 is located on the envelope surface. A ntibodies m ay be unable to access 
com plem entary epitopes in this context because o f  steric hindrance, possible by other 
H CM V or host-encoded envelope proteins b locking antibody binding. It is also possible 
that the m A bs do not recognise the m ature, fully glycosylated form  o f  the protein in the 
virion, present in d isulphide-bridged com plexes w hen unreduced. A lternatively, the 
m A bs m ay be binding virions but producing a signal below  the threshold level detectable 
by flow  cytom etry, w ith the m A bs binding w ithout neutralising.
As m entioned above I attem pted to detect gpUL141 on the virion by flow  cytom etry (fig 
5.7). This built on the techniques by B russaard and colleagues (2000) who showed that 
they could detect purified fluorescent-labelled virions from  a wide range o f  virus 
fam ilies. They could detect picornaviruses, baculoviruses retroviruses and fluorescent 
labelled H CM V virus particles. H aving confirm ed that fluorescent-tagged HCM V 
virions could be detected by flow  cytom etry, I attem pted to detect purified virions stained 
with antibodies. How ever, I w as lim ited by tim e and reagents. Several technical 
lim itations lim ited the detection o f  specific fluorescence. V irion size lim its the amount o f
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antigen they can contain. E xtrem ely  high concentrations o f  antibody w ere utilised before 
a positive signal could be detected; how ever, these condition inevitably led to a high level 
o f  non-specific staining. U nless the high background staining can be m inim ised then this 
technique is o f  lim ited usefulness. The use o f  high affinity  antibodies should reduce the 
non-specific staining. If  the non-specific fluorescence could be reduced then this could 
be a pow erful technique for the studying o f  envelope glycoproteins. A t the m om ent flow  
cytom etry o f  virions m ay be useful for counting  virus particles. I f  the ratio o f  m easured 
virus particles to plaque form ation units w as established then it w ould then be possible to 
count virus particles by flow  cytom etry  and com pare it w ith the infectivity.
gpUL141 is sensitive to Endo H in H CM V infected cells (Tom asec et al. 2005). 
gpUL141 in the virion, how ever, d isplays resistance to Endo H digestion (fig 5.3). Tw o 
glycoform s o f  gpUL141 are incorporated into virion; one that is com pletely resistant to 
Endo H digestion and one that is partially resistant. The developm ent o f  Endo H 
resistance is characteristic o f  processing through the Golgi apparatus, therefore gpUL141 
m ust be processed to an Endo H resistant form  in the Golgi apparatus before 
incorporation in the virion. The specific g lycoform s present in the virion do not 
accum ulate in the cell during infection; the Endo H resistant form s are only detected in 
the virion and not at early or late tim epoints during H C M V  infection. Tom asec and 
colleagues characterised UL141 as being expressed in cells as a doublet consisting o f  two 
differently sized glycoform s (Tom asec et al. 2005). This is correct early in infection (fig 
5.5); however, at latter tim es in infection the observed doublet consists o f  differently 
sized protein backbones. A t late tim es during infection, com plete deglycosylation o f  
cellular gpUL141 by PN Gase produces tw o separate products. The generation o f  this
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alternate, 32 kD a protein backbone form  o f  gpUL141 is not currently  know n. As the 
UL141 O RF does not have an obvious alternative start site (D avison et al. 2003; Dolan et 
al. 2004), the generation o f  this faster-m igrating  form  is presum ably  a consequence o f  
post-translational m odification. The function o f  this m odification  ( if  any) is also 
unknown. It is not required for the dow nregulation  o f  CD  155 as it occurs at early tim es 
during infection w hen this form  is not present. A lso the alternate form  is not detected in 
the virion, only glycoform s o f  the sm aller 32kD a are incorporated into the virion. It is 
possible UL141 may have additional roles late in H C M V  infection.
The role ofgpU L141 in the v irion is currently  unknow n. The possibility that virion 
gpUL141 dow nregulates CD  155 im m ediately upon virus entry can only be expected to 
w ork in a  local context; the am ount o f  CD  155 on a virion is not sufficient to impact 
globally on CD 155 on the new ly infected cell. Indeed, CD 155 dow nregulation cannot be 
detected until the late phase o f  infection (Tom asec et al. 2005). Perhaps the m ost 
intriguing possible function for virion gpUL141 is an involvem ent in virus entry. 
Recently, Soroceanu and colleagues (2008) identified the PDGF receptor (PDG FR) as an 
im portant receptor for H CM V . B locking o f  PD G FR function or knock down o f  the 
protein m ade cells non-perm issive for H C M V  infection. The envelope glycoprotein gB 
interacts directly w ith PD G FR  inducing receptor phosphorylation and the activation o f  
the phosphoinositide 3-kinase (PI3K ) and Atk. H C M V -induced upregulation o f  the PI3K 
pathw ay provides strong anti-apoptosis signals and is im portant for the initiation o f  viral 
DN A replication (Johnson et al. 2001). C D  155 is know n to co-localise on the cell 
surface with, and enhances the signalling from , the PD G F receptor (K akunaga et al. 
2004). CD 155 enhances PD G F-induced signalling  through the R as-Raf-M EK -ER K
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pathw ay (K akunaga et al. 2004) but there is no data yet on the effects o f  CD155 on the 
PD G F-dependant PI3K  and A tk signalling pathw ay. H ow ever, the close fam ily m em bers 
o f  CD 155. nectin-2 and nectin-3 have both been show n to enhance PD GF-induced 
activation o f  the PI3K -A tk pathw ay (K anzaki et al. 2008). This opens the possibility that 
CD155 may also affect the PI3K -A tk pathw ay as nectins and CD 155 share sim ilar 
cytoplasm ic signalling pathw ays (Sato et al. 2005).
a v p 3 integrin has been show n to bind the envelope glycoproteins gB and gH and act as a 
co-receptor for HCM V (W ang et al. 2005). O riginally  ay p 3 integrin was thought to 
function as a co-receptor, signalling in concert w ith the epiderm al grow th factor receptor 
(W ang et al. 2005), although a later study does show n that EG FR is not essential for 
H C M V  entry (Isaacson et al. 2007). Rem arkably, as w ith PDGF receptor, CD155 is 
know n to enhance signalling by avP3 integrin (Ikeda et al. 2004; M inam i et al. 2007a). 
This gives virion gpUL141 another potential m echanism  for enhancing intracellular 
signalling during H CM V  attachm ent and entry. In addition to cytoskeletal reorganisation 
integrin signalling can enhance signalling from  both EGFR and PD G FR  (Streuli and 
A khtar 2009).
A nother possibility is that gpUL141 does not enhance CD 155 signalling but rather that 
gpUL141 prom otes the physical attachm ent o f  the virion during entry. UL141 is non- 
essential for replication and is often lost during in vitro  passage o f  H CM V clinical 
isolates (Davison, D argan personal com m unication), how ever, that does not preclude it 
from  having a role in virus attachm ent and/or entry. A m utation in the UL128 locus 
(U L128, UL130 or U L131A ) is rapidly selected w henever HCM V clinical isolates are
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propagated in fibroblasts (D olan  et al. 2004), yet the g H :g O :g L :U L l28-131A com plex is 
essential for the productive infection o f  endothelial cells (R yckm an et al. 2008a;
Ryckm an et al. 2008b). A lthough UL141 is not essential in vitro, it may be required to 
expand virus tropism  in vivo. It is possib le that in v itro , the cells are supplied with 
sufficient grow th factors and anti-apopto tic  signals from  the serum  in the media, while, in 
vivo  addition anti-apoptotic signals are required to productively infect cells.
It is im portant to determ ine if  gpUL141 enhances PD G FR  signalling during HCM V 
entry. One way to determ ine this is to probe the phosphorylation state o f  intracellular 
signalling m olecules fo llow ing attachm ent and entry by HCM VAUL141 or strain M erlin 
HCM V. The phosphorylation state o f  m olecules from  the Ras-R af-M EK -ER K  pathw ay 
and the PI3K-Atk pathw ay should be probed. If  gpUL141 enhance PD G FR signalling 
then an increase in phosphorylation w ould be detected in M erlin strain HCM V infected 
cells com pared to HCM VAUL141 infected cells.
If  it transpires that gpUL141 is involved in virus entry then the next stage would be to 
determ ine its role in vivo. To answ er this, the first step should be to test the infectivity 
and grow th o f  the HCM VAUL141 and parental virus in a w ide range o f  cell types to see 
if  the presence o f  UL141 expands tropism  or enhances productive infection in specific 
cell types.
Interest in UL141 has focused on its role in suppressing cell surface expression o f  the 
pow erful N K  cell activating ligand C D 155. In this study, I show  the first indication that 
UL141 has additional roles during H C M V  infection. In addition to show ing that UL141
expression reducing cellu lar adhesion, the identification o f  UL141 as a  com ponent o f  the 
virion envelope m ay suggest that it is involved in cell entry. Further studies will be 
required to elucidate the function  o f  gpUL141 in the virion.
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